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1 Chapter 1 Introduction 
Crohn’s disease is a common inflammatory bowel disease affecting approximately 1 in 
1000 of the population in the UK.  Surgery for Crohn’s disease is common with the 
majority of patients requiring surgery at some point in the course of the disease.  Both 
genetic and environmental factors influence Crohn’s disease.  Smoking significantly 
influences the disease course in Crohn’s disease with more frequent relapses and 
increased need for surgery.  Recent research had concentrated on the genes 
predisposing to the development of Crohn’s disease.  In 2001 the CARD15 (NOD2) 
gene was identified and since then ~30 genes have been found to be associated with 
Crohn’s disease. This thesis aimed to investigate the influence of CARD15 (NOD2) on 
the time to second operation in terminal ileal Crohn’s disease. 
Crohn’s disease affects all parts of the gastrointestinal tract but particularly the 
terminal ileum.  A particular cell type, the Paneth cell, has been implicated in the 
pathogenesis of Crohn’s disease.  Paneth cells are located at the base of Crypts of 
Liberkühn throughout the small intestine but are found in greatest numbers in the 
terminal ileum.  Paneth cells contain and secrete antimicrobial peptides in response to 
bacterial products.  They have been found to express CARD15 (NOD2).  The 
expression of antimicrobial peptides and the CARD15 (NOD2) genotype were 
investigated using the technique of in situ hibridization.   
There are well characterized histological features of Crohn’s disease.  The are no 
known histological features of Crohn’s disease associated with the CARD15 (NOD2) 
genotype. These features were investigated.   
Osteoporosis is an important complication of Crohn’s disease and it’s treatment.  
Predictors of those at risk for the development of Crohn’s disease would be clinically 
useful in targeting therapy.  Genetic influences on bone mineral density and Crohn’s 
disease were investigated.  
Recent publications have furthered our knowledge of the genetic factors influencing 
the development of Crohn’s disease.  The Newcastle cohort of patients contributed to 
this knowledge.   
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1.1 History 
Inflammatory bowel disease is a common chronic condition with a current UK 
prevalence of 240 000 (Hellier, Sanderson et al. 2006).  It is a group of inflammatory 
diseases affecting the alimentary tract including Crohn’s disease and ulcerative colitis.  
The incidence of Crohn’s disease is around 8 per 100 000 and that of ulcerative colitis 
14 per 100 000 (Rubin, Hungin et al. 2000). Crohn’s disease causes significant 
morbidity with the cost of care estimated at £3000 per patient per year (Hellier, 
Sanderson et al. 2006).  The majority of people with Crohn’s disease will require 
surgery at some time in their lives (Forbes 1997).  The pathogenesis of Crohn’s disease 
is thought to be a complex interaction between genetic predisposition, the immune 
system and environment.   
The disease that was to become known as Crohn’s disease was first described in the 
medical literature as a chronic interstitial enteritis by T. K Dalziel in 1913 (Dalziel 
1913).  Probably the first case recorded in formal literature was that of a 20 year old 
man who died of a perforated terminal ileum in the 17th Century.  This was described 
by Giovanni Battista Morgagni (1682-1771) the Italian anatomist as granulomatous 
enterocolitis (Morgagni 1769).  Dalziel wrote of a number of cases in which a varying 
amount of the small and large intestine were involved.  The histopathological 
appearance however was similar between all cases.  In the British Medical Journal in 
1913 Dalziel described the case of a fellow Doctor who suffered prolonged intestinal 
obstruction and then died (Dalziel 1913).  The event occurred at the turn of the 20th 
Century.  Preceding the terminal event he had suffered colic, diarrhoea and fever.  
Dalziel operated on the Professor and found that his internal organs were fixed; now 
known as “fat wrapping” with chronic inflammation and nodal enlargement.  He noted 
that the samples taken were negative for tuberculosis.  Dalziel went on to describe a 
further case from 1905.  This patient had a palpable mass with symptoms of sub-acute 
obstruction.  Dalziel operated on the patient and removed the “caput coli” (caecum) 
with the adjoining ileum.  He described a number of cases in whom discrete segments 
of the bowel were involved.  Dalziel described a characteristic pathology; “early 
vascular congestion and oedema with an infiltrate rich in polymorphs”.  He noted that 
the lymphoid aggregates seen were pathology free, i.e normal unlike those seen in 
intestinal tuberculosis.  There was loss of the epithelium with infiltration of the 
muscularis mucosae and necrosis.  Eosinophils and giant cells were seen.  In one 
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patient coliform bacteria were cultured from within the gut wall.  Dalziel postulated 
that there was no known aetiology.  He thought it was probably tuberculous, but the 
pathology was different with a smooth gut and notable absence of caseating 
granulomas.  However, there was a marked similarity to Johne’s disease of cattle that 
had been described in 1895.  No acid fast bacilli were found in any of Dalziel’s cases.  
Dalziel thought that many previous cases had been miss-diagnosed as intestinal 
tuberculosis were actually this disease of hyperplastic enteritis.  The only treatment 
option available at that time was surgery.  A ‘regenerative process’ was remarked 
upon.   
Interestingly, the similarity to cases of Johne's disease of cattle noted by Dalziel was 
not novel.  Johne’s disease is a chronic enteritis of cattle due to mycobacterium 
paratuberculosis.  However, in the human cases, the non caseous nature of the 
inflammation was distinguished.  The condition had been called hyperplastic enteritis 
by human pathologists for a number of years prior to Dalziel’s description.   
In 1932 in the Journal of the American Medical Association Burrill B Crohn described 
a regional ileitis (Crohn, Ginzberg et al. 1932) after whom Crohn’s disease is named.  
A case series of 14 was published.  The paper described disease affecting the terminal 
ileum with fever, diarrhoea and emaciation leading to obstruction (Crohn, Ginzberg et 
al. 1932).  At surgery they found disease affecting the ileocaecal valve extending 
towards the mouth for 20-30cm.  The disease often led to fistula formation to the colon 
or abdominal wall.  The disease was of unknown aetiology but followed a benign 
course.  They described an association of right iliac fossa mass, fistula, emaciation and 
anaemia, previous appendectomy and intestinal obstruction.  The disease was one of 
young adults with granulomas seen on microscopy with giant cells but no tuberculosis.  
They described the disease as only involving the terminal ileum, never the colon or 
perianal region.  They hypothesized that the disease progressed from one of acute 
inflammation to ulceration and enteritis with symptoms of abdominal pain and 
diarrhoea.  This progressed to stenotic disease with sub-acute and chronic small bowel 
obstruction.  They stated however that stenotic disease could be the primary 
manifestation.  The disease then progressed to fistula formation.  The diagnosis could 
be made using a barium meal.  Crohn suggested that this disease of the terminal ileum 
was a separate disease to that affecting the colon and that tuberculosis affecting just the 
terminal ileum was extremely rare.  The treatment was surgical resection.  Recurrence 
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was noted to be a problem occurring proximal to surgical anastomosis.  It was thought 
to be the result of leaving disease when performing the original operation.  Crohn and 
colleagues termed this disease regional enteritis.  A number of benign granulomatous 
conditions had been described but the condition that Crohn described was one of 
inflammation of the terminal ileum.  Crohn’s disease however is now understood to 
mean a chronic granulomatous inflammation of any of the small or large intestine.   
These initial descriptions of Crohn’s disease highlight clearly a number of issues; the 
description and diagnosis of Crohn’s disease is difficult, a number of diseases can 
masquerade as Crohn’s disease thereby weakening associations and studies.  Crohn 
identified that regional enteritis recurs unpredictably and often requires further surgery.  
From the first descriptions in the medical literuature the diagnosis of Crohn’s disease 
has presented a challenge.  It is a heterogeneous condition with variable clinical and 
pathological features.  This results in potential for diagnostic misclassification and 
leads to errors in association and outcome studies.  Recognised criteria for the 
diagnosis of Crohn’s disease were published by Lennard-Jones in 1989, some 57 years 
after Crohn’s paper, Table 1.  Crohn’s disease is diagnosed with 3 positive findings or 
one positive plus the finding of granuloma. 
In summary, to meet Lennard-Jones criteria there should be; 
 Typical diarrhoea history for at least 2 months; 
 Radiological features of Crohn’s disease: segmental distribution, deep 
ulcerations or cobblestone pattern, thickened bowel wall, coarse mucosal relief, 
stenotic segments and fistulae; 
Macroscopic diagnosis by endoscopy: patchy penetrating lesions, fissuring and 
strictures; 
 Fistulas and/or abscesses with typical intestinal disease 
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Table 1 Lennard-Jones anatomic criteria for the diagnosis of Crohn’s disease recognizable by 
clinical, radiological and pathologic examination.  A diagnosis of Crohn’s disease requires 3 
positive findings, or one positive finding with granulomas on histology. 
 
Clinical/ 
Endoscopy 
X-ray Biopsy 
Resected 
Specimen 
Mouth to anus     
Upper gut + + + + 
Anus +  + + 
Discontinuous + + + + 
Transmural inflammation    + 
    Fissure  +  + 
    Abscess + +  + 
    Fistula + +  + 
Fibrosis/Stenosis + +  + 
Lymphoid     
    Ulcers   + + 
    Aggregates   + + 
Mucin Retention   +  
Granuloma   ++ ++ 
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1.2 Clinical phenotypes and classification 
A standardised classification system enables disease phenotype and outcome to be 
compared consistently by different groups in different studies.  There are many clinical 
phenotypes with variable site and severity of disease; mild to severe, some requiring no 
intervention, some requiring multiple medical treatments and multiple surgeries.  The 
challenge is to create a simple, easy to use, reliable classification system with little or 
no inter-observer variation that gives normally distributed groups for ease of analysis.  
There are a number of problems with creating a classification system for Crohn’s 
disease.  Disease behaviour changes with time; it is a progressive unpredictable disease 
in the majority of people, relapsing and remitting.  Additionally there are 
environmental influences such as smoking on the disease process. 
An initial classification system published in 1975 by Farmer used an anatomical 
system only (Farmer 1975).  This gave 3 subgroups based on the anatomical 
distribution of disease.  This takes no account of the variability of disease behaviour in 
Crohn’s disease with time or between people with Crohn’s disease.   
The International Working Party published the Rome classification system in 1992 
(Sachar 1992).  This was based around anatomical distribution with clinical behaviour; 
inflammatory, stricturing or stenotic, and operative history included.  This created a 
classification system with 756 subgroups.   
A classification system was published in 2000, known as the Vienna Classification 
Table 2 from the International Working Party at the World Congress of 
Gastroenterology, Vienna, 1998 (Gasche, Scholmerich et al. 2000).  This uses three 
criteria to categorise Crohn’s disease; age, disease behaviour and disease location.  The 
categories for age are very broad, either above or below the age of 40 years at 
diagnosis.  Disease behaviour only allows one type of behaviour, when commonly in 
clinically practice more than one behaviour type is found.  Disease location is 
relatively inflexible and does not include perianal disease.  It may be included as a 
disease behaviour as “perforation” but this subgroup was intended for intestinal 
perforation, not isolated perianal disease.  Although superficially simplistic there are 
24 groups of disease which means that large study numbers are needed for phenotype 
studies.  Upper GI disease is included as an independent location even if ileum or 
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colon are involved.  The age of onset categories are very broad leaving no subgroup for 
childhood onset disease. 
Table 2 Vienna Classification 
Category   
Age at diagnosis A1 <40 years 
 A2 >40 years 
Disease behaviour B1 Inflammatory 
 B2 Stricturing 
 B3 Penetrating 
Disease location L1 Terminal ileum 
 L2 Colon 
 L3 Ileocolon 
 L4 Upper GI 
 
The Vienna classification system does not lead to normally distributed populations.  
This leads to difficulties with statistical analysis.  The Vienna classification system can 
be used to predict need for surgery and immunosuppression.  The advantages of the 
Vienna classification are that it is internationally recognised and relatively 
straightforward providing consistent classification of disease.   
The issue of the stability of disease classification over time is addressed in a study 
published in 2001 (Louis, Collard et al. 2001).  Extensive review of over 1000 patient 
records resulted 6% of the patients having a change in diagnosis.  As noted by Crohn in 
his 1932 paper, disease behaviour changes over time.  Disease location remains 
relatively stable over time with only 16% of patients having a change in location over 
10 years.  Change in behaviour is more likely with 45.9% of patients having had a 
change in behaviour over 10 years.  Most change was from inflammatory to stricturing 
disease in 27% or fistulising disease in 29%.  A study of 2002 patients with Crohn’s 
disease in France had similar results (Cosnes, Cattan et al. 2002); only 12% were found 
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not to have stricturing and/or penetrating disease after 20 years follow-up compared 
with 48% at 5 years.  In a further study of 231 patients (Smith, Arnott et al. 2004) only 
8% had no stricturing or penetrating disease after 20 years compared with 46% at 5 
years and 70% at diagnosis. 
Table 3 Montreal classification system (Silverberg, Satsangi et al. 2005) *L4 is a modifier that can 
be added when concomitant upper gastrointestinal disease is present, †p perianal disease modifier, 
added to B1-3 when concomitant perianal disease present 
Category   
Age at diagnosis A1 <16 years 
 A2 17-40 years 
 A3 >40 years 
Disease location L1 Ileal 
 L2 Colonic 
 L3 Ileocolonic 
 L4* Isolated upper gastrointestinal 
Disease behaviour B1 Inflammatory 
 B2 Stricturing 
 B3 Penetrating 
 p† Perianal disease modifier 
 
Most recently a working party at the 2005 Montreal World Congress of 
Gastroenterology revised the Vienna Classification system (Silverberg, Satsangi et al. 
2005), Table 3.  Early onset disease is classified separately.  It was felt this change was 
needed as a number of genotypes are associated with childhood onset disease.  Disease 
location was altered to allow upper gastrointestinal disease to co-exist with lower 
gastrointestinal disease, it was felt that as the upper gastrointestinal tract is more easily 
accessible with studies such as wireless capsule endoscopy the frequency of upper 
gastrointestinal disease is becoming more common (Satsangi, Silverberg et al. 2006).  
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Perianal disease, a common manifestation of Crohn’s disease, was added as a modifier 
in disease behaviour in the Montreal system.  There remains a problem with disease 
variability over time.  The number of relapses, need for surgery and other disease 
modifying drugs.  
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1.3 Genetics, the story so far 
1.3.1 A history of Crohn’s disease genetics 
As early as 1934 it was recognised that Crohn’s disease was found in multiple 
members of the same family.  Crohn reported regional enteritis in two sisters (Crohn 
1934).  A further case report of regional enteritis in 3 siblings was published in 1939 
(Brown and Scheifley 1939).  In this paper it was stated that in their current patient 
cohort of 2500 patients with ulcerative colitis at the Mayo clinic there were only 15 
familial pairs. 
The genetic basis for Crohn’s disease has long been investigated.  In 1971 Singer 
published a series of 646 patients with inflammatory bowel disease (Singer, Anderson 
et al. 1971).  113 of these had familial disease.  This study looked only at inflammatory 
bowel disease and the frequency of familial disease.  The number of patients with 
Crohn’s disease was not given.  The conclusion in this paper was that inflammatory 
bowel disease had very little genetic basis.   
A review in 1971 by McConnell (McConnell 1972) surmised that a family history of 
siblings with Crohn’s disease was more common than a vertical family history.  A 
family history of inflammatory bowel disease was more common in patients with 
Crohn’s disease than those with ulcerative colitis.  Familial disease was uncommon 
with only 1 in 15 to 1 in 50 having a first degree relative affected in this cohort.  An 
association with ankylosing spondylitis and inflammatory bowel disease was seen.  It 
was hypothesized that there was both a shared environment and shared genetic 
predisposition.  The inheritance pattern was not Mendelian but a complex polygenic 
disorder with a combination of environmental and genetic factors determining the 
development of Crohn’s disease.  It was suggested by the authors that there may be a 
number of genes in common between Crohn’s disease, ulcerative colitis and 
ankylosing spondylitis.   
In 1989 Küster published a paper using the technique of complex segregation analysis 
to investigate the pattern of inheritance found in Crohn’s disease (Küster, Pascoe et al. 
1989).  This was carried out by collecting the pedigree of each proband with Crohn’s 
disease including first degree relatives, second degree relatives and cousins.  All 
affected relative were contacted and the diagnoses confirmed making this a robust 
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study.  Analysis of 265 probands with Crohn’s disease developed a hypothesis of a 
recessive gene with incomplete penetrance.  By contrast ulcerative colitis was thought 
to represent the effects of a dominant gene with incomplete penetrance.   
A further complex segregation analysis was published in 1993 (Orholm, Iselius et al. 
1993).  662 patients with inflammatory bowel disease were included, but only 209 with 
Crohn’s disease.  Using multi-factorial model the conclusion of this paper was that in 
Crohn’s disease there was a major recessive locus with complete penetrance with 7% 
of patients with Crohn’s disease carrying the gene.  A considerable proportion of 
Crohn’s disease was considered sporadic. 
Analysis of the Swedish twin registry published in 1988 (Tysk, Lindberg et al. 1988) 
revealed 8 of 18 monozygotic twins to be concordant for Crohn’s disease and 1 of 26 
dizygotic twins.  This gave a proband concordance rate among monozygotic twins of 
58% in Crohn’s disease compared to 6% in ulcerative colitis.  A coefficient of 
heritability was calculated to be 1.0 (95% confidence interval 0.34-1.0) for Crohn’s 
disease and 0.53 (95% confidence interval 0.24-1.0) for ulcerative colitis.   
The low rate of familial disease is shown in the UK Thompson twin study (Thompson, 
Driscoll et al. 1996).  Twins were identified by contacting patients through the 
National Association for Colitis and Crohn’s disease.  150 twin pairs were identified.  
15 twins were concordant for disease.  Monozygotic twins were significantly more 
likely to be concordant for diagnosis.  The concordance rate was low at only 17% 
however, suggesting that there are a number of other significant factors influencing the 
development of Crohn’s disease.   
An estimate of the risk to siblings for the development of a given disease can be 
expressed λs.  This gives an estimate of the relative risk of development of the disease 
in siblings of affected people.  The λs for Crohn’s disease, ulcerative colitis and 
inflammatory bowel disease has been estimated to be 36.5, 16.6 and 24.7 from a study 
of relatives of people with inflammatory bowel disease in Oxford (Satsangi, Rosenberg 
et al. 1994).  Compared to other complex genetic diseases the λs for inflammatory 
bowel diseases is high.  The λs for type-1 diabetes estimated as 20, schizophrenia as 
11, Grave’s disease as 6.  However, the λs of single gene disorders is much greater, 
haemophilia 3750 and cystic fibrosis 750. 
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Overall these studies suggest a significant genetic basis to Crohn’s disease with 
environmental modifiers to the development of disease.  The mode of inheritance does 
not follow a simple Mendelian model but is polygenic typical of complex genetic 
disease. 
1.3.2 Association studies using candidate genes 
Some of the earliest genetic studies used candidate gene analysis.  Candidate gene 
analysis uses an identified gene and compares the frequency of carriage of a known 
mutation or variant among cases and controls.  It can be used to replicate positive 
findings from linkage studies in separate populations.  Due to the small sample sizes of 
many studies, and therefore low power, false positive results are not unusual.  For 
example, polymorphisms in the gene encoding the cytokine interleukin-1 receptor 
antagonist (IL-1RA) were thought to be associated with inflammatory bowel disease.  
This was first reported in 1994 (Mansfield, Holden et al. 1994).  The positive 
association was only replicated in subgroup analyses (Bioque, Crusius et al. 1995; 
Bioque, Bouma et al. 1996; Heresbach, Alizadeh et al. 1997; Tountas, Casini-Raggi et 
al. 1999).  Subsequently this positive association was refuted in the literature (Louis, 
Satsangi et al. 1996), Heresbach 1997, Hacker 1998, Stokkers 1998, Ferreira 2005, 
Mittal 2005 and Celik 2006) and by our own group, (Craggs, West et al. 2001). 
There are a number of limitations in this method; it can only be used with known 
genes, multiple genes needs correction for multiple testing, there is publication bias 
with positive findings more likely to be published.  There needs to be geographical and 
ethnic matching of cases and controls.  The probability of false positive results is high.   
The advantages of this technique are that a relatively small case-control population can 
be used and it is therefore good at finding genes with small effect, a potential 
advantage in complex diseases with multiple genes with small effect. 
A number of genes have been investigated in this way, mainly genes thought to be 
involved in the regulation of immune response.  In the 1970s a positive association 
with the major histocompatability complex (MHC) class I on chromosome 6 was 
found.  The first investigation included 18 patients with Crohn’s disease, 16 patients 
with ulcerative colitis and 50 controls (Gleeson, Walker et al. 1972).  In this very small 
study no association was found.  Subsequently in a larger study of 51 patients with 
Crohn’s disease an association with the class I antigen B18 was found (van den Berg-
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Loonen, Dekker-Saeys et al. 1977).  Association has been found with HLA B44Cw5 
(Purrmann, Bertrams et al. 1988), HLA A11 (Biemond, Burnham et al. 1986), HLA-
DR4 and 5 (Fujita, Naito et al. 1984).  A large number of HLA alleles have 
subsequently been investigated but only a small number replicated (Yap, Ahmad et al. 
2004).   
A modification of candidate gene analysis has subsequently been used to attempt to 
identify relevant genes within susceptibility loci highlighted in genome-wide linkage 
and genome-wide association studies.  This will be explored later in 1.3.4. 
1.3.3 Linkage studies 
The genetics of inflammatory bowel disease was advanced by the development of 
genome-wide linkage studies.  The first linkage map was published in 1992 using 814 
polymorphic markers across the entire genome (Weissenbach, Gyapay et al. 1992).  
These markers cover 90% of the genome, but are spaced widely.  This linkage map 
allows variation in nucleotides at these markers to be compared between disease 
groups and control groups using panels of affected sibling pairs and their first degree 
relatives.  The main disadvantage is a lack of power; multiple tests are applied to the 
cohort.  The gaps between the tested genetic markers are wide; therefore it is difficult 
to identify the location of the causative mutation.   
The LOD score is calculated: a statistical estimate of linkage.  A LOD score of >3.0 
suggest that the likelihood of linkage between the marker of interest and a gene 
associated with disease is 1000x greater than if there was no linkage.  In inflammatory 
bowel disease there have been only 5 significant LOD scores.  The remaining LOD 
scores being only suggestive.   
In 1996 Hugot published the first genome-wide search in inflammatory bowel disease 
(Hugot, Laurent-Puig et al. 1996).  Two panels of multiply affected families were used 
in this investigation.  25 families in the first panel and 53 in the second independent 
panel were genotyped.  This was done by initially studying 270 highly polymorphic 
markers spread over the entire genome.  Four markers with the highest LOD score 
were then genotyped in the second panel, i.e. 4 markers on chromosomes 1 and 16 in 
this first panel had increased allele sharing between sibling pairs. An independent 
panel of 53 families were then used to try to replicate this finding.  Two of these 
markers on chromosome 16 were confirmed to have increased allele sharing.  To 
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narrow down the area on chromosome 16 further markers at closer intervals were used.  
The degree of allele sharing and the estimated ratio for the dominant genetic variant to 
the total genetic variance was consistent with the expected finding of a recessive mode 
of gene inheritance.  This locus was termed IBD1, a susceptibility locus in the 
pericentromeric area of chromosome 16.  This was to be identified later as CARD15 
(NOD2) (Hugot, Chamaillard et al. 2001; Ogura, Bonen et al. 2001), see section 1.3.5.   
A two-stage genome-wide-linkage search published in 1996 identified 3 further loci on 
chromosomes 3, 7 and 12 (Satsangi, Parkes et al. 1996).  This investigation used a 
panel of 89 sibling pairs with inflammatory bowel disease and their first degree 
relatives.  260 markers were used in the initial panel.  The markers with the highest 
probability of linkage were then studied in a further panel of 97 sibling pairs.  In this 
data set the locus on chromosome 16 was not found to have significant linkage.   
The pericentromeric region on chromosome 16 was confirmed in US genome-wide 
linkage study in 1999 (Cho, Nicolae et al. 1998).  This study of 439 patients with 
inflammatory bowel disease from 174 families identified significant areas of linkage 
on chromosomes 1p, 3q, 4q and 5q.  The previously reported areas of linkage on 
chromosomes 2, 3p and 12 did not show linkage in this scan.  This study did find 
linkage with chromosome 16; however it was over a broad area.  
Linkage was replicated further on chromosome 16 by Hampe in 1999 (Hampe, 
Schreiber et al. 1999).  353 affected sibling pairs were used in a linkage study.  This 
scan highlighted areas of linkage on chromosomes 1, 6, 10 and 12.  Interestingly the 
maximum LOD in this study was on the X chromosome.  
A Canadian cohort used 183 affected sibling pairs with 312 markers and their available 
parents (Rioux, Silverberg et al. 2000).  This genome wide search identified two novel 
loci in chromosomes 19p13 and 5q31.  The previously reported linkage on 
chromosome 3p and 6p was replicated.  The 5q31 haplotype had a significant LOD 
only in a sub-group of early onset Crohn’s disease.   
A later genome-scan by van Heel (van Heel, Dechairo et al. 2003) used markers 9.4cM 
(137 relative pairs from 112 families) across the genome.  This identified two areas 
with a significant LOD; chromosome 3q, LOD 2.1 and chromosome Xp, LOD 2.0.  
They then stratified the cohort by IBD5 haplotype.  This revealed three further 
significant LOD scores; chromosome 3p, LOD 2.2, chromosome 12p, LOD 2.3 and 
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chromosome 19, LOD 2.4.  The cohort was then stratified by CARD15 (NOD2) 
genotype.  Interestingly there was an additional significant region found on 
chromosome 16 in CARD15 (NOD2) negative Crohn’s disease; 16q LOD 2.2.  This 
indicates that there is likely another gene contributing to disease risk on chromosome 
16.  An area on chromosome 19 had a significant LOD (2.9) in CARD15 (NOD2) 
negative Crohn’s disease.   
In a study of 92 Finnish affected relative pairs with IBD, 12q23 was found to be 
significantly associated with Crohn’s disease (Paavola-Sakki, Ollikainen et al. 2002).  
There was very little linkage with chromosome 16.  A second Finnish study identified 
a region on chromosome 11p12-q13 (Lappalainen, Paavola-Sakki et al. 2006). 
A meta-analysis of the 10 published genome-wide linkage scans in 2004 (van Heel, 
Fisher et al. 2004) combined the genotyping data from 1952 affected relative pairs with 
inflammatory bowel disease.  This enabled a much larger cohort than each individual 
study. The Genome Scan Meta-Analysis allowed for different genotype analysis 
methods and needed no assumptions of inheritance models.  However this technique 
lacks precision and divided the genome into 34cM bins.  Linkage was detected on 
chromosome 16 with Crohn’s disease which acted as a positive control.  Areas 
suggestive of linkage with Crohn’s disease were found on chromosomes 2q, 3q, 12q 
17q and 19p, of which the linkage on chromosomes 2q and 17q were novel findings.  
Significant linkage was found with chromosome 19q and within the HLA region 6p.  
Table 4 has a summary of candidate gene findings.   
These studies have been able to identify areas of the genome that are likely to contain 
genes that influence the development and/or disease behaviour.  The genes within these 
most of these areas still await identification.  There is great heterogeneity between 
studies with little reproducibility.  It became clear that a new method of investigating 
complex disease genetics needed to be developed. 
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Table 4 summary of candidate gene studies, *different genetic variants 
Author Date Loci Association Gene CD/control Replication 
Mansfield (UK) 1994  None IL-1RA 78/261  
Pokorny (USA) 1997  Positive MLH1 45/45 No 
Bioque (Netherlands) 1995  None IL-1β 
IL-1Ra 
79/71 Yes 
Heresbach (France) 1997  None IL-1β 
IL-1Ra 
141/113  
Stokkers 
(Netherlands) 
1998  None IL-1β 
IL-1Ra 
72/270  
Hacker (Germany) 1998  None IL-1β 
IL-1Ra 
64/196  
Nemetz (Hungary) 1999  Positive IL-1β 98/132 No 
Craggs (UK) 2001  None IL-1β 
IL-1Ra 
182/289  
Mittal (India) 2004  Positive IL-1Ra 21/141  
Olavesen (UK) 2000 16 None IL-4R 435/ Yes 
Aithal (UK) 2001  Positive 
None 
IL-4 
IL-4R 
86/321  
De Jong 
(Netherlands 
2003 16 
16 
12 
None IL-4 
CD11B 
STAT6 
  
Seegers (USA) 2002  None IL-12 150/145  
Haslam (UK) 1999  None FVL 30/55 No 
Negoro (Japan) 1999 6p Positive TNF 103  
Pierik (Belgium) 2004  Positive 
(smokers) 
TNF-R 344/  
Zipperlen (Canada) 2005  None TNF-α 128/103  
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Author Date Loci Association Gene CD/control Replication 
Fowler (Australia) 2005  Positive TNF-α 
IL-10 
304/231  
Castro-Santoz 
(Spain) 
2006  None TNF-α 
IL-10 
146/303  
Ferreira (Portugal) 2005  Positive 
None 
TNF-α 
IL-1β/Ra 
235/312  
Cantor (Canada) 2005  None TNF-α, TGF-β, 
IL-10, IL-6, IFN-
γ 
138/92  
Rioux (USA) 2001 5q31 Positive 5q31*  Yes 
Stoll (Germany) 2004 10q23 Positive DLG5   
Daly (USA) 2006  Positive DLG5  Yes 
Yamazaki (Japan) 2004  Positive 5q31 
(SLC22A4&5)* 
DLG5* 
  
Martinez (Spain) 2006  Positive  5q31 
(SLC22A4&5) 
309/408  
Palmieri (Italy) 2006  Positive OCTN1&2 444/611  
Török (Germany) 2005  Positive 
 
None 
5q31 
(SLC22A4&5) 
DLG5 
625/1012  
 
Yes 
Noble (Scotland) 2005  None DLG5 374/294  
Newman (Canada) 2006  Positive DLG5 402/537  
Haslam (UK) 2001  None  Prothrombin 24/100 No 
Kyo (Japan) 2001  Positive MUC3A   
Simmons (UK) 2000  Positive VDR 245/164  
Matsuzwa (Japan) 2003 19p13 Positive ICAM-1 79/103  
Papa (Italy) 2004  Positive ICAM-1 75/187  
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Author Date Loci Association Gene CD/control Replication 
Low (UK) 2004  Positive ICAM-1 228/407  
Hong (New Zealand) 2007  None 
 
ICAM-1 
NFKB1A 
182/188  
Zweirs (Netherlands) 2004  None IL-12B   
Annese (Italy) 2002  Positive MLH-1   
Kojima (Japan) 2001  Positive NRAMP-1 
(SLC11A1) 
  
Chermesh 
(Ashkenazi) 
2007  None NRAMP-1 131/131  
Franchimont 
(Belgium) 
2004  Positive  TLR-4 344 
&114/140 
 
Török (Germany) 2004  None TLR-4 
CD-14 
102/145  
Gazouli (Greece) 2005  Positive TLR-4 
CD-15 
120/100  
Suraweera (UK) 2004 7q None NCF-1 
ncf-1 
/181  
Brant (USA) 2003 7q Positive MDR-1   
Schwab (Germany) 2003  None  MDR-1 126/998  
Potocnik (Slovenia) 2004  Positive MDR-1 163/355  
Urcelay (Spain) 2006  Positive MDR-1 321/352  
Oostenbrug 
(Netherlands) 
2006  None MDR-1 /315  
Machida (Japan) 2005  Positive NAT-2 
CTLA4 
60/200 
79/200 
 
Rueda (Spain) 2005  None CTLA4 284/454  
Tamura (Japan) 2002  Positive IL-18 promoter   
Haas (Germany) 2005  None IL-18 promoter 470/347 Yes 
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Author Date Loci Association Gene CD/control Replication 
Takagawa (Japan) 2005  None IL-18 promoter 205/212  
King (UK) 2003 16p11 None IGSF6   
Glas (Germany) 2002  Positive IL-16 promoter 103/120  
Martin (Spain) 2005  None PTPN22 569/812  
De Jager (Canada) 2006  None PTPN22 1019/207  
Gerwitz (Jewish 
USA) 
2006  Negative TLR-5 296/416  
Pierik (Belgium) 2006  Negative 
None 
TLR-1 
TLR-2-10 
/191  
Lappalainen 
(Finland) 
2006 11p12 None TRAF-6 290/320  
Dring (Ireland) 2006  Positive PXR (NR1I2) /350  
McGovern (UK) 2006 19q Positive TUCAN 
(CARD8) 
372/365  
Tremelling (UK) 2006 7p14.3 None NOD1 (CARD4) 645/760  
Van Limbergen (UK) 2007 Hap-
tagging  
None NOD1 (CARD4) 2296  
Papp (Hungary) 2007  Positive Haptoglobin 468/384  
Leshinsky-Silver 
(Israel) 
2007  None NFKB1A 231/100  
Oliver (Spain) 2007  Positive MMIF 336/361  
Weersma 
(Netherlands) 
2007 12q14 None IRAK-M 309/305  
Parkes (UK) 2007 5q31.1 Positive IRGM  Yes 
Magyari (Hungary) 2007  None CTLA4 130/170  
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1.3.4 Genome wide association studies 
Despite the evidence that Crohn’s disease has a strong heritability up until 2006 there 
were only two genetic loci that could be reliably replicated; CARD15 (NOD2) and 
5q31 with a third on chromosome 10q23 with less consistent replication together with 
the MHC region on chromosome 6.  The combined, modest effect of these genetic loci 
is not sufficient to account for the genetic load in Crohn’s disease.  It was put forward 
in 1996 that large-scale testing by association analysis was going to be necessary to 
detect the multiple genes of modest effect implicated in complex diseases (Risch and 
Merikangas 1996).  The first published genome-wide association scan was in 2005 
(Yamazaki, McGovern et al. 2005).   
Genome wide association studies use a case-control method to investigate association 
between disease and thousands of SNPs throughout the genome.  Technological 
progress through the human genome project and the development of the HapMap has 
enabled this technique.  The HapMap is a schematic of the human genome in which a 
minimal number of SNPs can be used to tag common haplotype blocks, rather than 
using every known SNP throughout the genome.  The technique can use either SNPs 
evenly spaced across the entire genome or use the HapMap to tag common haplotypes.  
Allele frequencies are then compared between cases and controls. Large sample size 
and well matched ethnic and geographical controls are needed due to the multiple 
testing employed and the modest increase in disease risk conferred by any variant.  
Statistical methods have had to be developed to enable interpretation of the large 
number of results produced and replication in a similar number of cases and controls. 
The first genome-wide association study published in 2005 (Yamazaki, McGovern et 
al. 2005) was an investigation in Japanese and European populations.  The most 
reliably replicated genetic associations in European cohorts; CARD15 (NOD2) and 
5q31 haplotype have not been found in Japanese patients with Crohn’s disease 
(Yamazaki, Takazoe et al. 2002; Negoro, McGovern et al. 2003; Yamazaki, Takazoe et 
al. 2004; Tosa, Negoro et al. 2006).  This investigation initially identified SNP loci in 
94 patients with Crohn’s disease and 752 controls.  The 1888 SNP were then 
investigated in a second cohort of 484 Crohn’s disease.  22 SNP with p<10-4 were 
identified, the highest number around the 9q32 locus.  High density SNP map was then 
used to attempt to identify the causative SNP.  The most significant association was in 
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TNFSF15 gene at the 9q32 locus.  10 markers across this region were then investigated 
in two Caucasian cohorts from the UK and a positive association was found.  This 
investigation used a relatively small number of Crohn’s disease cases.  It has 
previously been established that the genetic associations in people of European 
Caucasian ancestry is different to those with Japanese ethnicity, therefore the validity 
of replicating association within a different ethnic group could be questioned.   
The next genome-wide association study was performed on 567 people with ileal 
Crohn’s disease with non-Jewish European ancestry (Duerr, Taylor et al. 2006) in 
North America.  Two loci were identified within the CARD15 (NOD2) gene, p 2.86 x 
10-9, p  8.82 x 10-10.  A third (Arg381Gln) was within the interleukin 23 receptor 
(IL23R) gene, p 5.05 x 10-9.  Nine other SNPs were identified around chromosome 
1p31 and the IL23R gene with less significant association.  This association was then 
replicated in an independent case-control panel of 401 Crohn’s disease and 433 
controls.  It was found in a panel of 833 IBD nuclear families that there was a 
significant distortion in allele transmission.  Combined data from all three groups 
showed a highly significant association of 10 IL23R markers with IBD.  Interestingly 
the glutamine allele at position 381 was found to be protective against the development 
of Crohn’s disease; it is significantly under transmitted from heterozygous parents to 
affected offspring.   
A genome-wide association study in Germany (Hampe, Franke et al. 2007) of 735 
Crohn’s disease and 368 controls identified a gene within chromosome 2q37; 
ATG16L1.  This group used non-synonymous SNPs spread across the genome.  The 
initial positive results with p <0.01 were then investigated in a second panel of 380 
trios, 498 sporadic Crohn’s disease cases and 1032 healthy controls.   
Libioulle published a large genome-wide association study of 547 Crohn’s disease and 
928 controls with replication in 1266 Crohn’s disease and 559 controls (Libioulle, 
Louis et al. 2007).  The Arg381Gln SNP of IL23R was significantly associated with 
Crohn’s disease as was CARD15 (NOD2).  The association with ATG16L1 was 
replicated, but no association with OCTN, DLG or TNFSF15 was found.  A novel 
association was reported within the gene desert of chromosome 5p13.1.  An attempt 
was made to identify the causal variant using haplotype linkage disequilibrium (LD).  
The area of highest significance was closest to PTGER4 as well as CARD6, and 3 
complement factors.   
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In an extension of the genome-wide association study by Duerr 988 Crohn’s disease 
and 1007 controls were used in the initial panel (Rioux, Xavier et al. 2007).  ~300 000 
SNPs were used.  The results were replicated in 530 trios then an independent case-
control study of 353 Crohn’s disease and 207 controls.  The two most significant loci 
corresponded to CARD15 (NOD2) and IL23R.  The 5q31 haplotype was not among the 
top loci in this study.  By examining the LD structure and fine mapping it there was 
found to be significant association at 2q37.  One corresponding to the previously 
reported ATG16L1 gene.  Novel associations were found at 10q21.1 an intergenic 
region, 4p13 possibly implicating PHOX2B, 22q31.1 NCF4 and 16q24.1.  
The significant associations of IL23R and ATG16L1 were replicated in the UK study in 
June 2007 (WTCCC 2007).  Again the CARD15 (NOD2) gene was positively 
associated with Crohn’s disease.  This very large study of 7 common disease used 
~2000 cases of each disease and 3000 controls.  Further areas of significant association 
were identified 10q21, 5p13, 5q33, 3p21, 10q24 and 19p11.  No gene has been 
identified for the area of association within 10q21.  The area of association with 5p13.1 
occurs within a gene desert.  There were four novel associations reported.  5q33.1 
includes several SNPs around IRGM.  The areas on 3p21 and 10q24 involve a number 
of possible genes.  The association on 18p11 was found upstream of PTPN2.  A 
number of other associations were found with significance levels p<10-7 including the 
previously reported association with TNFSF15, the MHC region on chromosome 6, an 
area on the X chromosome and a number of areas of interest with genes known to 
interact with the CARD15 (NOD2) pathway.  The positive findings were replicated in 
an independent Crohn’s disease cohort (Parkes, Barrett et al. 2007).   
A further genome-wide association study was performed on a genetically isolated 
population in Canada, originating from 17th Century French migrants (Raelson, Little 
et al. 2007).  The initial panel included 383 trios with a second replication panel of 477 
trios with 2 additional independent cohorts of 521 German trios, 750 cases and 828 
controls.  Four novel loci were identified, 3p21.3 BSN, 4p16.1 JAKMIP1, 17q11.1 
haplotype and 17q22-23 haplotype in strong LD.  These loci were replicated in the 
German cohort suggesting that they are not unique to the genetically homogeneous 
Quebec population. 
A meta-analysis of three genome-wide association studies from European derived 
Crohn’s disease populations combined to a total of 3230 Crohn’s disease and 4829 
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controls (Barrett, Hansoul et al. 2008).  This identified and replicated 21 novel loci to 
bring the current total of significant association to ~30.  526 SNPs within this study 
were found to have p value <5x10-5 within 74 genomic loci.  The combined power of 
the three studies enabled a significant association to be found for odds ratio of 1.2, this 
highlights the problem of significance level in these large studies with multiple testing.  
32 of the 526 associations SNPs correlated with known non-synonymous SNPs.  21 
areas have no known genes.  It may well be that this meta-analysis does not include a 
large enough case or control population to identify significant genes albeit with small 
effect.  There is current work proceeding to establish an international consortium to 
include 20 000 patients with Crohn’s disease.   
The above genome-wide association study (GWAS) have consistently identified three 
genes associated with Crohn’s disease; IL23R, ATG26L1 and IRGM.  A significant 
problem with the genome-wide association study is the identification of the causal 
variant and/or gene product of the SNPs identified from these investigations, rather 
than the tagging SNP which is positive for the association.  In the case of CARD15 
(NOD2) the OR of the homozygotes is 30-40 when the causative SNPs were examined, 
but only 3 when the GWAS data is examined.  A predisposition to Crohn’s disease 
may result from altered transcription or expression of a gene product rather than a gene 
mutation per se.  The current genome-wide association studies do not incorporate 
methods for identifying copy number variants as disease modifiers but such an 
experiment is in progress under the umbrella of the WTCC, results in 2009.   
To date the genetics studies have identified genes which predispose to Crohn’s disease.  
The clinical benefit has come from identifying the pathophysiological pathways in the 
development of Crohn’s disease rather than in predicting the course of the disease.  
Interestingly the GWAS have highlighted a number of genes important in autophagy, 
innate immunity and functioning IL23 pathway.  Autophagy is an ancient mechanism 
by which cell organelles, cell breakdown products and bacteria are engulfed and 
disrupted.  IL23 is important in regulation of T regulatory cells and control of 
inflammation.  See Chapter 6 Genetics and Appendix for more detail. 
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1.3.5 CARD15 (NOD2) 
The area of linkage on chromosome 16 has been investigated in order to identify the 
gene within this region associated with Crohn’s disease.  By candidate gene analysis 
interleukin-4 (Olavesen, Hampe et al. 2000) and CD19 and CD43 (Hugot 1999) were 
found not to be associated with Crohn’s disease.   
In 2001 back to back papers (Hugot, Chamaillard et al. 2001; Ogura, Bonen et al. 
2001) were published in Nature identifying the gene associated with Crohn’s disease 
located within the susceptibility locus on chromosome 16.  Hugot et al (Hugot, 
Chamaillard et al. 2001) used a positional cloning technique, initially 26 microsatellite 
markers spaced 1cM apart over the pericentromeric region of chromosome 16.  Then 
linkage analysis in 77 affected relative pairs and transmission disequilibrium testing 
identified a region containing the CARD15 (NOD2) gene.  SNPs were then investigated 
within this gene and three were found to be carried more frequently in Crohn affected 
patients.  These regions were sequenced and compared with known characterised 
genes. 11 SNPs (1-11) from within these regions were then subsequently searched for 
in families with Crohn’s disease.  Significant excess transmission was found with most 
of the SNPs investigated.  Four of these SNPs (5-8) and an addition two SNPs (12 and 
13) were found to be within a single gene.  It was subsequently found that four (2, 4, 5 
& 6) of the original SNPs were not transmitted independently of SNP13.  These final 8 
SNPs within a single gene were found to identify 41 haplotypes, three of which were 
preferentially transmitted to people with Crohn’s disease.  Each of these contained an 
allele of either SNP 8, 12 or 13.  There was found to be a gene dosage effect with 
carriage of two SNPs being associated with the greatest risk.  This is again consistent 
with the recessive model of inheritance in Crohn’s disease.  Each of these SNPs is 
functional resulting in a change in the nature of the protein product.   
Ogura et al (Ogura, Bonen et al. 2001) used candidate gene analysis of CARD15 
(NOD2) showing that a frame shift mutation 3020insC is associated with Crohn’s 
disease.  CARD15 (NOD2) was known to be involved in recognising bacterial 
components and was therefore hypothesized to have a role in the pathogenesis of 
Crohn’s disease.  The CARD15 (NOD2) gene was then sequenced in a number of 
families with Crohn’s disease as well as controls.  An insertion SNP was found that 
resulted in truncation of the CARD15 (NOD2) protein.  The transmission of the 
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mutation was investigated among families with Crohn and families with ulcerative 
colitis.  There was an excess of transmission only in families with Crohn’s disease. 
This mutation was then searched for in a number of unrelated Crohn’s disease cases in 
a case-control fashion.  This confirmed the association of this SNP with 8.2% 
frequency in patients with Crohn’s disease (n=412) and a frequency of 4% in controls 
(n=287). Two other SNPs in CARD15 (NOD2) were mentioned in this paper as being 
associated with Crohn’s disease.   
The association of Crohn’s disease with the CARD15 (NOD2) gene was found by two 
different groups by differing methods.  Positional cloning using microsatellite markers 
and SNPs in multiply affected families and candidate gene analysis.  At around the 
same time another European group also identified a functional mutation in the 
CARD15 (NOD2) gene that was significantly associated with Crohn’s disease (Hampe, 
Cuthbert et al. 2001).  All of the SNPs found in the CARD15 (NOD2) gene are 
individually rare.  The three SNPs that are occur most commonly in association with 
Crohn’s disease are SNP8 R702W, SNP12 G908R and SNP13 L1007fs.  These SNPs 
only very rarely occur on the same haplotype (<0.2%) (Cuthbert, Fisher et al. 2002).  
NOD2 is synonymous with CARD15 (capsase recruitment domain 15) (Human 
Genome Organisation approved name) NOD2 (nucleotide oligomerization domain 2) 
and has been identified as part of a large family of intracellular pattern recognition 
receptors.  The association of mutations in the CARD15 (NOD2) and Crohn’s disease 
has been replicated in many large studies. 
There has been intense investigation of the CARD15 (NOD2) gene and its association 
with Crohn’s disease.  A mutational analysis on the CARD15 (NOD2) was undertaken 
by Lesage et al in 2002 (Lesage, Zouali et al. 2002).  This identified 67 sequence 
variations in 483 unrelated patients with Crohn’s disease of whom 287 had familial 
disease.  31 of these variations were considered to be potential disease causing 
mutations as they could result in functional changes in the peptide gene product.  The 
three previously reports SNPs were confirmed to be associated with Crohn’s disease in 
this population.  13% of Crohn’s disease chromosomes had a rare sequence variation 
compared with 6% of control chromosomes independent of the three main disease 
causing mutations.  In total at least one mutation was found in up to 50% of patients 
with Crohn’s disease.  Of note no difference in allele frequencies was found between 
familial and sporadic Crohn’s disease.  Phenotypic study of this cohort revealed an 
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association between stenotic disease behaviour and younger age at diagnosis and 
carriage of two CARD15 (NOD2) mutations.  Colorectal disease was found to be less 
common in Crohn’s disease patients with CARD15 (NOD2) mutation.  Stenotic disease 
behaviour remained significantly associated with CARD15 (NOD2) mutations even 
after correction for disease location.  There was no significant difference in surgical 
interventions between the groups.  R702W, G908R and L1007fs represent 81% of 
CARD15 (NOD2) mutated alleles.  
The contribution to disease risk of each of these three CARD15 (NOD2) SNPs was 
investigated in a large study of 688 unrelated people with Crohn’s disease (Cuthbert, 
Fisher et al. 2002).  This was the first study that investigated the phenotype of Crohn’s 
disease associated with CARD15 (NOD2) mutations.  R702W, G908R and 3020ins C 
(L1007fs) SNPs were genotyped and the relative risk calculated.  The highest risk for 
heterozygotes was associated with carriage of G908R SNP with an odds ratio of 6.3.  
Homozygotes and compound heterozygotes were found to have similar risk with a 
combined odds ratio of 23.4 and a population attributable risk of 26%.  In this cohort 
35.8% of patients were carriers of at least one CARD15 (NOD2) mutation, with 8.0% 
carrying two mutations.  7 people were found to be homozygous for CARD15 (NOD2) 
mutation but had a diagnosis of ulcerative colitis.  The phenotype of Crohn’s disease 
related to CARD15 (NOD2) genotype was investigated in 444 cases of Crohn’s disease.  
The frequency of CARD15 (NOD2) mutation was significantly increased in patients 
with ileal and ileocolonic disease over colon only disease.  The CARD15 (NOD2) 
allele frequency of patients with colon only Crohn’s disease approached that of 
controls.  Carriage of a CARD15 (NOD2) mutation was associated with ileal disease 
with an odds ratio of 2.04.   
In a study published at the same time of 244 people with Crohn’s disease the highest 
risk was associated with L1007fs SNP not G908R SNP (Ahmad, Armuzzi et al. 2002).  
However, a similar overall population attributable risk was calculated of 27%.  It is not 
clear in the methodology of this paper whether all patients were unrelated.  This may 
account for the higher overall frequency of CARD15 (NOD2) mutations in this study 
compared with the Cuthbert paper.  A significant association was again found between 
carriage of a CARD15 (NOD2) mutation and ileal disease.  Stenotic disease was also 
found to be associated with CARD15 (NOD2) mutations; however this was not 
independent of ileal disease.  158 patients required surgery for stenotic disease of 
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whom 77 had a second operation.  This was not found to be associated with CARD15 
(NOD2) mutations.  CARD15 (NOD2) mutations were not found to be associated with 
fistulising disease.  In a further study of 97 people with Crohn’s disease in 2002 
(Radlmayr, Török et al. 2002) carriage of CARD15 (NOD2) L1007fs mutation was 
found to be associated with fistulising and fibrostenotic disease and also need for 
surgical intervention.  This study is again small with only 39 patients having had 
surgery.   
The association of CARD15 (NOD2) mutations with ileal Crohn’s disease is well 
established and has been replicated many times.  However association of CARD15 
(NOD2) mutations with disease behaviour is variable.  A number of studies have found 
there to be an association with stricturing and/or fistulising disease (Ahmad, Armuzzi 
et al. 2002; Lesage, Zouali et al. 2002; Radlmayr, Török et al. 2002; Brant, Picco et al. 
2003; Helio, Halme et al. 2003; Abreu and Yang 2004) this is not always consistent 
(Hampe, Grebe et al. 2002; Louis, Michel et al. 2003; Esters, Pierik et al. 2004).  
CARD15 (NOD2) mutations have been associated with ileal location (Cuthbert, Fisher 
et al. 2002; Büning, Genschel et al. 2004) and fibrostenosing (Abreu, Taylor et al. 
2002) phenotype.   
A meta-analysis of the phenotypic effects of CARD15 (NOD2) was published in 2004 
(Economou, Trikalinos et al. 2004).  This meta-analysis included studies of the 
common variants of CARD15 (NOD2): R702W (SNP8), G908R (SNP12) and L1007fs 
(SNP13), termed high-risk alleles, and their frequency in Crohn’s disease, Ulcerative 
colitis and healthy controls.  Studies that investigated the association between alleles 
and Crohn’s disease phenotype were included.  The meta-analysis investigated 
prevalence of CARD15 (NOD2) mutation, the association between CARD15 (NOD2) 
and disease susceptibility, phenotype and dose response.  Familial disease and carriage 
of CARD15 (NOD2) risk allele and colonic disease and healthy controls was 
investigated.  Odds ratio with 95% confidence intervals (CI) were used.  42 studies 
were included.   
There was a significant variation in high-risk allele prevalence between ethnic groups.  
In healthy non-Jewish Caucasians the high-risk allele frequency was 6.7-19.3% in 
Jewish population 23.2% (95% CI 16.7-31.2%).  Overall in the non-Jewish population 
carriage of at least one high-risk allele gave an OR of 3.15 for Crohn’s disease (95% 
CI 2.76-3.59), in Jewish population OR 1.55 (95% CI 0.99-2.42), limited data was 
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available.  Carriage of SNP13 conferred the highest OR 4.09 (95% CI 3.23-5.18), 
SNP8 2.20 (95% CI 1.84-2.62), and SNP12 2.99 (95% CI 2.38-3.74).  There was found 
to be a dose response effect with carriage of one high-risk allele giving an OR of 2.39 
(95% CI 2.00-2.86) and two high-risk alleles an OR of 17.1 (95% CI 10.7-27.2). 
Carriage of CARD15 (NOD2) was associated with familial disease; 1.41 (95% CI 1.17-
1.69), small bowel involvement 2.53 (95% CI 2.01-3.16) and stricturing disease; 1.94 
(95% CI 1.61-2.34).  Carriage of CARD15 (NOD2) was overall found to be associated 
with colonic Crohn’s disease 1.49 (1.18-1.87) in contrast to other studies (Ahmad, 
Armuzzi et al. 2002; Cuthbert, Fisher et al. 2002).  It is not clear in this study whether 
the association with stricturing disease is independent of the small bowel association.   
In a long-term follow-up study of patients with Crohn’s disease in Edinburgh carriage 
of CARD15 (NOD2) mutation was found to be associated with late progression of 
disease, considered to be no stricturing or penetrating disease after 3.9 year follow-up 
(Smith, Arnott et al. 2004).  No association was found between CARD15 (NOD2) 
carriage and evolution of disease behaviour after 5 year follow-up (Louis, Michel et al. 
2003).  CARD15 (NOD2) mutation carriage has been associated with both ileal 
resection and reoperation at the terminal ileum (Büning, Genschel et al. 2004), 
however this is not independent of the association of CARD15 (NOD2) with ileal 
disease.  An Italian study of 193 patients with ileal Crohn’s disease found that 
CARD15 (NOD2) carriage was associated with no stricturing or penetrating disease but 
with ileal resection (Laghi, Costa et al. 2005) 
Carriage of CARD15 (NOD2) has been associated with younger age at disease 
diagnosis (Büning, Genschel et al. 2004; Laghi, Costa et al. 2005; Onnie, Fisher et al. 
2008) 
The association of CARD15 (NOD2) with Crohn’s disease varies over geographical 
populations.  The frequency of CARD15 (NOD2) mutations is lower in Northern 
Europe in both Crohn’s disease and controls, and is much more rare in Scandinavia 
Table 5.  This was first noted by Hampe et al 2002 (Hampe, Cuthbert et al. 2001; 
Hampe, Grebe et al. 2002) in a study of German and Norwegian Crohn’s disease 
populations.  The estimated haplotype frequencies in Norwegian compared to German 
populations was significantly lower (p<0.001).  In the Finnish population (Helio, 
Halme et al. 2003) overall CARD15 (NOD2) carriage was 15.7% in Crohn’s disease 
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and 6.7% controls.  There was no significant difference in allele frequency of G908R 
or R702W betweens Crohn’s disease and controls.  Carriage of L1007fs allele was 
significantly higher in Crohn’s disease than in controls.  CARD15 (NOD2) was again 
associated with ileal disease.  Although a total of 271 people with Crohn’s disease 
were included in this study, due to the low carriage of CARD15 (NOD2) mutations data 
regarding phenotype association has low power and may be unreliable.  A summary of 
international CARD15 (NOD2) frequencies is in Table 5. 
Crohn’s disease is more common in Caucasian populations.  Inflammatory bowel 
disease has a 2-8 times greater prevalence in Jewish population compared to non-
Jewish (Sandler and Golden 1986; Yang, McElree et al. 1993).  There is a two-four 
fold increased incidence of Crohn’s disease among the Jewish population.  A study 
with 64 Ashkenazi-Jewish families and 144 non-Jewish Caucasian families  and an 
independent case control panel of 112 Ashkenazi-Jewish patients and 116 non-Jewish 
Caucasian patients with Crohn’s disease identified a novel haplotype (JW1) associated 
with Crohn’s disease in Ashkenazi-Jewish patients with Crohn’s disease (Sugimura, 
Taylor et al. 2003).  It was not associated with Crohn’s disease in the non-Jewish 
population.  JW1 is situated in the non coding region of the CARD15 (NOD2) gene 
therefore it is unclear at present whether it exerts a direct effect on gene expression or 
is merely a marker for an as yet unknown gene mutation.  In this study R702W was not 
found to be associated with Crohn’s disease in the Jewish population.  Further study of 
Ashkenazi and Sephardic Jewish populations has shown that Ashkenazi Jews with 
Crohn’s disease have an increased carrier rate of CARD15 (NOD2) mutations 
compared with Sephardic Jews (Karban, Waterman et al. 2004).  Carriage of all three 
SNPs was increased in Crohn’s disease compared to controls.  The L1007fs was almost 
nonexistent with the Sephardic Jewish population in this study.  Carriage of CARD15 
(NOD2) was not significantly associated with ileal disease in this population.  
Sephardic Jews in this study were much more likely to be smokers than those of 
Ashkenazi origin.  This suggests a different environmental role for the pathogenesis of 
Crohn’s disease in this population.  This further demonstrates the genetic heterogeneity 
in Crohn’s disease.  
In a study of CARD15 (NOD2) within families with Crohn’s disease (Esters, Pierik et 
al. 2004) 570 people with Crohn’s disease and 762 first degree relatives were studied, 
along with 165 healthy controls and 173 people with ulcerative colitis.  A significant 
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number of healthy first degree relatives were carriers of CARD15 (NOD2) mutations, 
37.3% one mutation and 3.1% two mutations.  There was no difference found in the 
frequency of CARD15 (NOD2) among sporadic, familial or mixed IBD families.  
Segregation analysis was performed on 137 families in which genotypes were known 
for all members.  Maternal transmission of the CARD15 (NOD2) variant allele was 
associated with a lower proportion of affected individuals compared to paternal 
transmission.  This study is interesting as it clearly shows that there are other 
influences on the development of Crohn’s disease other than CARD15 (NOD2), both 
genetic and environmental.  Carriage of CARD15 (NOD2) does not explain the 
concordance found in Swedish twins (Halfvarson, Bresso et al. 2005), indicating that 
there are other genes associated with Crohn’s disease other than CARD15 (NOD2). 
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Table 5 Summary of allele frequency for international studies in Crohn’s disease, ¤includes single 
rare mutations not used in other studies *Belgium, Denmark, France, Germany, Ireland, Italy, 
Spain and Sweden 
Author Year Country n= 
Crohn’s disease Control 
Any 
variant 
R702W G908R L1007fs any 
variant 
Cuthbert 2002 England 429 35.8% 9.1% 3.4% 6.6% 11.7% 
Ahmad 2002 England 
(Oxford) 
244 38.5% 12.5% 3.3% 9.4% 15.8% 
Abreu 2002 USA 201 35.3% 16.4% 11.4% 11.4% 10.9% 
(UC) 
Lesage 2002 Europe* 453 49.4%¤ 11% 6% 11% 20% 
Hampe 2002 Germany 
Norway 
552 
55 
28.9% 
7.0% 
n/a n/a n/a 9.5% 
5.0% 
Heliö 2003 Finland 271 15.5% 3.3% 0.6% 4.8% 6.7% 
Brant 2003 USA 275 39.3% n/a n/a n/a n/a 
Louis 2003 Belgium 163 45.5% n/a n/a n/a n/a 
Esters 2004 Belgium 570 46.3% 12.9% 6.0% 8.6% 20.6% 
Weiss 2004 Israel (Jewish 
population) 
144 37.5% 11% 6% 6% n/a 
Karban 2004 Israel Jewish 
population 
180 41.1% 5% 13.6% 5.8% 10.7% 
Smith 2004 Scotland 218 23.8% n/a n/a n/a n/a 
Büning 2004 Germany 250 35.6% 7.2% 4.2% 12.2% 15.5% 
Laghi 2005 Italy 239 33% 10% 4.6% 7.7% n/a 
Cruyssen 2005 Belgium 156 49.3% 15% 5.4% 8.7% 21.8% 
Crawford 2005 USA (South) 254 32% 9% 5% 8% 11% 
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1.3.6 IBD5 
A risk haplotype was identified in 2000 on chromosome 5; 5q31 (Rioux, Daly et al. 
2001) by a genome wide search in Canadian families with inflammatory bowel disease.  
A significant LOD score (3.9) was found when the cohort was stratified by early onset 
disease.  The locus identified spanned 18cM.  Using 256 family trios, high density 
mapping revealed a common haplotype spanning 250kb containing a cytokine gene 
cluster.  The causative gene was not identified. 
Association with the 5q31 haplotype and Crohn’s disease has been replicated in 
Caucasian (Armuzzi, Ahmad et al. 2003; Mirza, Fisher et al. 2003; Negoro, McGovern 
et al. 2003; Noble, Nimmo et al. 2005; Török, Glas et al. 2005; Latiano, Palmieri et al. 
2006), but not Japanese populations (Negoro, McGovern et al. 2003; Yamazaki, 
Takazoe et al. 2004; Tosa, Negoro et al. 2006).  Carriage of 5q31 seems to be 
associated with early age of onset (Rioux, Daly et al. 2001; Mirza, Fisher et al. 2003; 
Török, Glas et al. 2005; Onnie, Fisher et al. 2008).  There are a number of reports of 
association with perianal disease (Armuzzi, Ahmad et al. 2003; Vermeire, Pierik et al. 
2005; Onnie, Fisher et al. 2008) and one study associated carriage of the 5q31 
haplotype with a reduced need for surgery (Török, Glas et al. 2005). 
Attempts have been made to identify the causative mutation within the haplotype.  
Mutations in the SLC22A4 gene and SLC22A5 promoter region have been suggested 
to be causative (Peltekova, Wintle et al. 2004).  This gene encodes for an organic 
cation transporter.  Association with SNPS within SLC22A4/5 have not been 
consistent with some studies showing no association with SNPs within SLC22A4/5 
independent of the 5q31 haplotype (Noble, Nimmo et al. 2005; Vermeire, Pierik et al. 
2005).   
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1.4 Smoking 
Smoking was suggested to play a role in the aetiology of inflammatory bowel disease 
in 1982 when a series of papers noted that non-smoking was a feature of ulcerative 
colitis (Harries, Baird et al. 1982; Benoni and Nilsson 1984; Logan, Edmond et al. 
1984).  In 1984 (Somerville, Logan et al. 1984) a series of 252 patients with 
inflammatory bowel disease were studied.  52% of patients with Crohn’s disease were 
smokers compared with 8% of patients with ulcerative colitis.  A meta-analysis in 1989 
established the relationship between smoking and an increased likelihood of Crohn’s 
disease (Calkins 1989).  There is thought to be up to a 4.1 matched relative risk of 
Crohn’s disease in smokers as compared with non-smokers (Tobin, Logan et al. 1987).  
There appears to be a dose response to number of cigarettes smoked and risk of 
developing Crohn’s disease with those smoking over 20 cigarettes a day at greatest 
risk, odds ratio 2.8 compared with 1.2 for smoking less than 10 per day (Lindberg, 
Tysk et al. 1988; Calkins 1989; Corrao, Tragnone et al. 1998).  Smoking is associated 
with a worse clinical course and more frequent relapses, including re-operation 
(Cosnes, Carbonnel et al. 1999; Cosnes, Beaugerie et al. 2001; Ryan, Allan et al. 
2004), although the mechanism through which smoking exerts this effect is unknown.  
Cessation of smoking results in improvement of relapse rate to that of non-smokers 
(Cosnes, Beaugerie et al. 2001), Figure 5.  
Smoking has been associated with fistulising and stricturing Crohn’s disease (Louis, 
Michel et al. 2003; Picco and Bayless 2003) although this finding is not consistent 
(Smith, Arnott et al. 2004). Smoking has been found not to be associated with Crohn’s 
disease in Jewish patients in Israel (Reif, Lavy et al. 2000), however the effect of 
smoking on the clinical course of Crohn’s disease in this population is not known.  
A higher concordance 72% vs. 34% for smoking has been found in siblings with 
Crohn’s disease than in healthy siblings of people with Crohn’s disease, suggesting 
that smoking interacts with genetic predisposition for Crohn’s disease (Brignola, 
Belloli et al. 2000).  In siblings with both ulcerative colitis and Crohn’s disease the 
smokers tended to develop Crohn’s disease and the non-smokers ulcerative colitis 
(Bridger, Lee et al. 2002).  This provides further evidence that a genetic predisposition 
may be influenced by environmental factors such as smoking. 
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Figure 1 From (Cosnes, Beaugerie et al. 2001); Kaplan-Meier estimates of the risk of flare-up in 
the 3 groups.  The numbers above the curves indicate the numbers of patients at risk in each 
group at 18 and 36 months after inclusion, respectively.  P value refers to comparison between 
quitters and continuing smokers. 
The interaction between smoking and CARD15 (NOD2) genotype was investigated in a 
cohort of 275 patients with Crohn’s disease in a multicentre study in the USA (Brant, 
Picco et al. 2003)  43 patients classified as having inflammatory disease were excluded 
from this study as they had a disease duration of less than 8 years.  Age at diagnosis 
was not found to be significantly associated with CARD15 (NOD2) until adjustments 
for attained age at study entry were made.  Ileal disease and non-inflammatory 
behaviour, i.e. stricturing and fistulising disease were found to be associated with two 
CARD15 (NOD2) mutations.  It was found by logistic regression with ileal disease as a 
constant that CARD15 (NOD2) mutations increased the risk of stricturing or fistulising 
disease with an odds ratio of 1.88 for each mutant allele.  Ileal disease was associated 
with shortest time to first surgical resection, as was smoking and age at diagnosis.  
Carriage of two mutant CARD15 (NOD2) alleles was not associated with shorter time 
to first surgery.  It is not stated in this study how many patients had surgery for ileal 
disease (217 had any ileal disease) and nor the number of these who carried one or 
more CARD15 (NOD2) mutations.  Stricturing and fistulising disease were considered 
together as complications of disease.  Smoking was found to be a risk factor for ileal 
disease independent of CARD15 (NOD2) genotype.   
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Several other risk factors in the development of Crohn’s disease have been studied 
including oral contraceptive use, appendectomy, antibiotic usage and various markers 
for childhood hygiene (Corrao, Tragnone et al. 1998; Sicilia, Miguel et al. 2001; Card, 
Logan et al. 2004) 
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1.5 Human antimicrobial mechanisms 
The gastrointestinal tract contributes one of the largest proportions of the human 
immune system.  Immune mechanisms can be divided crudely into the innate and 
adaptive immune systems.  The innate immune system comprises mechanical, 
chemical and cellular mechanisms to maintain generic protection against pathogens 
prior to the generation of specific immune response.  The adaptive immune system is 
mediated by both T and B cells.  The immune response is directed to specific antigens 
with differentiated lymphocytes and antibody response.  There is necessity for 
mechanism to differentiate self from commensal and pathogenic organisms.   
There is a mechanical barrier to pathogens in the gastrointestinal tract in the form of 
the mucus layer and the epithelial cell layer with tight junctions between.  So called 
pattern recognition receptors (PRR) within the epithelial cell barrier and lamina propria 
recognise pathogen associated molecular patterns (PAMP) present in the majority of 
microorganisms, but not in the mammalian host, with the resultant triggering of 
signalling pathways to eliminate microbial pathogens.  The signalling cascade may 
result in the secretion of antimicrobial peptides from Paneth cells including lysozyme, 
sPLA2 and the human defensins as well as the process of autophagy.  PAMP include 
lipopolysaccharide, present in the cell wall of gram negative bacteria, and muramyl 
dipeptide (MDP), the minimal bacterial cell wall motif.  PRR include the toll-like 
receptors (TLR) and nucleotide-binding oligomerization domain (NOD) proteins.  TLR 
comprise a family of extracellular receptors for a number of unique microbial antigens.  
NOD proteins are intracellular.  In the gastrointestinal tract NOD1 (CARD4) and 
CARD15 (NOD2) are receptors for bacterial petidoglycan.  CARD15 (NOD2) is 
expressed in Paneth cells and is a receptor for MDP.  A further microbicidal method of 
killing is that employed by neutrophils by the generation of hydrogen peroxide.   
Paneth cells can be found in small numbers in the normal right colon, but are only 
found in the transverse and left colon in inflammatory bowel disease.  They can be 
found in the stomach only with intestinal metaplasia, not in the normal stomach (Day, 
Jass et al. 2003).  Paneth cells do not proliferate (Troughton and Trier 1969) but are 
derived from undifferentiated stem cells of the crypt, they normally migrate 
downwards to the base of the crypt (Cheng 1974; Mathan, Hughes et al. 1987).  
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Human Paneth cells have secretory eosinophillic granules containing antimicrobial 
products, that include defensins (Jones and Bevins 1992; Jones and Bevins 1993). 
Defensins were first identified from purified rabbit granulocytes (Selsted, Szklarek et 
al. 1984; Selsted, Brown et al. 1985).  Similarly structured peptides were then 
identified from human neutrophils and named human defensins (Ganz, Selsted et al. 
1985).  Defensins are small molecules with a molecular weight of <3500 containing 
29-35 amino acid residues.  There is a highly conserved nucleotide region at the 5’ end 
of defensin genes (Jones and Bevins 1992; Jones and Bevins 1993).  Defensins 1-3 
extracted from human neutrophils, and have been found in vitro to be bactericidal 
against Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli; 
fungicidal to  Cryptococcus neoformans, and have antiviral activity against herpes 
simplex virus (Ganz, Selsted et al. 1985), by selectively disrupting membranes (Kagan, 
Ganz et al. 1994).  In the Ganz et al study 1985, by immunogold transmission electron 
microscopy, the defensins 1-3 were shown to be localized to azurophil granules in 
human neutrophils.  A 4th neutrophil defensin has been characterized (Wilde, Griffith 
et al. 1989). 
1.5.1 Intestinal defensins 
Defensins have been localised to epithelial cells in the mouse small intestine 
(Ouellette, Greco et al. 1989) and trachea (Diamond, Zasloff et al. 1991).  Jones and 
Bevins in 1992 (Jones and Bevins 1992) used Southern blot techniques and genomic 
clone analysis to investigate whether there were more than four defensin like genes in 
the human genome.  This is possible due to the presence of a highly conserved 
nucleotide sequence, between all species and tissues, in the defensin gene.  Numerous 
areas were found within the human genome containing the conserved defensin 
sequence.  A screen was then performed of tissue cDNA and genomic DNA using one 
of the new identified defensin gene probes using a PCR reaction and subsequent 
hybridization with a labelling probe.  This showed that the identified gene, defensin 5, 
was found in intestinal tissue cDNA.  The defensin gene was then sequenced fully.  
The cellular localization of the defensin 5 mRNA was then investigated by in situ 
hybridization.  This revealed the defensin 5 mRNA to be localised to Paneth cells of 
the small intestine.  A second Paneth cell defensin, defensin 6, was identified in 1991 
(Jones and Bevins 1993).  Screening of cDNA from human intestine has not revealed 
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any further defensins (Mallow, Harris et al. 1996), this is in direct contrast to other 
mammals, such as mice, where at least 16 defensins type peptides are found in the 
small intestine (Ouellette, Hsieh et al. 1994). 
Expression of defensin 5 and 6 mRNA coincides temporally with Paneth cell 
detectability in the human fetal intestine (Mallow, Harris et al. 1996).  Neonates have 
significantly less defensin activity than adults, premature neonates less than full term, 
possibly increasing vulnerability to gastrointestinal infections such as necrotising 
enterocolitis (Salzman, Polin et al. 1998).  However in cases of necrotising 
enterocolitis levels of HD-5 and HD-6 expression per Paneth cell are increased to three 
times that in controls (Salzman, Polin et al. 1998), this may be a function of reduced 
Paneth cell number.  Human defensin-5 is expressed at a ratio of approximately 4:1 to 
human defensin-6.  HD-5 is expressed in normal Paneth cells of the terminal ileum but 
is also seen in metaplastic Paneth cells found in inflammatory bowel disease in the 
colon (Cunliffe, Rose et al. 2001). 
The human defensin 5 and 6 genes are expressed in Paneth cells (Jones and Bevins 
1992; Jones and Bevins 1993).  Paneth cells store defensins as propeptides in large 
isoforms (Porter, Poles et al. 1998; Cunliffe, Rose et al. 2001).  Defensins undergo 
posttranslational processing during or after secretion (Cunliffe, Rose et al. 2001) by 
matrilysin, a metalloproteinase, to the biologically active form (Wilson, Ouellette et al. 
1999; Cunliffe, Rose et al. 2001).  This was shown in an investigation of mice α-
defensins in which it was found that matrilysin cleaved the pro segment from the 
precursor form in vitro.  By subsequently generating matrilysin deficient mice, it was 
shown that intestinal peptide preparations had reduced antimicrobial activity.  Bacterial 
preparations administered orally to the matrilysin deficient mice survived in greater 
numbers when compared to bacteria in wild-type mice.  The matrilysin deficient mice 
succumbed more rapidly and to lower numbers of the bacterium Salmonella 
typhimurium.  Subsequently it has been shown that HD-5 is processed by trypsin in 
Paneth cells (Ghosh, Porter et al. 2002).  It is possible to isolate defensins from urine 
obtained from surgically constructed bladders made from ileum (Porter, Poles et al. 
1998).  The defensin peptides isolated from the urine were shorter that those isolated 
from tissue.  Comparison of these isolates to recombinant defensins suggests that there 
is posttranslational processing of these propeptides to shorter microbicidal peptides 
(Porter, Poles et al. 1998).  Recombinant HD-5 has been found to be active in vitro 
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against a variety of organisms including Listeria monocytogenes, Escherichia coli, 
Salmonella typhimurium as well as against the yeast Candida albicans (Porter, van 
Dam et al. 1997).  Trypsin fails to inactivate this peptide, suggesting that HD-5 would 
remain biologically active in the lumen of the small intestine.   
Murine Paneth cells have been shown to secrete defensins in response to both whole 
bacteria and bacterial products (Ayabe, Satchell et al. 2000).  Intact crypts were 
isolated from mouse small intestine.  Cholinergic response of the crypt was 
maintained.  The crypts were then exposed to various stimuli.  It was found that Paneth 
cells degranulated and secreted their contents into the crypt lumen in response to whole 
bacteria Salmonella typhimurium, Escherichia coli and Staphylococcus aureus.  The 
secreted products had high microbicidal activity.  Secreted products from matrilysin 
deficient mice had significantly lower microbicidal activity than that of wild-type mice 
indicating that the majority of microbicidal activity was due to defensin activity.  The 
antimicrobial activity was significantly attenuated by direct antibody to the murine 
defensins.  A variety of bacterial antigens stimulated Paneth cell secretion including 
lipopolysaccharide, lipid A, lipoteichoic acid, liposomes of phospholipid and 
muramyldipeptide.  Fungal pathogens Candida albicans and Cryptococcus neoformans 
did not induce Paneth cell secretion of antimicrobial products.  This study indicates 
that Paneth cell are able to secrete antimicrobial products with sufficient microbicidal 
activity to maintain crypts of Lieberkühn sterile.  Paneth cells degranulation is 
modulated by a calcium-gated potassium channel that controls uptake of extracellular 
calcium (Ayabe, Wulff et al. 2002).  Inhibitors of this channel were found to block 
Paneth cell degranulation. 
Other defensins are found in human intestinal epithelial cells.  It has been predicted by 
analysis of the human genome that there would be 28 β-defensins (Schutte, Mitros et 
al. 2002) of which 8 have been identified.  Human β-defensins are expressed in 
epithelial cells (Lehrer and Ganz 2002).  Human β defensin-1 is expressed 
constitutively in human colonic cells whereas human β-defensin 2 expression is 
upregulated by pro-inflammatory cytokines in colonic cell lines (Wehkamp, 
Fellermann et al. 2002).  Human β-defensin was shown to be expressed in a greater 
proportion of biopsies from patients with inflammatory bowel disease and particularly 
biopsies from ulcerative colitis, than in biopsies from controls.  Expression of human 
β-defensin 3 was found to be increased in biopsies from patients with ulcerative colitis 
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(Wehkamp, Harder et al. 2003).  Expression of human β-defensin 2 and 3 were found 
not to be increased in this study in biopsies from patients with Crohn’s disease 
suggesting a possible defect in inducible defensin expression.  The expression of 
human β-defensin 3 and 4 in human small and large intestinal epithelial cells has been 
investigated (Fahlgren, Hammarstöm et al. 2004).  Human β-defensin 3 is expressed at 
higher levels than human β-defensin 4.  Expression was higher towards the base of 
crypts of Lieberkühn.  In agreement with the Wekamp 2003 study (Wehkamp, Harder 
et al. 2003), expression of human β-defensins 3 and 4 were increased in colonic 
epithelial cells from biopsies from patients with ulcerative colitis, with no increase in 
expression in biopsies from patients with Crohn’s disease compared to controls.  The 
expression in small intestinal epithelial cells was not investigated. 
It is thought that defensins exert their antimicrobial action by disruption of structural 
elements in the target cell membrane (Selsted and Ouellette 2005).  This is evidenced 
by the cationic nature of the peptides that bind electrostatically to negatively charged 
constituents of the microbe surface membrane and induce an increase in permeability 
that correlates with antimicrobial activity.  Interaction of defensins with antimicrobial 
membranes has been demonstrated with model membranes with human β-defensins 
and some animal defensins, but not with human α-defensin 5 and 6.   
1.5.2 Tumour necrosis factor alpha (TNF-α) 
TNF-α is a pro-inflammatory cytokine implicated in the pathogenesis of Crohn’s 
disease.  It has been suggested that TNF-α increases uptake of antigen in people with 
Crohn’s disease (Söderholm, Streutker et al. 2004).  This was demonstrated using 
horseradish peroxidise as the antigen in a chamber experiment on resected human ileal 
tissue.  When normal tissue was exposed to TNF-α uptake of horseradish peroxidise 
was increased.  This could therefore be a mechanism by which inflammation in 
Crohn’s disease is potentiated.  In a study of a cohort of children with Crohn’s disease, 
ulcerative colitis and normal controls, increased TNF-α was found in all intestinal 
biopsies of children with Crohn’s disease compared with those with normal intestine 
and a proportion of those with ulcerative colitis (MacDonald, Hutchings et al. 1990).  
Using antibody to TNF-α, TNF-α was found throughout the lamina propria and 
submucosa of the intestine and appeared to be localised in macrophages (Murch, 
Braegger et al. 1993).  The number of cells secreting TNF-α has been found to be 
50 
increased (Breese, Michie et al. 1994) in Crohn’s disease.  Increased levels of TNF-α 
were associated with mild inflammation, with significantly increased TNF-α found in 
biopsies from patients with Crohn’s disease compared with patients with ulcerative 
colitis and normal controls (Breese, Michie et al. 1994).  Investigation of TNF-α 
expression using isotopic in situ hybridization revealed TNF-α mRNA in Paneth cells 
of mice (Keshav, Lawson et al. 1990) and human (Tan, Hsueh et al. 1993).  TNF-α 
mRNA can be demonstrated in Paneth cells of normal small bowel biopsies (Tan, 
Hsueh et al. 1993), levels are then elevated in bowel from neonates with necrotising 
enterocolitis.  In these cases, TNF-α expression can be demonstrated in eosinophils and 
macrophages as well as in Paneth cells.   
Mouse-human chimeric antibody is an effective treatment in a proportion of people 
with Crohn’s disease (Hanauer, Feagan et al. 2002).  Anti-TNF-α antibody treatment is 
costly and not without significant side-effects.  A number of people with Crohn’s 
disease are non-responders to treatment.  There are no known factors that predict 
response to treatment. 
1.5.3 CARD15 (NOD2) and defensins 
Carriage of functional mutations in the CARD15 (NOD2) gene, located on 
chromosome 16, have been well established to be associated with an increase 
susceptibility to Crohn’s disease (Hugot, Chamaillard et al. 2001; Ogura, Bonen et al. 
2001), and particularly ileal Crohn’s disease (Ahmad, Armuzzi et al. 2002; Cuthbert, 
Fisher et al. 2002).  Using monoclonal antibody to CARD15 (NOD2) it has been 
demonstrated that Paneth cells of the terminal ileum in patients with Crohn’s disease, 
ulcerative colitis and normal controls express CARD15 (NOD2) (Ogura, Lala et al. 
2003).  In this study CARD15 (NOD2) was also found in metaplastic Paneth cells of 
the colon in patients with inflammatory bowel disease.  On microscopy, CARD15 
(NOD2) was located in the cytosol in close proximity to the granules of Paneth cells.  
Minimal CARD15 (NOD2) was located in the villous epithelium.  By further 
investigation using in situ hybridization CARD15 (NOD2) mRNA was found in Paneth 
cells of normal controls and in patients with Crohn’s disease (Lala, Ogura et al. 2003).  
CARD15 (NOD2) mRNA was localised in the same investigation to monocytes, but not 
macrophages or in granulomas.  CARD15 (NOD2) is found in the cytosol of Paneth 
cells not in the secretory granules (Ogura, Bonen et al. 2001; Lala, Ogura et al. 2003).  
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An investigation using paediatric colonic tissue and CARD15 (NOD2) antibody 
however demonstrated expression in macrophages and epitheliod giant cells within 
granulomas (Berrebi, Maudinas et al. 2003).  This group found CARD15 (NOD2) in 
epithelial cells in severely inflamed Crohn’s disease resection sections.  On close 
inspection the cells could be said to look like Paneth cells.   
In an investigation using biopsies from human ileum it was shown that biopsies taken 
from inflamed areas of ileum in patients with Crohn’s disease had less α-defensins than 
in biopsies from normal and unaffected ileum by real-time PCR (Wehkamp, Harder et 
al. 2004).  It has recently been suggested that the expression of human defensins 5 and 
6 (Wehkamp, Salzman et al. 2005) are reduced in ileal Crohn’s disease and particularly 
in those with CARD15 (NOD2) mutations (Wehkamp, Harder et al. 2004).  However a 
more recently published investigation has not replicated these findings and suggests 
that the reduced α-defensins found in Crohn’s disease is an artefact of inflammation 
rather than a primary process (Simms, Doecke et al. 2008). 
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1.6 Histological features of Crohn’s disease 
The histological features of Crohn’s disease are varied.  The characteristic features of 
Crohn’s disease are considered to be skip lesions and focal ulceration with transmural 
inflammation, lymphoid aggregates and granulomas (Day, Jass et al. 2003).  Pyloric 
metaplasia is a well recognised feature of Crohn’s disease (Koukoulis, Ke et al. 2002; 
Day, Jass et al. 2003).   
Paneth cells were first described as granular cells found at the base of crypts of 
Lieberkühn in the epithelial cell layer of the small intestine by Joseph Paneth in 1888 
(Paneth 1888) Figure 2.  They are thought to  develop from stem cells mid-way up the 
crypt and migrate to the crypt base (Troughton and Trier 1969).  Paneth cells express 
genes for a number of antibacterial products, including lysozyme (Chung, Keshav et al. 
1988), secretory phospholipase A2 (Keshav, McKnight et al. 1997), and the α-defensins 
human defensin 5 (Jones and Bevins 1992) and human defensin 6 (Jones and Bevins 
1993).  They have been found to secrete α-defensins in response to bacteria in crypts 
(Ayabe, Ashida et al. 2004).  CARD15 (NOD2) has been found to be expressed in 
Paneth cells (Lala, Ogura et al. 2003; Ogura, Lala et al. 2003).  The product of 
CARD15 (NOD2) is involved in bacterial sensing and NF-κB response (Bonen, Ogura 
et al. 2003; Kobayashi, Chamaillard et al. 2005; Maeda, Hsu et al. 2005).  Results from 
real-time polymerase chain reaction (PCR) experiments have suggested that α-defensin 
secretion alters with CARD15 (NOD2) genotypes (Wehkamp, Harder et al. 2004).  
Normal small intestine crypts contain three to five Paneth cells (Rubio and Nesi 2003).  
The number and distribution of Paneth cells has been found to be increased in murine 
small intestine with infection by Trichinella spiralis (Kamal, Wakelin et al. 2001).  
The distribution has been suggested to be abnormal in CARD15 (NOD2) homozygotes 
(Abeya, Bromfield et al. 2005).  In humans Paneth cell numbers have been shown to be 
increased in patients with Crohn’s disease (Kelly, Feakins et al. 2004) and further 
increased in patients with two CARD15 (NOD2) mutations (Abeya, Bromfield et al. 
2005). 
Paneth cell deficient mice can be generated by the introduction of cell-type specific 
genes that code for cytotoxic gene products (Garabedian, Roberts et al. 1997).  When 
the cell lineage of interest differentiates it is therefore ablated by the cytotoxic gene 
product.  In the mouse there seems to be little effect, however, there have been a 
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number of case reports of patients with absent goblet cells, enteroendocrine and Paneth 
cells.  Interestingly, the description in humans is of severe diarrhoea with enterocolitis 
(Moore, Xu et al. 1995; Shaoul, Hong et al. 2005). 
Pyloric metaplasia also known as glands of the “ulcer associated cell lineage” (UACL) 
can be identified without difficulty on haematoxylin and eosin stained sections, Figure 
3.  Pyloric metaplasia is a recognised histopathological feature of Crohn’s disease first 
described by A. F Liber in 1942 (Liber 1951).  Pyloric metaplasia is not specific to 
Crohn’s disease but occurs in around 78% of patients with Crohn’s disease (Lee 1964).  
It is found much more commonly and extensively in Crohn’s disease than other 
diseases.  Little is known about the factors that affect the presence and amount of 
pyloric metaplasia in different patients.  UACL glands have been found to be 
associated with increased submucosal neomuscularisation (Borley, Mortensen et al. 
2001). Pyloric metaplasia is thought to be part of the regeneration process in the 
mucosa, however, in a study of cell proliferation the glandular cells were negative for 
the cell proliferation marker Ki-67 (Noffsinger, Unger et al. 1998).  In this 1998 study 
the glandular buds appeared to arise from the overlying crypts.  The cells express a 
number of growth factors including epidermal growth factor (Wright, Poulsom et al. 
1990) and trefoil peptides (Longmann, Douthwaite et al. 2000).  It has been suggested 
that the presence of pyloric metaplasia in terminal ileal biopsies is associated with the 
diagnosis of Crohn’s disease (Koukoulis, Ke et al. 2002). 
 
 
Figure 2 (a) Schematic of Paneth cells, shaded, situated at the base of crypts of Lieberkühn.  B 
Haematoxylin and eosin staining of human small intestine highlighting the eosinophillic granules 
within Paneth cells (arrow). 
a b 
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Lymphoid aggregates are commonly found throughout the bowel wall in Crohn’s 
disease.  They form the characteristic “Crohn’s Rosary” when distributed along the 
outside of the smooth muscle coat of the bowel wall (Morson Colour Atlas of 
Gastrointestinal Pathology).  They can be defined as “pathological lymphoid cell 
clusters visible as distinct aggregates” (Borley, Mortensen et al. 2000).  The number of 
lymphoid aggregates has been found to correlate with the degree of fat wrapping found 
macroscopically in Crohn’s disease.  Fat wrapping correlates directly with stricture 
formation.  CARD15 (NOD2) genotype is associated with stricturing disease (Abreu, 
Taylor et al. 2002; Hampe, Grebe et al. 2002; Lesage, Zouali et al. 2002; Brant, Picco 
et al. 2003).    As CARD15 (NOD2) mutations result in defective bacterial sensing it 
was postulated that the number of lymphoid aggregates would be different between 
genotypes. 
 
Figure 3 Pyloric metaplasia on Haematoxylin and eosin staining of human small intestine 
(arrows).   
Granulomas are considered pathognomonic of Crohn, Figure 4.  They are found in 30 
to 70% (Shaoul, Karban et al. 2004), (Chambers and Morson 1979; Anseline, 
Wlodarczyk et al. 1997) of patients with Crohn’s disease, most commonly in the large 
bowel and rectum (Chambers and Morson 1979) and are more common in children 
than adults (Schmitz-Moormann and Schäg 1990).  There is conflicting evidence of an 
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association with the CARD15 (NOD2) genotype.  No association was found by Pierik 
et at in 161 surgical Crohn specimens (Pierik, de Hertogh et al. 2005) or by Shaoul et 
al in 230 specimens (Shaoul, Karban et al. 2004), although this was a mix of biopsy 
and surgical tissue.  Heresbach et al did however find a significant correlation between 
CARD15 (NOD2) genotype, particularly carriage of the R702W allele, and presence of 
granulomas (Heresbach, Alexandre et al. 2005) as did Lesage and Onnie (Lesage 2002, 
(Onnie, Fisher et al. 2008).  CARD15 (NOD2) has been found to be expressed in 
monocytes at the periphery of granulomas (Lala, Ogura et al. 2003) and found to be 
diffusely expressed in granulomas by another group (Berrebi, Maudinas et al. 2003).  
There is a variable association between granulomas and surgical recurrence (Wolfson, 
Sachar et al. 1982; Anseline, Wlodarczyk et al. 1997). 
 
Figure 4 Haematoxylin and eosin stained section of human small bowel showing (a) giant cell (x20) 
and (b) epitheloid granuloma (x5) (arrows) 
 
 
 
 
 
 
 
 
 
a b 
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1.7 Complications 
1.7.1 Short bowel syndrome 
Short bowel syndrome carries a significant morbidity and mortality (Schalamon, Mayr 
et al. 2003).  There is no accurate data on the incidence of short bowel syndrome in 
Crohn’s disease.  The prevalence of short bowel syndrome overall has been estimated 
to be 2-5 per million (Koffeman, van Gemert et al. 2003`).  Crohn’s disease is a 
common cause of short bowel syndrome due to multiple surgeries or development of 
fistula.  Up to 60% of some cohorts with short bowel have been attributed to Crohn’s 
disease (Nightingale, Lennard-Jones et al. 1992).  
1.7.2 Osteoporosis 
Osteoporosis is an important cause of morbidity in patients with Crohn’s disease with a 
fracture prevalence of up to 22% in those who are osteoporotic (Klaus, Armbrecht et 
al. 2002) and an overall increase in low energy fracture rate compared to the general 
population (Vestergaard, Krogh et al. 2000).  As the majority of osteoporotic fractures 
are asymptomatic at the time of fracture (Klaus, Armbrecht et al. 2002), low bone 
mineral density (BMD) provides a useful marker for risk of later symptomatic fracture 
(van Staa, Cooper et al. 2003).  Osteoporosis is more common in people with Crohn’s 
disease than those with ulcerative colitis (Marshall, Johnell et al. 1996). 
The pathogenesis of the reduced BMD found in people with Crohn’s disease is multi-
factorial.  Various risk factors have been identified for reduced BMD including low 
body mass index (Jahnsen, Falch et al. 2004; Siffiledeen, Fedorak et al. 2004; Taylor, 
Schreiner et al. 2004), disease duration (Schulte, Dignass et al. 1998), age (Robinson, 
al-Azzawi et al. 1998) and smoking (Pollak, Karmeli et al. 1998).  In addition several 
genes have been implicated in the pathogenesis of osteoporosis in other at risk 
populations.  Twin studies indicate that 60-80% of BMD may be genetically 
determined (Andreassen, Hylander et al. 1999). 
Finding a genotype that is a marker for those at risk of lower BMD could enable 
targeted therapy before osteoporosis develops.  Twin studies have linked 
polymorphisms of the vitamin D receptor (VDR) gene and BMD in healthy women 
(Silvennoinen, Lehtola et al. 1996),  although these findings have not always been 
reproducible (Ralston 2003).  A meta-analysis of 16 studies suggest a weak effect for 
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VDR polymorphisms (Spector, Keen et al. 1995).  The vitamin D receptor is an 
important regulator of calcium metabolism and bone cell function.  In addition VDR 
polymorphisms have been found to influence calcium absorption from the intestine 
(Hustmyer, Peacock et al. 1994).  VDR polymorphisms have also been implicated in 
susceptibility to Crohn’s disease (Cooper and Umbach 1996). 
The pro-inflammatory cytokine interleukin-6 (IL6) has also been implicated in the 
pathogenesis of osteoporosis.  IL6 influences osteoclast function and stimulates bone 
resorption (Dawson-Hughes, Harris et al. 1995).  Studies have found a link between 
polymorphisms in the IL6 gene and BMD in otherwise healthy women (Simmons, 
Mullighan et al. 2000) and in people with inflammatory bowel disease (Manolagas 
1995). 
Collagen type 1α1 gene (COL1A1) mutations are responsible for the condition 
osteogenesis imperfecta (Murray, McGuigan et al. 1997).  Less dramatically, 
polymorphisms in this gene have been found to influence BMD in previous studies in 
the healthy population (Willing, Pruchno et al. 1992; Schulte, Dignass et al. 2000).  
Polymorphisms in the COL1A1 gene have been found to alter bone strength by altering 
binding affinity for the transcription factor Sp1 (Uitterlinden A G, Burger H et al. 
1998).  To date there are no published studies of the effect of COL1A1 on BMD in 
inflammatory bowel disease.   
Polymorphisms in the CARD15 (NOD2) gene on chromosome 16 have been identified 
as susceptibility markers for Crohn’s disease (Hugot, Chamaillard et al. 2001) and are 
known to be associated with ileal disease rather than purely colonic disease (Cuthbert, 
Fisher et al. 2002). 
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1.8 Surgery and recurrence after surgery 
Crohn’s disease is characterised by its relapsing-remitting disease course leading to 
intermittent abdominal pain, diarrhoea and malabsorption.  Relapses are unpredictable 
with variable frequency between patients.  There are few reliable predictors of relapse 
but smoking habit is well recognised as worsening disease the disease course and 
increasing the frequency of relapses (Cosnes, Carbonnel et al. 1999; Cosnes, Beaugerie 
et al. 2001; Picco and Bayless 2003; Ryan, Allan et al. 2004), see 1.4.  Requirement for 
surgery is common with over 50% of patients with Crohn’s disease undergoing surgery 
at some point in their disease course (Forbes 1997).  People with terminal ileal Crohn’s 
disease more often require surgery than those with disease in other locations (Bernell, 
Lapidus et al. 2000; Louis, Michel et al. 2003; Smith, Arnott et al. 2004), with a 
relative risk for surgery of 3.2 compared to patients with purely colonic Crohn’s 
disease (Bernell, Lapidus et al. 2000).  Requirement for multiple surgeries has 
implications in terms of cost, morbidity and mortality and the development of short 
bowel syndrome with the potential to require long term parenteral nutrition.  The risk 
of reoperation following ileocaecal resection has been found to be up to 89% after 15 
years, with a clinical recurrence rate of 94% (Greenstein, Sachar et al. 1975).  In a 
cohort of 1424 patients with Crohn’s disease in Sweden, 74% had had at least one 
surgical operation (Bernell, Lapidus et al. 2000).  In ileocaecal Crohn’s disease 83% of 
patients have had surgery 10 years from diagnosis (Bernell, Lapidus et al. 2000).  The 
cumulative reoperation rate is high with up to 89% reoperative rates in some studies 
(Greenstein, Sachar et al. 1975).  Surgery has implications for patient and health 
service in terms of associated morbidity and health related costs.   
Smoking increases recurrence rates (Cosnes, Carbonnel et al. 1999) and smokers are 
more likely to have reoperations than non-smokers (Ryan, Allan et al. 2004).  It would 
be important to be able to predict those people in whom re-operation is likely in order 
to target interventions and more aggressive medical therapies to those at greatest risk.   
In a study of age at operation (De Dombal, Burton et al. 1971) 168 patients with 30 
year follow-up, 79 with small bowel disease were investigated.  There was a very high 
perioperative mortality, with 9 of 182 dying in the immediate post-operative period. 
This study found a ~34% crude reoperation rate, however duration of disease and 
follow-up time introduces bias, with younger patients there is inevitably a longer 
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follow-up and therefore more chance of further operation.  The conclusion was that 
small bowel disease is more likely to recur post surgery.  No difference was found 
between urgent or emergency operation vs. elective surgery.  It was found that the 
extent of disease at operation and location of disease was predictive of recurrence.  
Small bowel disease was more likely to recur with 60% requiring re-operation. A 
biphasic pattern of recurrence was described with peaks at 1-2 years or 5-15 years. 
Younger age at diagnosis has been found to be a risk factor for surgery (Bernell, 
Lapidus et al. 2000).  Perianal disease and long segment resection in this study of 907 
patients were risk factors for recurrence.  Surgery for ‘palpable mass or abscess’ had a 
lower risk for recurrence.  There was no effect seen for gender, age at diagnosis or 
presence of granulomas in this study.  Clinical recurrence rates of 94% are seen after 
surgery for Crohn’s disease (Greenstein, Sachar et al. 1975).  Endoscopic recurrence is 
seen in 73% of patients after only 1 year and 85% of patients at 3 years (Rutgeerts, 
Geboes et al. 1990). 
Factors other than smoking have been suggested to influence the rate of relapse in 
patients with Crohn’s disease.  In a study of 541 people with Crohn’s disease from one 
referral centre in the Netherlands it was found that female patients have second surgery 
for Crohn’s disease within a shorter time than male patients (Wagtmans, Verspaget et 
al. 2001).  Ileocaecal resections were also performed more frequently in female 
patients with Crohn’s disease.  Women have been found to have a slightly increased 
risk of recurrence post resection than men (Bernell, Lapidus et al. 2000).  The more 
surgery a patient has, the more likely they are to relapse (Rutgeerts, Geboes et al. 
1990).  This may well be an indication of more severe and aggressive disease.    
In a recent cohort study of 207 patients with ileocaecal resections for Crohn’s disease 
in Rome, early surgery was found to be associated with shorter time to clinical 
recurrence, as defined by symptomatic plus endoscopic or radiological recurrence 
(Aratari, Papi et al. 2007).  However, early surgery, that is surgery at the time of 
diagnosis, was not found to be associated with longer surgical remission.  No 
difference has been previously reported for early age at diagnosis and risk of 
recurrence (Bernell, Lapidus et al. 2000). 
CARD15 (NOD2) has been shown to be associated with terminal ileal Crohn’s disease 
(Ahmad, Armuzzi et al. 2002), stricturing (Abreu, Taylor et al. 2002) and fistulising 
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disease (Brant, Picco et al. 2003). CARD15 (NOD2) is associated with terminal ileal 
Crohn’s disease (Cuthbert, Fisher et al. 2002).  A number of studies have shown that 
carriage of one or more mutations in the CARD15 (NOD2) gene is associated with 
more severe disease i.e. more frequent recurrence and fistulising and stenotic disease 
(Abreu, Taylor et al. 2002; Hampe, Grebe et al. 2002; Radlmayr, Török et al. 2002; 
Brant, Picco et al. 2003; Helio, Halme et al. 2003; Büning, Genschel et al. 2004; 
Alvarez-Lobos, Arostegui et al. 2005).  It is therefore hypothesized that carriage of one 
or mutations in the CARD15 (NOD2) gene will be associated with more frequent re-
operations and less time to re-operation than those people with wild-type CARD15 
(NOD2).  See section 1.3.5.  Mutations within the 5q31 haplotype; SLC22A4 and 
SLC22A5 have been associated with reduced need for surgery (Török, Glas et al. 
2005). 
A number of people present acutely with severe disease.  These people often have 
surgery within one year of diagnosis.  It would be useful to know whether this cohort 
of people with Crohn’s disease are likely to require multiple surgeries and therefore 
may benefit from early immunosuppressive therapy.   
Although not an intervention study, a proportion of people have received 
immunosuppressive therapy with thiopurines such as azathioprine and 6-
mercaptopurine.  The association between use of these drugs and reoperative rate was 
investigated.   
Diversion of the faecal stream post terminal ileal resection prevents recurrent disease 
(Rutgeerts, Peeters et al. 1991) suggesting that microbial and environmental factors 
play a large role in the development of recurrent disease.  Infusion of ileal fluid has 
been found to precipitate an inflammatory response in people with Crohn’s disease 
(D'Haens, Geobes et al. 1998).  The diversity of intestinal microflora (Eckburg, Bik et 
al. 2005) has been implicated.  Recurrence has been prevented with nutritional therapy 
(Esaki, Matsumoto et al. 2005), however the long term use of enteral nutritional 
therapy is limited by understandably limited patient compliance. 
It has been suggested that Crohn’s disease recurs at the anastomosis due to residual 
disease at the resection margin, however, a number of studies have confirmed that 
residual disease after resection does not influence recurrence (Rutgeerts, Geboes et al. 
1984; Kotanagi, Kramer et al. 1994).  It has been suggested that the type of surgery, 
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e.g. stricturoplasty vs. resection influences the time to relapse.  No difference has been 
found between the type of surgery and recurrence of Crohn’s disease (Poggioli, 
Pierangeli et al. 2002).  In a retrospective study of 100 patients with first resection for 
Crohn’s disease, increased anastomotic recurrence rate was investigated in relation to 
evidence of microscopic disease at resection margins (Kotanagi, Kramer et al. 1994).  
No association between disease at the resection margin and anastomotic recurrence 
was found.   
1.8.1 Definitions of recurrence 
The definition of relapse post resection in Crohn’s disease is variable.  Relapse can be 
defined clinically, endoscopically, radiologically, surgically and histologically.  
Clinical relapse can be defined as the return of obstructive symptoms of: nausea, 
vomiting, colicky abdominal pain, abdominal distension and constipation.  Up to 70% 
of patients with have endoscopic recurrence within 6 months to 1 year of resection 
(Rutgeerts, Geboes et al. 1990; Bourreille, Jarry et al. 2006).  However 80% may 
remain asymptomatic despite evidence of endoscopic recurrence (Rutgeerts, Geboes et 
al. 1990).  Not many centres routinely endoscope patients who are asymptomatic after 
resection.   
The availability of endoscopic investigation has increased greatly in the last 20 years.  
A 72% endoscopic recurrence at 1 year has been found post surgery (Rutgeerts, 
Geboes et al. 1984).  In a more recent study of endoscopic recurrence, 73% had 
endoscopic recurrence at 3 months, 93% at 1 year and 100% at 3 years, whereas 
symptomatic recurrence was 33% at 3 months, 37% at 1 year and 86% at 3 years 
(Olaison, Smedh et al. 1992) raising the question of the relevance of endoscopic 
recurrence. 
The definition of recurrence varies between studies.  It may be based on symptoms and 
clinical findings, radiological investigation and endoscopic findings or a combination.  
Clinical practice and referral rates for surgery vary between clinicians.  This study 
inevitably includes patients from different clinicians.  This could be considered a 
confounding factor.  However, in a longitudinal review of the literature over the last 40 
years, disease outcome and recurrence rates have not changed (Wolters, Russel et al. 
2004).   
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In a study of a cohort of 907 patients with ileocaecal Crohn’s disease is Sweden it was 
found that the overall resection rate was 83% at 10 years with a recurrence rate of 36% 
at 10 years after first surgery (Bernell, Lapidus et al. 2000).  Recurrence was defined as 
symptoms consistent with “and later verified as, recurrent Crohn’s disease”.  It is not 
clear what methods were used to verify recurrent disease.  43% were said to have a 
symptomatic recurrence at a median of 6.8 years.  A history of perianal disease, and a 
long segment resection (>50cm) increased the risk of relapse.  There was no 
association with gender, age at diagnosis, duration of disease, type of resection or 
presence of granuloma with increased recurrence.   
Radiological recurrence can be considered when there is evidence of anastomotic 
stricture on barium studies or anastomotic inflammation on white cell scan.  However 
radiological investigations involve a not insignificant radiation dose therefore they tend 
to be done only after clinical evidence of recurrent disease and therefore will provide a 
bias towards longer time to relapse. 
Rates of surgery over time have not changed with the increasing use of 
immunosuppressants (Cosnes, Nion-Larmurier et al. 2005), reiterating the need for 
parameters that may predict recurrence. 
1.8.2 Disease definitions 
It appears that misdiagnosis is common in studies of Crohn’s disease.  By its nature it 
can be difficult to diagnose clinically.  There is therefore the potential for errors 
(Silverberg, Daly et al. 2001) and misdiagnosis with the inclusion of people without 
proven Crohn’s disease.  In order to minimize the chances of these errors 
histopathological confirmation of diagnosis on surgical resection specimens was 
required in this investigation for confirmation of a diagnosis of Crohn’s disease.  This 
therefore provides a robust definition of the recurrence of Crohn’s disease.  The 
symptoms of clinical recurrence are non-specific and not always due to active Crohn’s 
disease, for example, surgical adhesions may cause obstruction.  To be consistent in 
the definition of relapse and to have a reproducible definition of relapse, second ileal 
resection was taken as the definition of relapse in this investigation.  It has been said 
that the most relevant clinical outcome after intestinal resection for Crohn’s disease is 
the requirement for second surgery (Penner, Madsen et al. 2005).  Many factors have 
been postulated to effect recurrence of Crohn’s disease after surgery. 
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In 2000 there was a large retrospective cohort study of 1424 patients with at least one 
intestinal resection in Stockholm county, Sweden, (Bernell, Lapidus et al. 2000).  
Recurrence was taken to be the first presentation with symptoms after surgery that was 
verified by a diagnostic procedure, or required treatment.  All surgery for Crohn’s 
disease was investigated, rather than dividing by location.  Female sex, ileocolonic 
disease and perianal fistulae were found to be significant predictors of further surgery.  
In a further study by the same group of 907 with primary ileocaecal Crohn’s disease, 
taken from the same cohort of patients with Crohn’s disease, only presence of perianal 
disease and a long initial segment of resection were found to be predictors of relapse 
(Bernell, Lapidus et al. 2000).   
 
 
 
 
2 Chapter 2 Terminal ileal resections and Crohn’s disease 
2.1 Introduction and aims 
The aim of this study was to investigate survival to second operation in terminal ileal 
Crohn’s disease.  The effect of environmental factors including smoking and exposure 
to thiopurines was investigated.  In particular the effect of CARD15(NOD2) genotype 
and carriage of the 5q31 haplotype was studied.   
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2.2 Patients and methods 
Patients were identified from clinical coding databases using the codes for ilectomy, 
right hemicolectomy and Crohn’s disease in order to identify those who had undergone 
small bowel resection for Crohn’s disease.  Patients were also identified during routine 
clinic visits.  Consent for a venous blood sample for DNA extraction was obtained.  
Patients were also asked for consent to return to small bowel specimens held in the 
hospital archives.  A smoking and family history were taken.  Follow-up was defined 
as date of last clinic attendance.  Local region ethics committee (LREC) approval was 
sought and granted in 2002.  Consent forms and information sheets can be found in the 
appendix. 
Data was collected from the hospital notes onto standardised forms.  10ml venous 
blood was obtained from each patient into commercial plastic tubes containing EDTA 
using standard precautions.  Blood samples were then labelled with a unique code and 
frozen at –20°C until DNA extraction.  Blood samples were kept frozen while 
transported to the Genetics Department, Guys, Kings and St. Thomas’ School of 
Medicine, London.  
2.2.1 DNA Extraction 
10ml of blood was defrosted, rolled constantly and placed on ice.  Blood was then 
decanted into a clearly labelled 50ml falcon tube and made up to 45ml with lysis 
buffer.  The falcon was inverted to mix for 1 minute.  The lysed blood was then 
centrifuged using a desk-top centrifuge for 20 minutes at 3000rpm at 4°C.  The 
supernatant was then poured off.  The excess was then removed using a plastic Pasteur 
pipette ensuring the visible white cell pellet was not disturbed.  4.5ml 1X SET was 
then added and the pellet broken up pipetting up and down.  250µl 10% SDS and 
100µl proteinase K were then added, briefly mixed and incubated at 37°C overnight. 
Once the suspension had cleared, if it was not clear after an overnight incubation, a 
further 100µl proteinase K was added and incubated for 2-3 hours at 37°C, made up to 
7.5ml with 1X SET.  2.5ml prewarmed saturated salt solution was then added.  An 
equal volume of 1:24 isoamylalcohol:chloroform solution was added and mixed by 
inversion for 1 minute.  This was then centrifuged for 20 minutes at 3000rpm at 4°C.  
The clear supernatant was then transferred using a Pasteur pipette to a clean clearly 
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labelled falcon taking care not to transfer any of the interface.  Two volumes of ice 
cold absolute ethanol was then added to precipitate the DNA.  For each sample two 
1.5ml eppendorfs were prepared; one with 1ml 70% ethanol, the second with 50-400µl 
(depending on the quantity of DNA precipitated) TE buffer.  The DNA precipitate was 
removed using an inoculating loop and washed in 70% ethanol, air dried then dissolved 
in TE buffer.  The DNA was then incubated at 60°C for 1 hour to ensure homogeneity 
and then stored at 4°C. 
This was performed either in Newcastle or on arrival at Prof C G Mathew’s laboratory, 
Guy’s King’s and St. Thomas’ School of Medicine, London by myself or by a member 
of his team. 
2.2.2 Genotyping 
Samples were genotyped for the 3 common CARD15 (NOD2) SNPs and the 
IGR2063b_1 SNP of the 5q31 haplotype in Prof. C G Mathew laboratory, Guy’s, 
King’s and St. Thomas’ School of Medicine, London using published techniques 
(Cuthbert, Fisher et al. 2002). 
2.2.3 Analysis 
Results were analysed using SPSS software for Windows, version 12.  Chi squared, 
Kaplan-Meier survival analysis and one-way ANOVA were used.  Survival was 
measured in months to second operation.  Data was censored when follow up ceased: 
most recent clinic appointment/patient death before the second operation occurred.   
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2.3 Results 
2.3.1 Demographic details, Table 6 
346 patients with terminal ileal Crohn’s disease and ileal resection for Crohn’s disease 
were included.  Mean number of surgeries per patient was 1.8, median 1.  94 people 
had two operations, 64 people had three operations, 11 people had four resections, 5 
patients had five resections and one person had seven resections. 
 
2.3.2 Genotyping results; Table 7, Table 8 
282 patients with terminal ileal Crohn’s disease had complete genotyping for CARD15 
(NOD2).  250 wild type, 12 heterozygote for G908R genotype, 0 homozygote for 
G908R genotype, 1 heterozygote G908R/L1007fs, 3 heterozygote G908R/R702W, 19 
heterozygote L1007fs, 4 homozygote L1007fs, 4 heterozygote L1007fs/R702W, 43 
heterozygote R702W and 4 homozygote R702W. 
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Table 6 Demographic details 
346 (n)  
Gender m/f (346) 124/222 
Smoking (340) Never smoked 127 
Ex smoker 88 
Current smoker 125 
Family history y/n (329)  61/268 
Age A1 <40 271 
A2 >40 75 
Disease location (346) L1 Terminal ileum 148 
L2 Colon 0 
L3 Ileocolon 164 
L4 Upper GI 34 
Perianal Disease 71 
Disease behaviour B1 Inflammatory 24 
B2 Stricturing 206 
B3 Penetrating 116 
CARD15 (NOD2) 
genotype (286)  
Wild type 198 
Heterozygote 72 
Compound heterozygote/ 
homozygote 
16 
Age at diagnosis years mean [range] 31.1 [4.4-78.8] 
Age at first operation mean [range] 34.5 [7.0-80.6] 
One resection only 173 
2 or more resections 173 
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Table 7 CARD15 (NOD2) genotyping results; wild type =198, heterozygotes =72, 
homozygotes/compound heterozygotes (2 mutations) =16. 
CARD15 (NOD2) 
genotype (286) 
n= 
Wild type 198 
G908R 12 
G908R/G908R 0 
G908R/L1007fs 1 
G908R/R702W 3 
L1007fs 19 
L1007fs/L1007fs 4 
L1007fs/R702W 4 
R702W 43 
R702W/R702W 4 
 
Table 8 5q31 haplotype carriage results 
5q31 haplotype carriage 
(163) 
n= 
Wild type 44 
Heterozygote 80 
Homozygote 39 
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2.3.3 Cohort survival; Table 9, Figure 5 
For the entire cohort the mean time to second operation was 261 months (95% 
confidence interval 241-280 months).  Median time to second operation was 236 
months (95% CI 220 to 251 months), Figure 5. 
 
Figure 5 Kaplan Meier survival curve for cohort, n=347.  Time in months to second operation.  
Crosses represent censored data.  Dotted line represents 50% cumulative survival.  Mean survival 
225 months.  Median survival 135 months. 
 
2.3.4 Gender and time to second small bowel resection 
There was no difference seen in time to second small bowel resection between male 
and female patients. 
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Table 9 Summary of Kaplan Meier survival times.  Follow up months from first operation, 
defining event; second operation.  Significant difference *p=0.002, §p=0.001, ¦p=0.001, ∆p=0.000 
Factor n= Mean 
Estimate 
(months) 
95% Confidence 
interval 
Median 95% Confidence 
Interval 
Lower Upper Lower Upper 
Gender  Female 222 220 177 265 123 102 144 
Male 124 200 165 235 151 116 186 
Smoking Never 127 279* 208 350 203* 71 335 
Current 125 148* 116 179 113* 94 132 
Ex 88 193* 152 233 140* 69 211 
Current 
Smoking 
No 215 261§ 211 311 173§ 124 222 
Yes 125 148§ 116 179 113§ 94 132 
Age A1 (<40y) 271 229 191 268 135 107 163 
A2 (>40y) 75 151 104 198 126 74 178 
Disease 
behaviour 
Inflammatory  24 306¦ 259 353    
Stenotic 206 244¦ 198 290 139¦ 112 166 
Fistulising 116 159¦ 128 190 112¦ 89 135 
Surgery At diagnosis 88 231 172 290 139 89 189 
Post diagnosis 258 195 168 222 133 115 151 
Presentation 
to surgery 
Acute <12m 177 216 173 260 126 104 148 
Chronic >12m 169 199 162 237 140 99 181 
Thiopurine 
use 
None 176 242∆ 208 276 184∆ 118 250 
Current 85 141∆ 107 174 103∆ 76 130 
Previous 82 167∆ 112 221 113∆ 93 133 
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Table 10 Summary table of Kaplan-Meier survival times for CARD15 (NOD2) genotype and 5q31 
haplotype carriage.  Follow up months from first operation, defining event; second operation. 
Factor n= Mean 
Estimate 
(months) 
95% Confidence 
interval 
Median 
Estimate 
(months) 
95% Confidence 
Interval 
Lower Upper Lower Upper 
CARD15 
(NOD2) 
genotype 
Wild-type 198 177 149 205 123 105 141 
heterozygote 72 219 146 292 129 81 177 
2 mutations 16 208 135 280 203 150 256 
5q31 
haplotype 
Wild type 44 195 141 248 140 21 259 
Heterozygote 80 212 140 284 133 85 181 
Homozygote 39 228 157 299 158 58 258 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
2.3.5 Age at diagnosis and time to second small bowel resection 
There was no significant difference in time to second operation and age at diagnosis by 
the Vienna classification, Figure 6. 
 
Figure 6 Kaplan-Meier survival curve of Vienna age at diagnosis and time (months) to second 
operation.  There is no difference in time to second operation between groups.  A1=age at 
diagnosis <40 years, A2 =age at diagnosis >40 years.  Dotted lines represent 50% cumulative 
survival. 
2.3.6 Disease behaviour and time to second operation 
Inflammatory disease behaviour had significantly longer mean time to second 
operation than stricturing or fistulising disease behaviour, p=0.001, this group was too 
small to derive median survival.  There was no significant difference in time to second 
operation and stricturing or fistulising disease behaviour. 
 
 
 
74 
2.3.7 Smoking and time to second small bowel resection, Table 11. 
Smoking reduced time to second small bowel resection.  Patients who had never 
smoked had an estimated median time to second operation of 203 months (16.9 years) 
compared to 113 months (9.4 years) in current smokers and 140 months (11.6 years) in 
ex-smokers, p=0.002.   
Smoking was significantly associated with second operation chi squared p=0.02, with 
58% of smokers having had 2 or more resections compared to 45% of non smokers. 
Table 11 Smoking behaviour at follow up and 2 or more resections, chi squared test for 
significance p=0.02. 
 Second_operation Total 
One resection 2 or more 
resections 
 
Smoking behaviour 
 
Non smoker 118 98 216 
Smoker 52 73 125 
Total 170 171 341 
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Figure 7 Kaplan-Meier survival curve for smoking and time to second operation.  Smoking 
significantly reduces time to second operation p=0.002.  Mean time to second operation from first 
operation; 279 months-never smoked, 193 months –ex-smokers, 148 months-current smokers.  
Median time to second operation from first operation: 203 months-never smoked, 140 months-ex-
smokers, 113 months-current smokers.  Dotted lines represent 50% cumulative survival. 
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2.3.8 Time to second operation and timing of the first resection 
There was no significant difference in time to second operation if surgery was 
performed at the time of diagnosis rather than later in the disease process Figure 8.  
There was no significant difference in time to second operation if first surgery was 
performed within 12 months of diagnosis, Figure 9. 
 
Figure 8 Kaplan-Meier survival curve of surgery at the time of diagnosis of Crohn’s disease and 
surgery later in diagnosis.  There is no significant difference in time to second operation.  
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Figure 9 Kaplan-Meier survival curve for operation within 12 months of diagnosis and time to 
second operation.  There is no significant difference in time to second operation.  Dotted line 
represents 50% cumulative survival. 
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2.3.9 Azathioprine and time to second small bowel resection 
Azathioprine use was significantly associated with shorter survival to second small 
bowel resection, p=0.000, Figure 10. 
 
Figure 10 Kaplan-Meier survival curve for thiopurine use and time to second operation, p=0.000.  
Thiopurine use was significantly associated with shorter time to second.  Mean time to second 
operation from first operation; 242 months-no thiopurine use, 167 months –previous thiopurine 
use, 141 months-current thiopurine use.  Median time to second operation from first operation: 
184 months-no thiopurine use, 113 months –previous thiopurine use, 103 months –current 
thiopurine use.  Dotted lines represent 50% cumulative survival. 
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2.3.10 CARD15 (NOD2) and time to second small bowel resection 
There was no difference in time to second small bowel resection between CARD15 
(NOD2) genotypes, Figure 11. 
 
Figure 11 Kaplan-Meier survival curve for CARD15 (NOD2) genotype and time to second 
operation.  There is no difference in survival. 
2.3.11 CARD15 (NOD2), smoking and time to second small bowel 
resection 
Smoking significantly reduced survival to second small bowel resection in all CARD15 
(NOD2) genotypes, p=0.011, Table 13.   
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Figure 12 Kaplan Meier survival curve for carriage of 5q31 haplotype and time to second 
operation (months).  There is no difference in survival. 
2.3.12 5q31 and time to second small bowel resection 
There was no difference in survival to second small bowel resection between carriage 
of 5q31 haplotypes, Figure 12. 
2.3.13 5q31, smoking and time to second small bowel resection 
Smoking reduced survival in wild-type, heterozygotes and homozygotes for 5q31 
haplotype, Table 14. 
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2.3.14 Decade of first operation and time to second small bowel 
resection 
There was no significant difference in decade of first operation and time to second 
small bowel resection p=0.065, Figure 13.  CARD15 (NOD2) genotypes were normally 
distributed in each decade of first operation, Figure 14. 
 
Figure 13 Kaplan-Meier survival curve of decade of first small bowel resection and time to second 
small bowel resection (month).  There is no significant difference in time to second small bowel 
resection over the decade of first small bowel resection.   
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Table 12 Summary table of Kaplan-Meier survival times for decade of first small bowel operation.  
Follow up months from first operation, defining event; second operation.  There is no significant 
difference in survival to second operation. 
Decade n= Mean 
Estimate 
(months) 
95% Confidence 
Interval  
Median 
Estimate 
(months) 
95% Confidence 
Interval 
Lower Upper Lower Upper 
1950 2 90.000 31.200 148.800 60.00   
1960 7 314.917 229.352 400.481 332.00 97.757 566.243 
1970 30 224.449 178.788 270.109 206.000 88.406 306.371 
1980 70 138.920 119.345 158.496 123.000 88.406 157.594 
1990 63 107/359 96.562 118.155 115.000 96.571 144.429 
2000 6 56.263 49.639 62.887    
 
 
Figure 14 Bar chart displaying CARD15 (NOD2) genotype distribution over the decade of first 
small bowel operation.  The genotypes are normally distributed. 
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Table 13 Smoking and CARD15 (NOD2) genotype, follow up time, defining event second 
operation.  Time to second operation, mean, median and 95% confidence intervals, *p=0.013. 
CARD15 
(NOD2) 
genotype 
Smoking n= Mean 
Estimate 
(months) 
95% Confidence 
Interval 
Median 
estimate 
(months) 
95% Confidence 
Interval 
Lower Upper Lower  Upper 
Wild-type Non smoker 118 196* 157 234 140* 95 185 
 Smoker 75 144* 104 184 104* 82 126 
Heterozygote Non smoker 46 250* 156 345 146* 58 234 
 Smoker 26 131* 147 292 129* 62 196 
2 mutations Non smoker 11 194 151 237 203 144 262 
 Smoker 5 208 37 135 221 44 398 
 
Table 14 Smoking and 5q31 haplotype carriage and time to second operation, follow-up, defining 
event second operation.  Mean, median and 95% confidence interval and time to second operation, 
*p=0.009. 
5q31 
haplotype 
Smoking 
status 
n= Mean 
Estimate 
months 
95% Confidence 
Interval 
Median 
Estimate 
months 
95% Confidence 
Interval 
Lower  Upper  Lower  Upper  
wild type Non smoker 23 173* 107 239 140* 53 227 
Smoker 20 219* 132 306 221* 39 403 
heterozygote Non smoker 50 269* 169 269 171* 104 238 
Smoker 29 105* 76 134 97* 74 120 
homozygote Non smoker 24 318* 224 412 332* 147 517 
Smoker 14 122* 74 170 117* 96 138 
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2.4 Discussion 
This is a large investigation of the time to second operation in people who have 
undergone terminal ileal resections for Crohn’s disease.  The influence of gender, age 
at diagnosis, time to first surgery, disease behaviour, smoking habit and azathioprine/6-
mercaptopurine use was investigated.  The influence of CARD15 (NOD2) genotype 
and 5q31 haplotype carriage on time to second operation in people with Crohn’s 
disease was explored, although the number of people carrying two CARD15 (NOD2) 
mutations was small.    Data was collected from case notes and by direct interview on 
age at diagnosis, age at first operation, age at second and subsequent operations, 
smoking behaviour and treatments for Crohn’s disease.  The relationship between 
modifiable variables and time to second operation was then investigated using Kaplan-
Meier survival curves.  Previous outcome studies have investigated the influence of 
CARD15 (NOD2) with in all Crohn’s disease and not investigated purely ileal Crohn’s 
disease. 
No difference was found in time to second operation when analysed by gender or age 
at diagnosis.  This study demonstrates that CARD15 (NOD2) genotype does not 
influence time to second operation in terminal ileal Crohn’s disease.  Carriage of the 
5q31 haplotype was not associated with shorter survival to second operation.  Smoking 
was associated with a significantly shorter time to second operation.  Thiopurine use 
was associated with a shorter time to second operation. 
The finding of no association between outcome and CARD15 (NOD2) genotype is in 
contrast to previous published studies that have shown that CARD15 (NOD2) genotype 
is associated with a shorter time to reoperation (Büning, Genschel et al. 2004).  The 
Büning study however was a much smaller study with only 41 patients with terminal 
ileal resection for Crohn’s disease; twelve of 29 CARD15 (NOD2) negative patients 
had a second operation and two of only 12 CARD15 (NOD2) positive patients had a 
second operation.  In a further study of 193 patients with ileal Crohn’s disease in Italy, 
187 of which had had at least one operation (Laghi, Costa et al. 2005), carriage of one 
or more CARD15 (NOD2) mutation was associated with shortened time to second 
operation.  They found no effect of smoking on survival to second operation in patients 
with CARD15 (NOD2) mutations, of which there were 34.  A German investigation by 
Seiderer (Seiderer, Schnitzler et al. 2006) found that carriage of the 1007fs mutation 
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was associated with surgery and an increased risk of restenosis, however this was a 
subgroup analysis of 19 patients. 
These studies showing a positive association of CARD15 (NOD2) with shorter time to 
second operation were small, low powered studies.  By taking an unselected cohort of 
patients with Crohn’s disease, there will be a bias of patients with ileal disease having 
CARD15 (NOD2) mutations.  These patients are also more likely to have surgery for 
Crohn’s disease.  Therefore there is bias towards a positive association with CARD15 
(NOD2).  By taking a cohort of patients all of whom have had resections for Crohn’s 
disease, this bias is reduced and the influence of CARD15 (NOD2) can be more 
accurately investigated.  
The effect of smoking on time to second operation in terminal ileal Crohn’s disease is 
not unexpected.  Smoking significantly reduces the median time to second operation in 
patients with resection for terminal ileal Crohn’s disease from 203 months in those 
who have never smoked to 113 months in those who are currently smoking.  Patients 
who were considered to be ex-smokers at follow-up also had a reduced median time to 
second operation of 140 months, however this is not significant and the survival of 
these patients to second operation closely matches that of non-smokers.  This further 
increases the evidence that it is current smoking habits that influence disease behaviour 
and that by stopping smoking patients can significantly improve their disease 
progression (Cosnes, Beaugerie et al. 2001).  The effect of smoking on time to second 
operation is maintained in all CARD15 (NOD2) genotypes. 
5q31, IBD5, is a haplotype with an established association with Crohn’s disease (Ma 
Y, Ohmen et al. 1999; Duerr, Barmada et al. 2000).  The 5q31 haplotype has been 
found to be associated with perianal Crohn’s disease (Armuzzi, Ahmad et al. 2003) 
although this is not consistent (Noble, Nimmo et al. 2005).  In this cohort of 374 
patients with Crohn’s disease, carriage of the 5q31 haplotype was found to be 
associated with progression of disease to a fistulising phenotype and was significantly 
associated with a need for surgery.  Therefore we investigated whether 5q31 haplotype 
carriage was a risk factor for reduced time to second operation in terminal ileal 
Crohn’s disease.  In our cohort of patients with terminal ileal Crohn’s disease, there 
was no significant effect found with carriage of 5q31 haplotype and time to second 
operation.  This may because this study does not have the power to detect a weak effect 
of this haplotype.  However that weak effect is unlikely to be of clinical significance.  
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Smoking reduced time to second operation in all patients, whether they carried one or 
two of the disease associated haplotypes. 
A study in 2007 of patients from two centres in Rome, a cohort of 635 patients 
revealed that people operated on at the time of diagnosis of Crohn’s disease had a 
longer surgical remission than people with more delayed surgery (Aratari, Papi et al. 
2007).  In contrast this investigation has shown the opposite effect.  Surgery either at 
diagnosis, or within 12 months of diagnosis was not associated in this cohort with a 
shorter time to second operation.  This may be related to different operative practices 
between different countries, requirement for early surgery may be a marker for more 
severe disease process in this cohort of patients, as this cohort was specifically chosen 
as all had had terminal ileal resection for Crohn’s disease. 
Thiopurine use has been shown to improve disease outcome in Crohn’s disease 
(Lémann, Mary et al. 2005).  The use of thiopurines in this cohort was associated with 
a shorter time to second operation.  One explanation for this is that thiopurine use tends 
to be reserved for those with more severe disease.  Its use in this context is therefore a 
surrogate marker for severity and or rapidity of disease progression. 
In a population based cohort study of 907 patients with ileocaecal Crohn’s disease a 
younger age at diagnosis was associated with a lower resection rate (Bernell, Lapidus 
et al. 2000).  In this investigation, no significant difference was found in between 
Vienna age at diagnosis and survival to second operation.   
Surgery for Crohn’s disease is more likely in patients with stricturing or 
fistulising/penetrating disease.  In this cohort only 24 patients were defined as having 
purely inflammatory disease.  These categories are rather clumsy.  Disease behaviour 
has been shown to change over the time course of the disease with 56 % of patients 
initially presenting with inflammatory disease eventually developing stricturing or 
fistulising complications (Louis, Collard et al. 2001).  As disease behaviour in this 
cohort was taken at a single time point, i.e. at the time of surgery, there will be bias 
towards stricturing and fistulising disease behaviour.  Fistulising behaviour was taken 
to be fistula seen on imaging before surgery, seen at the time of surgery or present in 
the resection specimen.  Stricturing behaviour was taken as being the presence of 
obstructive symptoms leading to surgery with the presence of stricturing disease on 
imaging or at the time of surgery in the absence of fistulising disease.  Most often 
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strictures and fistulae occur together in the same patient and it is rather artificial to 
divide the two.  
The strengths of this study are its large size, robust diagnostic criteria and length of 
follow-up data.  The study includes 346 people with terminal ileal resections for 
Crohn’s disease, all of whom have a robust histological diagnosis of Crohn’s disease.  
The mean length of follow up was 213 months, range 4 to 663 months.  The median 
survival to second operation was 135 months (95% confidence interval 113 to 157 
months).  Lennard-Jones stated that a “follow-up study excludes any diagnostic 
uncertainty as it concerns only patients with chronic regional ileitis who needed 
surgical treatment.  It therefore enables clear-cut, valuable data to be presented on the 
recurrence rate and mortality of Crohn’s disease” (Lennard-Jones and Stalder 1967).  
This investigation fulfills his suggestions. 
In conclusion, this investigation has confirmed the association with increased 
frequency of second operation in smokers with a significantly reduced time to second 
operation.  No significant difference in survival to second operation was found and age 
at diagnosis or timing of first surgery.  No association has been found in this cohort 
with shorter time to second operation and CARD15 (NOD2) genotype or carriage of 
5q31 haplotype.  This data and lack of association with CARD15 (NOD2) genotype can 
be considered to be robust due to the size and histological confirmation of diagnosis of 
Crohn’s disease. 
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3 Chapter 3 Paneth cells and defensins 
3.1 Introduction and aims 
This study investigated the expression of antimicrobial peptides in archival sections of 
terminal ileum from patients with terminal ileal Crohn’s disease and controls with 
colorectal cancer.  Expression of mRNA was detected using a non isotopic in situ 
hibridization technique and quantified using computed image analysis.  It was 
hypothesized that there would be no difference in expression of lysozyme or sPLA2 
mRNA between Crohn’s disease sections and controls.  It was hypothesized that there 
would be a reduction in expression of human defensin 5 and 6 mRNA in Crohn’s 
disease sections compared to control.  It was anticipated that there would be no 
difference between expression of lysozyme, sPLA2 and TNF-α mRNA and CARD15 
(NOD2) genotypes and that there would be a reduction in expression of human 
defensin 5 and 6 mRNA with the number of CARD15 (NOD2) mutations carried. 
There was expected to be increased TNF-α mRNA expression in Crohn’s disease 
sections compared to controls and that there would be no difference in TNF-α mRNA 
expression between CARD15 (NOD2) genotypes.  TNF-α mRNA expression and 
quantitation was used as a positive control for the technique. 
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3.1.1 In situ hybridization 
The technique of non radioactive in situ hybridization allows specific nucleic acid 
sequences to be detected in morphologically preserved tissue sections.  The cellular 
location of the labelled mRNA can be demonstrated with light microscopy.  Anti-sense 
RNA probes labelled with digoxigenin to the target mRNA are produced.  Antibody to 
digoxigenin in an immunohistochemical reaction enables staining of the labelled probe.  
The degree of staining can then be measured by densitometry by specific computer 
software.  The technique of in situ hybridization allows the measurement of staining 
density in specific cell types.   
Using densitometry the expression of mRNA in Paneth cells can be estimated and 
compared between Crohn’s disease sections and between CARD15 (NOD2) genotypes.  
This study investigated the expression of mRNA for antimicrobial peptides in Paneth 
cells by in situ hybridization.   
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3.2 Materials and methods 
Cases were identified from pathology databases at the Queen Elizabeth Hospital, 
Gateshead using the words Crohn’s disease, ileal and right hemicolectomy.  Cases 
were identified at the Freeman Hospital and Royal Victoria Infirmary, Newcastle upon 
Tyne by searching clinical coding databases using the words Crohn’s disease, 
ilectomy, right-hemicolectomy and hemicolectomy.  Cases notes were then reviewed 
to establish the diagnosis of Crohn’s disease and the details of operation.  Cases were 
included if Crohn’s disease in the terminal ileum was confirmed and resection of the 
terminal ileum had been performed.   
Controls were identified who had undergone right-hemicolectomy for caecal 
carcinoma and were only included if disease did not extend into the ileum.  The normal 
ileal sections were used as the control sections. 
Written informed consent was obtained from all participants.  The consent forms and 
information sheets can be found in the appendix. 
10ml venous blood was obtained from each patient into commercial plastic tubes 
containing EDTA using standard precautions.  Blood samples were then labelled with a 
unique code and frozen at –20°C until DNA extraction.  Blood samples were kept 
frozen while transported to the Genetics Department, Guys, Kings and St. Thomas’ 
School of Medicine, London.  
DNA was extracted using the salting out method, as previously described 2.2.1 above. 
Probes specific for lysozyme (LYZ), sPLA2, human defensin 5 (HD-5), human 
defensin 6 (HD-6) and TNF-α were generated in a bacterial culture.  Probes were 
purified.  Sections were incubated with probe then detected with anti-mouse antibody.  
This was then detected using anti-dig antibody and stained with peroxidase. 
3.2.1 Genotyping 
Samples were genotyped for the three common CARD15 (NOD2) SNPs (R702W, 
G908R and 3020insC) in Prof. C G Mathew laboratory, Guy’s, King’s and St. Thomas’ 
School of Medicine, London using published techniques (Cuthbert, Fisher et al. 2002). 
Groups of four were created with each genotype plus one control; i.e. wild-type, 
heterozygotes, homozygotes and normal section.  These groups were created by JCM 
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keeping CH blind to the genotype.  Paraffin blocks were obtained from each case from 
the hospital pathology library.  6 micron sections were cut onto poly-L-lyscine or 
APES prepared slides (VWR).   
3.2.2 Probe generation 
Table 15 Probe generation 
Replication of DNA and 
cloning and transfection done 
by SK, SL and CK. 
Construct 
(Parent vector/subcloned 
cDNA sequence) 
Probe length (base 
pairs) 
Restriction 
endonuclease 
RNA polymerase 
pGEM-LYZ  
(pGEM-3/lysozyme) 3605bp 
738 (corresponding to 
nucleotide positions 1 to 
738; NCBI accession 
number J03801) 
EcoRI 
HindIII 
Sp6 
T7 
pBS-PLA2 IIA 
(pBluescript II KS +/sPLA2 
IIA) 3363 bp 
402 corresponding to 
nucleotide positions 525 
to 927; NCBI accession 
number NM_000300) 
SstI 
HindIII 
HindIII 
T3 
T7 
T3 
pBS HD5 
(pBluescript II KS +/HD5) 
3204 bp 
204 (corresponding to 
nucleotide positions 94 
to 997; NCBI accession 
number BC069690) 
Pst I 
HindIII 
T3 
T7 
 
pBS HD6 
(pBluescript II KS +/HD6) 
3278 bp 
278 (corresponding to 
nucleotide positions 136 
to 413; NCBI accession 
number BC069728) 
Pst I 
HindIII 
T3 
T7 
3.2.3 Multiplication of DNA  
10ml selective starter cultures were inoculated from DH5α glycerol stocks.  These 
were then incubated overnight at 37º on a shaking platform in 50ml falcon tubes.   2ml 
were then added to 200ml selective LB medium into 500ml baffle flasks.  These were 
then incubated overnight at 37º on a shaking platform.  The DNA was then extracted 
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using QIAGEN 500 maxiprep kit with colour indicator.  Bacterial pellets were formed 
by centrifuging balanced tubes at room temperature for 15 minutes at 4000 rpm 
(Beckman Table Top centrifuge).  Pellets were then resuspended in 10ml by pipetting 
up and down to break up bacterial clumps in buffer P1 (RNase and colour indicator).  
This was then decanted into Oakridge 30ml centrifuge tubes.  Samples were then lysed 
using 10ml P2 lysis buffer by inversion of the tubes until the colour indicator turned 
blue, around 15 inversions until blue colour distributed evenly.  The tubes were then 
incubated at room temperature for 5 minutes.  10ml of pre-chilled to 4º buffer P3 was 
then added to neutralise and precipitate protein.  This turned the indicator clear and 
colourless.  Centrifuge tubes were inverted until all the blue colour had dispersed.  
Tubes were then centrifuged at 20000g for 30 minutes at 4º, tubes were balanced by 
the addition of H2O as necessary.  Supernatant was then decanted in to a second set of 
labelled Oakridge 30ml centrifuge tubes.  These were then centrifuged at 20000g for 
30 min at 4º to further clear particulate matter.   
10ml buffer QBT was then applied to labelled QIAGEN tips to equilibrate and allowed 
to drain freely into 50ml falcon tubes.  The supernatant from the Oakridge centrifuge 
tubes was then applied to the tips, care was taken that flow through did not build up 
and so the flow through was regularly discarded.  Tips were then washed with two lots 
of 30ml buffer Q.  Care was again taken not to let flow-through build up.   
DNA was then eluted off each tip into 30ml glass Corex centrifuge tubes using 15ml 
buffer QF.  DNA was precipitated by adding 10.5ml room temperature isopropanol to 
each Corex tube.  Solutions mixed by inversion.  Tubes were then centrifuged at 
15000rpm for 30 minutes at 4º.  The supernatant was decanted, opaque DNA pellet 
visible on side of Corex tube.  DNA was then washed with 5ml room temperature 70% 
ethanol.  Tubes were then centrifuged again at 15000rpm, 4º for 10 minutes.  
Supernatant was then decanted and the pellet air dried.  Then pellet was then 
resuspended in 400µL DEPC H2O.  DNA was then quantified by gel electrophoresis 
and UV spectrometry.   
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3.2.3.1 DNA estimation using UV spectrometry; 
10µL DNA diluted to 1mL in DEPC H2O, OD measured at 260 and 280nm.  The 
260/280 ratio was calculated to determine purity.  The DNA concentration was 
calculated;  
[DNA]µg/ml = OD260 x dilution factor x 50µg DNA/ml   
DNA was generated for lysozyme, secretory PLA2, human defensin 5 and human 
defensin 6.  SL provided TNF DNA 
DNA was then linearized in preparation for transcription using the following enzymes 
and buffers.  
Table 16 DNA linearization enzymes 
DNA Enzymes (Invitrogen) Buffer 
Lysozyme Eco RI 
HindIII 
React 3 
React 2 (double digest 
react 2) 
sPLA2 HindIII 
Sst I 
React 2 
React 2 
HD5 Pst I 
HindIII 
React 2 
React 2 
HD6 Pst I 
HindIII 
React 2 
React 2 
TNF Eco RI 
Ecl 
React 3 
It was aimed to linearize ≈8µL DNA each of LZM, PLA2, HD5 and HD6 in order to 
generate enough probe for the entire in situ experiment.   
 
 
94 
In a 50µL reaction volume the following quantities were used in 1.5mL labelled 
eppendorf; 
 DNA   3µL 
 10x buffer 5µL 
 Enzyme  4µL 
 DEPC H2O 38µL 
The digest was then incubated at 37° overnight.  Digest run on 1% agarose gel to check 
for linearization. 
Linearized DNA was then extracted using phenol precipitation method and stored as an 
ethanol precipitate at -20º; the volume of digest was made up to 100µL with DEPC 
H2O.  Then an equal volume i.e. 100µL of phenol:chloroform:IAA (25:24:1) was 
added.  This was mixed by vortexing, then spun at 13 000 rpm (16100g) for 5 minutes 
at room temperature.  The aqueous layer was then transferred to a fresh eppendorf 
containing 100µL chloroform.  This was again mixed by vortexing and spun at 13000 
rpm for 5 minutes at room temperature.  The aqueous layer was then aspirated to a 
fresh eppendorf, volume ≈100µL.  1:10 volume (10µL) 3M sodium acetate was then 
added and mixed by vortexing.  2x volume (250µL) 100% ethanol was then added and 
mixed by vortexing.  This mix was then stored at –20° overnight to precipitate (an 
alternate is to precipitate the DNA at –70° for 20minutes).  This was then mixed and 
spun at 14 000 rpm for 15 minutes at 4°.  An opaque pellet is formed on the outer edge 
of the eppendorf.  The supernatant was decanted and the excess pipetted off.  This was 
then washed with 2x volume (200µL) 70% ethanol, the pellet being dislodged off by 
vortexing.  The DNA was then spun again at 14 000 rpm for 15 minutes at 4°, a pellet 
forming at the outer edge of the eppendorf.  The supernatant was again discarded.  The 
pellet was centrifuged at 14 000 rpm for 1 minute at room temperature and the excess 
ethanol pipetted off.  The pellet was then air dried.  DNA was resuspended in 100µL 
DEPC H2O by gentle pipetting.   
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Table 17 RNA transcription enzymes 
Template Polymerase Probe 
PLA2 HindIII 
PLA2 Sst I 
T7 
T3 
Antisense 
Sense 
LZM HindIII 
LZM Eco RI 
T7 
T3 
Antisense 
Sense 
HD5 HindIII 
HD5 Pst I 
T7 
T3 
Antisense 
Sense 
HD6 HindII 
HD6 Pst I 
T7 
T3 
Antisense 
Sense 
TNF Ecl 
TNF Eco RI 
T7 
T3 
Antisense 
Sense 
3.2.4 Transcription 
RNA probes were generated by in vitro transcription using reagents from Roch RNA 
Labelling Kit (Roche 1175025).  The transcription reaction products for each probe 
were pooled in order to minimize variation in probe transcription reactions. 
In a 40µL reaction volume; 
    PLA2  LZM HD5 HD6 TNF 
DNA    29uL 3µL 3µL 5µL 7µL 
Nuclease free H2O  0 26µL 26µL 24µL 22µL 
10x dig mix  4µL 
10x buffer  4µL 
RNAse inhibitor 1µL 
RNA polymerase 2µL 
The reaction was then incubated at 37° for 1 hour 
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A further 1µL RNA polymerase added and the reaction was incubated for a further 1h 
at 37° giving a final volume of 41µL 
2µL was removed to run on 1.2% agarose gel, 2µL DNase I added to digest any 
remaining template.  4µL removed for quantification gel and dot blot. 
The reaction was then terminated by the addition of 0.2M EDTA (Sigma).  5µL 
10mg/mL tRNA (Roche 109495) was then added.  The total volume was then made up 
to 100µL by the addition of 56µL nuclease free water (Invitrogen 10977).  10µL 3M 
sodium acetate was then added with 250µL 100% ethanol to form a precipitate giving a 
total volume of 360µL.  This was then stored at –20°.  Care was taken throughout 
transcription reaction not to contaminate the experiment with RNase.  All equipment 
was either dedicated to RNA work or decontaminated by baking at 220° for 12 hours. 
 
 
Figure 15 Transcription gel left to right; (a) DNA ladder, TNF-α (x2), (b) DNA ladder, HD5 (x2), 
HD6 (x2), (c) DNA ladder, lysozyme (x4), sPLA2 (x4), HD5 (x4) 
2µL of the reaction was run on a 1.2% gel with a DNA ladder. The relative densities of 
the gel bands were then compared to estimate the quantity of RNA probe generated.   
1.2% gel 50ml TBE buffer (Invitrogen), 0.60g agarose (Sigma) run at 60mV for 45 
minutes 
 
 
 
 
 
 
a b c 
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3.2.4.1 Dot blot quantitation; Figure 16 
RNA was quantitated using immunological detection of nucleases.  A 10 x 12 cm 
section of membrane was cut and marked with sections.  A dilution series was set up 
using and inital control RNA at concentration of 100ng/mL.   
2µL of transcription RNA or control added to initial eppendorf and vortexed, 5µL then 
removed and added to 45µL and vortexed, 5µL removed and added to 45µL and 
vortexed and so on.  2µL of each dilution was then aliquoted on to the membrane 
starting with the most dilute solution on to the right of the membrane. 
The membrane was the briefly washed in washing buffer on a shaking platform in a 
clean tray.  The membrane was then incubated in 30mL blocking solution for 
20minutes.  4µL antibody (mouse anti-digoxigenin) was then added to 20mL blocking 
solution, the membrane was then incubated with the antibody solution for 20 minutes.  
The membrane was then washed twice for 10minutes with 50mL each time washing 
buffer.  The membrane was then equilibrated with 20mL Detection buffer.  10mL 
Colour substrate was then freshly prepared and the membrane was then kept static in 
the dark overnight.  The reaction was halted by washing in distilled H2O.   
The probe concentration was then estimated by comparison of dot density to control.   
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Figure 16 Dot blot quantitation of mRNA probes 
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3.2.5 In situ hybridization 
3.2.5.1 Groups 
Sections were run in groups matched for, but blinded to, genotype together with a 
normal control and positive jejunum control.  Each groups therefore comprised 
lysozyme; 4 sections (control, Crohn’s disease CARD15 (NOD2) wild-type, Crohn’s 
disease CARD15 (NOD2) heterozygote, Crohn’s disease CARD15 (NOD2) 
homozygote), PLA2, 4 sections (control, Crohn’s disease CARD15 (NOD2) wild-type, 
Crohn’s disease CARD15 (NOD2) heterozygote, Crohn’s disease CARD15 (NOD2) 
homozygote), HD6, 4 sections, (control, Crohn’s disease CARD15 (NOD2) wild-type, 
Crohn’s disease CARD15 (NOD2) heterozygote, Crohn’s disease CARD15 (NOD2) 
homozygote) and HD5, 5 sections, (jejunum control, control, Crohn’s disease CARD15 
(NOD2) wild-type, Crohn’s disease CARD15 (NOD2) heterozygote, Crohn’s disease 
CARD15 (NOD2) homozygote).  The density of staining could then be compared 
through each run to the jejunum control.  Care was taken throughout in situ not to 
contaminate experiment with RNase.   
3.2.5.2 In situ hybridization 
Sections were placed in Schiefendecker staining jars holding 100ml total volume.  
Sections were de-waxed in serial xylene (VWR) washes at room temperature on a 
shaking platform; 3 washes of 20 minutes each.  Then rehydrated in serial alcohols at 
room temperature on a shaking platform, 100% ethanol for 5 minutes, 95% ethanol for 
5 minutes, and 70% ethanol for 5 minutes.  The sections were then washed twice in 
DEPC H2O for 5 minutes.  Sections were then fixed using 4% paraformaldehyde in 
PBS prewarmed to 25° before use for 20 minutes on a shaking platform.  Sections were 
then washed twice in sterile PBS for 5 minutes at room temperature on a shaking 
platform. To improve probe penetration sections were then treated with 200mM HCl 
(1.72mL cHCl made up to 100mL with DEPC H2O) for 20 minutes at room 
temperature on a shaking platform.  Sections were then washed twice in DEPC H2O for 
5 minutes at room temperature.  Sections were then equilibrated with proteinase K 
buffer for 5 minutes at room temperature.  Sections were then digested for 17 minutes 
at 37° at 45rpm in a shaking water bath in proteinase K buffer with 40µg/mL 
proteinase K (Sigma-Aldrich P2308) (timing for proteinase K digestion optimised by 
experimentation with timings from 15 minutes to 25 minutes).  Sections were then 
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washed in proteinase K buffer for 5 minutes at room temperature on a shaking 
platform.  Sections were then washed twice in sterile PBS at room temperature on a 
shaking platform.  Sections were then dehydrated in serial alcohols; 20% ethanol for 5 
minutes, 40% ethanol for 5 minutes, 60% ethanol for 5 minutes, 80% ethanol for 5 
minutes and 100% ethanol for 5 minutes, each at room temperature on a shaking 
platform.   
Table 18 in situ protocols 
Transcription 
date 
Probe [probe] 
ng/µL 
ng of 
probe 
used 
Vol of 
ethanol 
precipitate 
70% 
ethanol 
to 
300µL 
Hybe 
mix/section 
(total) 
No 
slides 
Vol 
NF 
HsO 
for 
pellet 
17/11/05 LZM T7 1.4 840 40 260 150 (600) 4 24 
17/11/05 PLA2 T7 1.0 600 46 254 150 (600) 4 24 
17/11/05 HD5 T7 1.0 900 58 242 150 (750) 5 30 
17/11/05 HD6 T7 1.0 600 58 242 150 (600) 4 24 
24/1/06 TNF T3 0.8 320 136 164 60 (480) 8 20 
24/1/06 TNF T7 0.6 1280 560 440 60 (1920) 32 80 
 
Prepared hybe master mix was used in 180µL aliquots, enough for 1mL total mix, 
stored at –20° and thawed prior to use.  50% Dextran sulphate was heated to 65° and 
200µL/ml added to the mix and vortexed thoroughly.  500µL deionised formamide 
(Sigma-Aldrich F9037) was then added and vortexed.  The mix was then incubated on 
ice for 10 minutes and centrifuged at 13 000rpm, 4° for 10 minutes. The supernatant 
was the pipetted into clean eppendorfs.  RNA probes were used as follows for 1 run of 
17 sections, for the TNF in situ hybridization one run comprising all Crohn’s disease 
sections (32) plus HD5 jejunum control was done, Table 18. 
The RNA was extracted from the ethanol precipitate by the addition of a volume of 
70% ethanol to make a total volume of 300µL.  This was then centrifuged at 13 000 
rpm, 4° for 15 minutes.  The supernatant decanted and the pellet air dried.  The RNA 
was then resuspended in nuclease free H2O.  The probe was then heated to 80° for 5 
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minutes and snap cooled on ice.  The probe was then added to the hybe mix.  150µL 
hybe mix was then pipetted over each section.  The slides were then incubated in a 
humid container at 42° overnight. 
3.2.5.3 Post hybridization 
Sections were then placed in Schiefendecker staining jars.  Sections were washed twice 
in 2X SSC buffer at 37° for 15 minutes in a shaking water bath.  Sections were then 
placed in glass staining rack kept specifically for RNase washes and rinsed in NTE 
buffer then incubate in NTE buffer containing 20µg/mL RNase A (Sigma-Aldrich 
R4642) for 30 minutes at 37° in a shaking water platform.  Sections were then rinsed in 
NTE buffer.  Sections were then placed back into the Schiefendecker staining jar and 
rinsed twice with 0.2X SSC buffer at 37° for 30 minutes.   
3.2.5.4 Immunological detection 
Sections were washed in PBS for 10 minutes at room temperature.  Sections were then 
transferred to Sequenza coverslips and washed with PBS.  Sections were then blocked 
with PBS blocking solution for 30 minutes at room temperature.  Primary antibody was 
added; 1:250 dilution mouse anti-DIG antibody in PBS blocking solution was added to 
the sections and left to incubate for 90 minutes at room temperature.  Sections were 
then washed for 5 minutes with PBS.  Sections were then blocked with PBS blocking 
solution for 30 minutes at room temperature.  Secondary antibody was added; 1:200 
biotinylated anti-mouse antibody in 1.5% horse serum in PBS was added to the 
sections and incubated for 30 minutes at room temperature.  Sections were then 
washed for 5 minutes with PBS.  Sections were then blocked with PBS blocking 
solution for 30 minutes at room temperature.  ABC reagent was then added to sections 
and incubated for 30 minutes at room temperature.  Sections were then washed for 5 
minutes with PBS.  Sections were then removed from the Sequenza coverslips. 
200µL freshly prepared DAB-Peroxidase substrate solution was then pipetted over 
each section.  The reaction was monitored microscopically.  The reaction was then 
stopped by washing with distilled H2O.   
Sections were then counterstained for 10 seconds with haematoxylin and washed in 
running tap water.  Sections were then washed in 70% ethanol for 2 minutes then 
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100% ethanol for 2 minutes then in 3 xylene washes for 2 minutes.  Sections were 
mounted with DPX and dried overnight.  
3.2.5.5 Microscopy and photography 
All sections were imaged using Zeiss Axioskop 2 microscope with the following 
lenses; Plan-Neofluar 10x, 20x, 40x.  Images were captured using Zeiss Axiocam MRc 
0.63x 2/3”.  The standard image set up was; Axiocam MRc with Plan NeoFLUA 40x 
lens at point 5 on light source.   
3.2.5.6 Densitometry 
Images were processed using the Automatic measurement programme written using 
the programme writing wizard, programme named 191205.xml (Axiovision re1.4.4 
Axiovision automatic measurement programme generation. Software; Axiovision Rel. 
V4.4 Zeiss UK (06-2005) Sp1).  No changes were made to contrast, sigma, shading 
correction or delineation of objects.  Density is measured in arbitrary units as light 
transmission, therefore the lower the measurement unit the more intense the density of 
stain and therefore expression of mRNA. 
Colour phases were obtained interactively and the outline filled.  Objects were 
separated automatically.  Artefacts and background were deleted manually.  Each 
[icture was given an identity.  The area of density measured.  Maximum, minimum and 
mean density of fields measured in red, blue and green together with the overall mean 
for all of the image and for regions within the image.  Density was measured in amount 
of light transmitted, therefore the darker the picture the less light is transmitted. 
The picture was then saved with the regions measured outlined.   
Jejunum standard was measured twice for indication of consistency.  The background 
density was measure in a similar way using 2 interactive phases for DAB (brown-red) 
staining and haematoxylin (blue) staining.  Programme backgroundmeasurement.xml.  
All images were saved as .zvi (Zeiss format) and .tif files.  Data files saved as text –
comma separated files .csv and converted to Excel for import into SPSS.   
Results are demonstrated as crude density measurement and corrected to the jejunum 
standard.  Correction to the jejunum standard was performed to allow for between run 
variation in probe binding and digoxigenin staining.  
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All images were analysed blind to genotype. 
3.2.5.7 Analysis 
Analysis of mean density was by ANOVA using SPSS software. 
3.3 Results 
Lysozyme, sPLA2, human defensin 5 and human defensin 6 were all found within the 
secretory granules of Paneth cells, Figure 17 and Figure 19, TNF-α was found within 
Paneth cells, Figure 20.   
 
Figure 17 In situ hibridization with anti sense probes showing labelling of mRNA in Paneth cells, 
arrows, images of control (ileum) sections at x40.  (a) lysozyme (b) sPLA2 (c) human defensin 5 (d) 
human defensin 6 
a b 
c d 
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Figure 18 In situ hibridization using sense probes showing no mRNA labelling.  This is the 
negative control. Images at x40 (a) lysozyme (b) sPLA2 (c) human defensin 5 (d) human defensin 6  
10 in situ hybridization runs were performed for lysozyme, sPLA2, human defensin 5 
and human defensin 6.  A total of 40 sections were probed for lysozyme, sPLA2 and 
human defensin 6 and 50 sections for human defensin 5.  There were a total of 10 
jejunum standards.  Sections from paraffin blocks dating back to 1977 were used.  
Successful staining however was not achieved on the oldest 1977 sections for any of 
the probes used. 
a b 
c d 
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Figure 19 In situ hibridization images of jejunum controls showing labelling of mRNA in Paneth 
cells.  Probes: (a) lysozyme (b) sPLA2 (c) human defensin 5 (d) human defensin 6 
a b 
c d 
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Figure 20 In situ hibridization anti sense and sense probes for TNF-α (a) antisense TNF-T7 (b) 
sense TNF-T3 showing labelling of TNF-α in Paneth cells and macrophages with the antisense 
probe (arrow). 
3.3.1 Lysozyme densitometry 
There was no significant difference in mean density of lysozyme staining between 
CARD15 (NOD2) genotype groups.  There was no significant difference in the total 
lysozyme staining between CARD15 (NOD2) genotype groups.  There was no 
significant difference in the mean or total lysozyme staining between controls and 
sections from patients with Crohn’s disease, Figure 23, Figure 25.  This applied to 
crude analysis and correction of density to jejunum standard Figure 21 and Figure 22. 
3.3.2 sPLA2 densitometry 
There was no significant difference in mean density of sPLA2 staining between 
CARD15 (NOD2) genotype groups, Figure 21 and Figure 22.  There was no significant 
difference in the total sPLA2 staining between CARD15 (NOD2) genotype groups.  
There was no significant difference in the mean or total sPLA2 staining between 
controls and sections from patients with Crohn’s disease, Figure 23, although there was 
a trend to an increase in sPLA2 staining in the Crohn’s disease sections, Figure 25. 
a b 
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Error Bars show 95.0% Cl of Mean
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Figure 21 Mean density (arbitrary units) for RNA probes studied compared over CARD15 (NOD2) 
genotypes.  There was no difference in mean density between sections.  Density is uncorrected to 
the standard. 
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Figure 22 Mean density (arbitrary units) corrected to the HD-5 labelled jejunum standard 
compared between CARD15 (NOD2) genotype groups for the RNA probes studied.  There is no 
significant difference in mean density. 
3.3.3 Human defensin 5 densitometry 
Human defensin 5 was found in Paneth cells in all sections.  There was no significant 
difference in mean density of human defensin 5 staining between CARD15 (NOD2) 
genotype groups, Figure 21 and Figure 22.  There was no significant difference in the 
total human defensin 5 staining between CARD15 (NOD2) genotype groups, Figure 23.  
There was no significant difference in mean or total human defensin 5 staining 
between controls sections and sections from patients with Crohn’s disease, Figure 25.   
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Figure 23 Total density measured for each section for each RNA probe compared between 
CARD15 (NOD2) genotypes 
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Figure 24 Sum of density corrected to jejunum standard for each RNA probe compared between 
CARD15 (NOD2) genotypes 
3.3.4 Human defensin 6 densitometry 
Human defensin 6 was found to be expressed in Paneth cells in all sections.  There was 
no significant difference in mean density of human defensin 6 staining between 
CARD15 (NOD2) genotype groups, Figure 21.  There was no significant difference in 
mean density of human defensin 6 staining between CARD15 (NOD2) genotype 
groups, Figure 22.  There was no significant difference in the total human defensin 6 
staining between CARD15 (NOD2) genotype groups, Figure 23.  There was no 
significant difference in mean or total human defensin 6 staining between controls 
sections and sections from patients with Crohn’s disease, Figure 25.   
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Figure 25 mean density of each RNA probe compared between control sections and Crohn’s 
disease sections 
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Figure 26 Mean density of RNA probes corrected to jejunum standard between control sections 
and Crohn’s disease sections 
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Figure 27 Total density of RNA probes compared between control sections and Crohn’s disease 
sections 
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Figure 28 Total density corrected to jejunum standard compared between control sections and 
Crohn’s disease sections 
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Figure 29 Mean density (arbitrary units) of mRNA probe and age at operation.  There is no 
significant association between mRNA probe density and age at operation. 
 
 
 
 
 
 
 
 
 
 
 
116 
3.3.5 TNF-α densitometry  
There was significantly more TNF-α in the Crohn’s disease sections than the control 
sections as measured by mean densitometry p=<0.001, Figure 30.  There was no 
significant difference in mean density in CARD15 (NOD2) genotype groups, Figure 31.  
Three sections from patients with Crohn’s disease did not demonstrate TNF-α 
expression.  These sections had previously demonstrated positive in situ reaction to 
lysozyme, sPLA2 and human defensin 5 and 6. 
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Figure 30 Mean TNF-α density between control sections and Crohn’s disease sections.  There is a 
significant difference in expression of TNF-α in Crohn’s disease sections compared to controls, 
p=<0.001. 
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Figure 31 Mean density for each section for RNA probe for TNF-α.  There is reduced light 
transmission indicating increased TNF expression in Crohn’s disease sections. 
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3.4 Discussion 
In order to investigate a possible link between Paneth cells, CARD15 (NOD2) and 
Crohn’s disease in situ hybridization technique was used to estimate the relative 
quantity of mRNA for the antimicrobial peptides in Paneth cells of normal terminal 
ileum and that of patients with Crohn’s disease.  In addition the possible relationship to 
CARD15 (NOD2) genotype was investigated.  TNF-α is a proinflammatory cytokine 
that is found in Paneth cells (Keshav, Lawson et al. 1990). It is implicated in the 
pathogenesis of Crohn’s disease.  Treatment with anti-TNF antibody is known to be of 
benefit in Crohn’s disease.  
This investigation has confirmed that Paneth cell secretory granules contain mRNA for 
antimicrobial peptides; lysozyme, sPLA2 and human α-defensins 5 and 6.  TNF-α 
mRNA can be demonstrated in Paneth cells, although not in secretory granules.  This 
study aimed to further investigation the expression of lysozyme, sPLA2 and human 
defensins 5 and 6 mRNA in Paneth cells of paraffin imbedded sections of ileum taken 
at time of surgery for terminal ileal Crohn’s disease, the most normal ileum from each 
resected section was used in order to maximise architectural preservation.  The 
expression of TNF-α and important pro-inflammatory cytokine expressed in Paneth 
cells was also investigated.  The expression of mRNA can be detected archival 
material preserved in paraffin wax, however tissue of 30 years old does not have 
reliable detection.   
There was no difference in expression of lysozyme, sPLA2 and human defensin 5 and 
6 mRNA between control and Crohn’s disease sections as measured by computerized 
densitometry.  There is no difference in expression with age.  By this method no 
difference in human defensin 5 and 6 expression could be shown between CARD15 
(NOD2) genotypes.  No difference in mRNA expression of lysozyme, sPLA2 could be 
demonstrated between CARD15 (NOD2) genotypes.   
TNF-α mRNA expression was demonstrated in Paneth cells.  There was an increase in 
TNF-α expression in sections from patients with terminal ileal Crohn’s disease 
compared to controls.  No difference was seen between CARD15 (NOD2) genotypes.  
Of interest three sections from three different patients with terminal ileal Crohn’s 
disease Crohn’s disease did not express TNF-α.  This represents 10% of the total 
number of people with Crohn’s disease in this study. 
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It has previously been shown by quantitative real-time PCR techniques that expression 
of α-defensin is reduced in biopsies from human ileum with Crohn’s disease, and 
reduced still further in patients who carry two mutations in the CARD15 (NOD2) gene 
(Wehkamp, Harder et al. 2004; Wehkamp, Salzman et al. 2005).  A study published in 
2005 (Wehkamp, Harder et al. 2004; Wehkamp, Salzman et al. 2005) demonstrated a 
decrease in human defensin 5 and 6 expression between healthy controls and people 
with Crohn’s disease, and a further decrease was seen in people with two CARD15 
(NOD2) mutations.  A more recent investigation however has not confirmed these 
findings (Simms, Doecke et al. 2008).  Instead it suggests that the reduced human 
defensins found in the previous Wehkamp studies was a function of destruction of 
Paneth cell and therefore a reduction in cell products, as a result of inflammation rather 
than genotype effect.   
The increase in TNF-α gene expression in people with Crohn’s disease relative to 
controls is an expected finding and concurs with current literature.  This validates the 
technique used in this investigation.  It shows that densitometry can be used semi-
quantitatively to demonstrate a difference in mRNA expression in archival tissue 
sections. 
An advantage of this technique was that it enabled use of archival tissue and thereby 
increased the pool of available tissue from patients carrying CARD15 (NOD2) 
mutations.  All patients used in this study had confirmed Crohn’s disease.  As each 
section was examined by hand, areas with the least inflammation were identified and 
used for the in situ process.  This therefore reduces the confounder of inflammation 
and suggests any difference found would be potentially related to genotype rather than 
a function of inflammation and therefore Paneth cell number.  The sections were 
grouped therefore minimizing intra-experimental variation. 
In situ hybridization is a relatively insensitive method for detection of differential 
expression of mRNA, however it would be expected to demonstrate a significant 
deficiency in defensin expression that was suggested by the Wehkamp group.  The 
difference in results seen may be accounted for by the fact that the method of in situ 
hybridization is highlighting defensin mRNA expression within secretory granules and 
therefore may be a marker of propeptide formation.  Defensins undergo post-
translational processing on release from the secretory granules to the active peptide 
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form.  There may still be a defect in this process leading to a deficiency in functional 
peptide formation that would not be shown by this technique. 
There was an absence of TNF-α expression in a number of sections from people with 
Crohn’s disease.  This is warrants further investigation.  If a number of patients with 
Crohn’s disease do not have a TNF-α dependent pathway of inflammation, or have a 
reduced level of TNF-α expression this could potentially be used to predict who may 
respond to anti-TNF-α therapy. 
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4 Chapter 4 Histology phenotypes 
4.1 Introduction and aims 
We hypothesized that there would be different histological phenotypes associated with 
CARD15 (NOD2) mutations and smoking status.  We therefore investigated whether 
the number and distribution of Paneth cells is altered in CARD15 (NOD2) genotypes, 
whether the presence of pyloric metaplasia is associated with CARD15 (NOD2) 
genotype and whether there is an increased area of pyloric metaplasia in CARD15 
(NOD2) mutants.  We investigated the association between granulomas and CARD15 
(NOD2) and lymphoid aggregates and CARD15 (NOD2).   
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4.2 Materials and methods 
Cases were identified from clinical coding and pathology databases using the terms 
ilectomy, right-hemicolectomy, hemicolectomy and Crohn’s disease.  All were surgical 
cases, no biopsies were used.  Patients were also identified during routine clinic visits 
by review of clinical notes.  All patients had a confirmed diagnosis of Crohn’s disease 
according to standard clinical, radiological and histological methodology.  Controls 
were identified as recent cases at the routine Newcastle Hospitals Multidisciplinary 
meeting having had right hemicolectomy for colorectal cancer.  Patients were all 
resident of the Newcastle-Gateshead area.  Venous blood from patients with Crohn’s 
disease was obtained for genotyping.  All patients gave written informed consent to 
participate to return to small bowel specimens held in the hospital archives, for forms, 
see appendix.  Ethical approval was granted by Newcastle and South Tyneside research 
ethics committee and Gateshead Local research ethics committee. 
Genotyping was undertaken for the three main CARD15 (NOD2) SNPs (R702W, 
G908R, and 3020insC) by Prof. C G Mathew’s team at the Department of Genetics, 
Guy’s, King’s and St. Thomas’ School of Medicine, London, by published 
methodology (Cuthbert, Fisher et al. 2002). 
Sections were obtained from Queen Elizabeth Hospital, Gateshead and Newcastle 
Acute Hospital NHS trust encompassing the Royal Victoria Infirmary, Freeman 
Hospital and Newcastle General Hospital.  All specimens had been routinely processed 
in hospital pathology.  Archival haematoxylin and eosin sections were retrieved along 
with the paraffin embedded blocks where available.  Groups were matched for 
CARD15 (NOD2) genotype; 2 mutations, 1 mutation and wild-type.  In addition a 
cohort of control sections was used with healthy terminal ileum obtained at right 
hemicolectomy for colorectal cancer.   
Clinical characteristics were recorded on each patient from patient notes and direct 
interview; smoking history, age, gender, immunomodulatory drug usage, including 
azathioprine/6-mercaptopurine and infliximab, onset of symptoms and diagnosis and 
date of operation. 
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4.2.1 Scoring of histological features 
All sections were scored using an Olympus CH-2 microscope.  Each set of sections 
were evaluated for degree of inflammation based on the scoring system by Borley et al 
2000, see Table 19 (Borley, Mortensen et al. 2000). 
Table 19 Adapted from (Borley, Mortensen et al. 2000) histological scoring of inflammatory 
features in surgically resected specimens 
 
4.2.2 Paneth cell identification haematoxylin and eosin 
Paneth cells were identified by their autofluorescent granules with routine 
haematoxylin and eosin (Rubio and Nesi 2003) and the absolute number in each well 
oriented crypt counted (Kamal, Wakelin et al. 2001).  The height of the furthest Paneth 
cell from the base of the crypt was counted in epithelial cell nuclei in all well oriented 
crypts (Figure 32).  Paneth cells height was also measured in nm using Axiovision 
software.  Paneth cells were considered to have migrated if they were separated from 
the other Paneth cells at the base of the crypt by columnar epithelial cells. 
Score Lymphoid aggregate 
score 
Granuloma Score Inflammatory score 
0 None - Structural change only 
1 Mucosa No granuloma Chronic inflammation 
2 Submucosa Mucosal and/or 
submucosal granuloma 
Or >10 granuloma 
present 
Lamina propria 
neutrophils 
3 Muscularis propria Granuloma in all bowel 
layers with or without 
granuloma in 
mesenteric lymph 
nodes 
Crypt destruction 
4 Serosa or extramural 
fat 
- 
Erosions or ulcers 
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Figure 32 Schematic of Paneth cell height measurement.  Maximum Paneth cell height = 2. 
4.2.3 Lysozyme immunohistochemistry 
6 µm sections for immunohistochemistry were cut into poly-l-lyscine slides.  Sections 
were dewaxed by three 5 minute washes in xylene on a shaking platform.  Sections 
were then rehydrated in graded ethanol washes for 5 minutes each; 100% ethanol, 95% 
ethanol, 70% ethanol.  Sections were then washed twice in distilled water for 5 
minutes.  Endogenous peroxidase activity was blocked by washing in 3% hydrogen 
peroxide in methanol for 10 minutes.  This was neutralised by two 5 minute washes in 
dH2O followed by one 5 minute wash in PBS.  Sections were then loaded into 
Sequenza coverslips and washed with PBS for 5 minutes.   
Sections were blocked for 30 minutes in 3% bovine albumin and 20% goat serum in 
PBS.  Sections were then incubated for 90 minutes with 1 in 500 primary antibody 
rabbit antihuman lysozyme.  Sections were washed twice for 5 minutes in PBS.  
Sections were then incubated with secondary biotinylated antibody, 1 in 100 goat anti-
rabbit antibody in 3% bovine albumin, 1% goat serum.  Sections were washed twice 
for 5 minutes in PBS.  Sections were then incubated with ABC reagent for 30 minutes. 
Sections were washed for 5 minutes in PBS.  Sections were removed from the 
coverslips and dried.   
Sections were then covered with DAB-H2O2.  Development of the colour reaction was 
monitored and stopped by washing in dH2O.   
Sections were then counterstained with haematoxylin for 10 seconds washed in cold 
running water then washed in 30% ethanol for 1 minute, 70% ethanol for 1 minute and 
100% ethanol for 1 minute.  This was followed by three sequential xylene washes for 1 
minute and mounted using DPX. 
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4.2.4 Pyloric metaplasia 
Pyloric metaplasia was identified according to published morphology (Lee 1964; Day, 
Jass et al. 2003).  The total area of pyloric metaplasia was measured.  The areas were 
photographed using a Leica DMR photomicroscope and captured using a JVC camera 
and QWin software (Leica Microsystems, Heidelberg).  In order to correct for the 
differences in the size of each section on the section the surface area of each section 
was measured.  Each section was photographed using an Olympus E1 digital SLR 
camera using a macro lens and scale.  Images were resized and processed using Adobe 
Photoshop v7.0.  Leica Qwin was calibrated to the scales used and the images 
imported.  Then the areas of pyloric metaplasia and the total section area was 
calculated by manually outlining the areas within QWin. 
In order to attempt to replicate the initial results all available histopathology reports for 
patients who had undergone terminal ileal resection for Crohn’s disease were 
reviewed.  The presence, absence or no mention of pyloric metaplasia was recorded.  
An association with CARD15 (NOD2) genotype and ATG16L1 genotype was 
investigated. 
4.2.5 Lymphoid aggregates 
The number of lymphoid aggregates below the muscularis mucosa were counted for 
each ileal section.  Lymphoid aggregates were defined as pathological lymphoid cell 
clusters visible as distinct aggregates at 40x magnification (Borley, Mortensen et al. 
2000).  For areas of confluent lymphoid follicles each germinal centre was counted as 
one aggregate.  This count was then corrected for total section surface area therefore 
reducing bias for the variation in section number. 
4.2.6 Granulomas 
The number of epithelioid granulomas were counted in each ileal section.  Granulomas 
were defined as 5 or more epithelioid cells in close association visible at 100x 
magnification according to published morphology (Borley, Mortensen et al. 2000).  
This count was then corrected for total section surface area therefore reducing bias for 
the variation in section number. 
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Assessment of each patients’ sections was performed blind to genotype, smoking 
history and order of resection.  Sections were preferably from the first small bowel 
resection or initial right hemicolectomy, however the second resection was used where 
the first was unavailable.  Scores for each feature were then compared between first 
and second resection to ensure the validity of using the second resections.  Only one 
resection was included for each patient.  Scores were then compared with respect to 
CARD15 (NOD2) genotype and smoking using analysis of variance, t-test and chi-
squared.   
In order to confirm the initial findings all available histopathology reports were read 
and the presence or absence/no mention of granuloma was recorded.  This was then 
compared among CARD15 (NOD2) and ATG16L1 genotypes. 
4.3 Results 
4.3.1 Demographics 
Sections for full histological scoring were from 59 patients, 49 patients with Crohn’s 
disease and 10 controls.  Patient demographics are shown in Table 13. Genotyping 
results are shown in Table 20.  There was no difference in inflammatory scores 
between CARD15 (NOD2) genotypes.  A mean of 24 (5 to 62) well orientated crypts 
were counted per patient.  An additional 10 sections were included in the Paneth cell 
counting group. 33 patients had had one operation only, 15 patients had had two 
resections, 8 patients had had three resections and 2 patients had had four resections. 
Table 20 Demographic details 
Characteristics of Crohn’s 
disease Patients 
n=49 
Mean age at operation (range) 34.7 (14 to 66) years 
Gender (male/female) 15/34 
Smoking (Yes/no) 32/17 
Controls n=10 
Mean age at operation (range) 73 (53 to 81) years 
Gender (male/female) 4/6 
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Table 21 CARD15 (NOD2) genotype, one genotype R702W/Rare SNP.  26 wild-type, 19 
heterozygotes and 13 homozygotes/compound heterozygotes. 
 Wild- type R702W G908R L1007fs Total 
Wild type 26    26 
R702W 11 3 3 3 20 
G908R 5  0 1 6 
L1007fs 3   2 5 
4.3.2 First and second resections 
There was no significant difference in the mean Paneth cell count, mean Paneth cell 
height, and corrected pyloric metaplasia score and order of resection, Table 22, Figure 
34.  Pyloric metaplasia was significantly more likely to be present in the first resection 
than the second, Table 23.   
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Figure 33 Comparison between mean Paneth cell count and lysozyme and H&E staining 
identification.  (PCC=Paneth cell count, H&E=haematoxylin and eosin staining, Lyz=lysozyme 
immunohistochemistry) 
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Table 22 Comparison of assessment scores over successive resections 
 Mean (95% confidence interval) 
First resection Second resection 
Inflammatory score 0.6 (0.16 to 1.0) 0.6 (0.04 to 1.1) 
Corrected pyloric 
metaplasia score 
145.36 (18.08 to 272 
.65) 
495.43 (-485 to 
1476) 
Granuloma score 0.0022 (-0.0017 to 
0.0061) 
0.001 (-0.0002 to 
0.0022) 
Lymphoid aggregate 
score 
0.034 (0.019 to 
0.049) 
0.056 (0.019 to 
0.094) 
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Figure 34 Error bars showing 95% confidence intervals indicating no significant difference in 
Paneth cell count (top) and Paneth cell height (bottom) between successive resections.  (PCC= 
Paneth cell count, PCH=Paneth cell height, H&E= haematoxylin and eosin stain, Op_No= 
operation number) 
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Table 23 Comparison of features over successive resections.  *Significant difference 
 Resection number 
1 2 
Paneth cell migration Present 5 4 
Absent 2 3 
Pyloric metaplasia* Present 7 2 
Absent 0 5 
Granuloma Present 3 3 
Absent 4 4 
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4.3.3 Paneth cell counts 
More Paneth cells were counted when H&E (mean 6.3) was used to identify Paneth 
cells compared with lysozyme (mean 5.3), Figure 33. 
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Figure 35 Mean Paneth cell count compared between control and Crohn’s disease section.  H&E 
(a) p=0.014, lysozyme (b) p=0.1. (PCC= Paneth cell count) 
There were significantly more Paneth cells counted by H&E in Crohn’s disease 
sections compared to controls, Figure 35. 
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The controls were significantly older than the Crohn’s disease patients.  There was no 
significant correlation between age and Paneth cell count (mean) in the Crohn’s 
disease patients, Figure 36. 
 
Figure 36 Scatterplot with linear regression plot showing no significant association between  
Paneth cell count (mean) and age in Crohn’s disease, F 3.211, p=0.08. 
There was no significant association between age and Paneth cell count (mean) in 
controls, Figure 37. 
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Figure 37 Scatterplot with linear regression plot showing no significant association between age 
and Paneth cell count (mean) in controls, F2.021, p=0.193. 
There was no significant difference in mean Paneth cell count and CARD15 (NOD2) 
genotype, Figure 38, Table 24. 
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Mean Paneth cell (lysozyme) count and NOD2 genotype
Error Bars show 95.0% Cl of Mean
Control
wild-type
heterozygote
homozygote/compound heterozygote
NOD2
3.0
4.0
5.0
6.0
7.0
M
e
a
n
 
PC
C




(b) 
Figure 38 Mean Paneth cell count using H&E (a) and Lysozyme (b) identification and CARD15 
(NOD2) genotype.  There is no significant difference between genotypes.  (PCC=Paneth cell count) 
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Table 24 Summary of Paneth cell counts for Crohn’s disease and controls and CARD15 (NOD2) 
genotype. *p=0.014. H&E=haematoxylin and eosin staining, Lysozyme=lysozyme 
immunohistochemical identification of Paneth cells. 
  Mean Paneth cell count 
H&E (n=) Lysozyme (n=) 
 Control 4.9*(10) 4.4(6) 
 Crohn 6.5*(57) 5.5(33) 
CARD15 
(NOD2) 
genotype 
Wild-type 6.8 (26) 5.6 (6) 
Heterozygote 6.6 (18) 5.7 (13) 
Homozygote/Compound 
heterozygote 
5.9 (12) 5.3 (9) 
smoking 
status 
Ex 5.8 (13) 5.9 (10) 
Never 6.9 (21) 5.5 (13) 
Current 6.7 (22) 5.3 (10) 
 Male 6.6 (16) 6.1 (13) 
Female 6.5 (40) 5.2 (20) 
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4.3.4 Paneth cell height 
No significant difference was found in Paneth cell height when H&E was used to 
identify Paneth cells compared with lysozyme, Figure 39. 
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Figure 39 Comparison between Paneth cell height (cells) and H&E and lysozyme identification 
(PCH=Paneth cell height). 
Paneth cells were found significantly higher up the crypt by cell height in Crohn’s 
disease compared to controls, p=0.015, Figure 40. 
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Figure 40 Mean Paneth cell height between Crohn’s disease and control measured in cell height 
(a) H&E, (b) lysozyme and nanometres (c) (PCH=Paneth cell height) 
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There was no difference in Paneth cell height and CARD15 (NOD2) genotype, Figure 
41, summary Table 25. 
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(b) 
Figure 41 Mean Paneth cell height and CARD15 (NOD2) genotype (a) H&E staining, (b) lysozyme 
immunohistochemistry. 
4.3.5 Paneth cell migration 
There was no significant association between CARD15 (NOD2) genotype and Paneth 
cell migration.  No Paneth cell migration was seen in controls.  There was no 
significant association between smoking and Paneth cell migration. 
139 
Table 25 Summary of mean Paneth cell height. *p=0.015.  H&E=haematoxylin and eosin staining, 
Lysozyme=lysozyme immunohistochemical identification of Paneth cells. 
 Mean Paneth cell height (cells) 
 H&E (n=) Lysozyme(n=) 
 Control 4.3* (10) 4.9 (6) 
Crohn’s disease 7.8* (57) 7.3 (33) 
CARD15 
(NOD2) 
genotype 
Wild type 8.6 (10) 7.8 (13) 
Heterozygote 7.7 (26) 7.7 (9) 
Homozygote/Compound 
heterozygote 
6.7 (18) 6.2 (11) 
smoking 
status 
Ex 7.1 (13) 8.5 (10) 
No 7.2 (21) 5.9 (13) 
Current 9.2 (22) 7.7 (10) 
 male 7.6 (16) 7.8 (13) 
female 8.0 (40) 6.9 (20) 
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4.3.6 Pyloric metaplasia 
There was no significant difference in area of pyloric metaplasia between CARD15 
(NOD2) genotypes as measured by this technique, Figure 42.  A single small area of 
pyloric metaplasia was seen in one control.  In a pilot study, pyloric metaplasia was 
significantly more likely to be present in compound heterozygotes/homozygotes and 
heterozygotes than in wild type Crohn’s patients, Figure 43.  There was no significant 
difference in pyloric metaplasia between smokers and non smokers. 
Corrected pyloric metaplasia score
Error Bars  show 95.0% Cl of Mean
Control
Wild-type
heterozygote
com pound hete rozygote /hom ozygote
CARD15
-250 .00
0.00
250 .00
500 .00
750 .00
Co
r_
PM



 
Figure 42 There was no significant difference in the mean pyloric metaplasia score between 
CARD15 (NOD2) genotypes (Cor_PM= corrected pyloric metaplasia score). 
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Figure 43 Pyloric metaplasia was significantly more likely in CARD15 (NOD2) compound 
heterozygotes/homozygotes than wild type (p=0.024) Crohn’s patients.  Pyloric metaplasia was 
significantly more likely in CARD15 (NOD2) heterozygotes than wild type Crohn’s patients 
(p=0.024). 
In order to confirm the initial findings, pathology reports for the entire cohort of 
patients with terminal ileal resections were reviewed.  A total of 115 patients had 
reports and genotyping results available.  No difference in was seen among CARD15 
(NOD2) genotypes and the number of patient with pyloric metaplasia mentioned in the 
histopathology report, Figure 44  There was no difference when the number of patients 
who had ever had pyloric metaplasia was investigated.  No difference in was seen 
among ATG16L1 genotypes (n=42) and the number of patient with pyloric metaplasia 
mentioned in the histopathology report, Figure 45. 
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Figure 44 Bar chart to demonstrate the finding of pyloric metaplasia (PM) in Crohn’s disease 
sections as mentioned in the pathology report.  There is no significant difference in the presence of 
pyloric metaplasia and the number of NOD mutations. 
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Figure 45 There was no significant difference in ATG16L1 genotype and the presence, as 
mentioned in the histopathology report, of pyloric metaplasia in Crohn’s disease sections. 
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4.3.7 Lymphoid aggregates 
There was no significant difference in number of lymphoid aggregates and CARD15 
(NOD2) genotype.  No lymphoid aggregates were found in controls.  There was no 
significant difference in number of lymphoid aggregates between smokers and non 
smokers. 
4.3.8 Granulomas 
Granulomas were not associated with CARD15 (NOD2) genotype.  No granulomas 
were found in controls.  There was no significant difference in number of granulomas 
between smokers and non smokers. 
A total of 115 patients had reports and genotyping results available.  No difference in 
was seen among CARD15 (NOD2) genotypes and the number of patient with 
granuloma mentioned in the histopathology report, Figure 46.  There was no difference 
when the number of patients who had ever had granuloma was investigated.  No 
difference in was seen among ATG16L1 genotypes (n=42) and the number of patient 
with granuloma mentioned in the histopathology report, Figure 47.  
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Figure 46 There was no significant difference in the presence of granuloma in pathology reports 
and CARD15 (NOD2) genotype. 
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Figure 47 There was no significant difference in ATG16L1 genotype and the presence of 
granuloma in the pathology report. 
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4.4 Discussion 
It was hypothesized that there would be a histological phenotype associated with 
CARD15 (NOD2) genotype.  There are a number of typical features of Crohn’s disease 
including transmural inflammation, lymphoid aggregates and granulomas (Day, Jass et 
al. 2003).  Pyloric metaplasia is a recognised feature of Crohn’s disease (Koukoulis, 
Ke et al. 2002; Day, Jass et al. 2003).  CARD15 (NOD2) mutations are associated with 
ileal (Cuthbert, Fisher et al. 2002; Büning, Genschel et al. 2004) and fibrostenosing 
(Abreu, Taylor et al. 2002) phenotype.  CARD15 (NOD2) is expressed in Paneth cells 
(Lala, Ogura et al. 2003; Ogura, Lala et al. 2003) and may influence Paneth cell 
morphology (Abeya, Bromfield et al. 2005).   
Smoking is associated with a higher risk of developing Crohn’s disease (Lindberg, 
Tysk et al. 1988; Calkins 1989).  It is associated with a worse clinical course and more 
frequent relapses (Cosnes, Carbonnel et al. 1999; Ryan, Allan et al. 2004) although the 
mechanism through which smoking exerts this effect is unknown.  It is possible that 
smoking would be associated with a more severe histological phenotype. 
People with Crohn’s disease had significantly more Paneth cells than controls.  There 
was no significant association with age and Paneth cell count in controls or in people 
with Crohn’s disease suggesting a genuine effect.  This is suggested by a previous 
investigation in which more Paneth cells were found in zone 2 of the small intestinal 
crypt in a small cohort of people with Crohn’s disease (Kelly, Feakins et al. 2004).  
There is evidence to suggest in intestinal metaplasia in the stomach there is 
deregulation of Paneth cell proliferation (Wong, Stamp et al. 2000).  Much work has 
been done to investigate the control of Paneth cell differentiation.  Migrated Paneth 
cells in mice have been found not to express Frizzled-5 (van Es, Jay et al. 2005).  
Paneth cells localised to the crypt base still express Frizzled-5.  The migrated Paneth 
cells lack expression of the Wnt signal transducer nuclear β-catenin, and the Wnt target 
genes EphB3, cryptidin-1 and cryptidin-6 (Batlle, Henderson et al. 2002).  It has been 
found that there is an increase in cell proliferation markers in Crohn’s disease 
(Noffsinger, Unger et al. 1998) with an increase in staining for Ki-67, a cell 
proliferation marker in the basal one-third of crypts.  Through an unknown mechanism 
CARD15 (NOD2), possibly through bacterial handling, mutations appear to alter 
Paneth cell proliferation.  The deregulated Paneth cell proliferation found in intestinal 
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metaplasia demonstrated by Wong et al 2000 could suggest a mechanism by which 
Paneth cells in Crohn’s disease are increased (Wong, Stamp et al. 2000). 
Pyloric metaplasia was initially found to be significantly associated with CARD15 
(NOD2) homozygotes/compound heterozygotes and heterozygotes compared with wild 
type Crohn’s patients.  As expected only one very small area of pyloric metaplasia was 
found in the control population.  Pyloric metaplasia is not found exclusively in Crohn’s 
disease.  There was no significant difference in the area of pyloric metaplasia in 
CARD15 (NOD2) homozygotes/compound heterozygotes than heterozygotes and wild 
type Crohn’s patients.  In an attempt to replicate these findings all available 
histopathology reports were reviewed.  No significant difference was found.  This may 
be because pyloric metaplasia, while known to be a feature, is not pathognomic of 
Crohn’s disease and therefore may not be specifically mentioned in reports.  However 
it would be likely that a genuine difference would be maintained between populations.  
In order to minimize this effect the number of patients who had ever had pyloric 
metaplasia mentioned in any histopathology report was investigated and no difference 
found.  This potential finding is interesting however and warrants further detailed 
review of a larger number of histology sections with the specific aim of identifying 
pyloric metaplasia.   
Pyloric metaplasia has been found to be associated with increased smooth muscle 
content (Borley, Mortensen et al. 2001).  This increase in smooth muscle content 
associated with pyloric metaplasia may explain the association between carriage of 
CARD15 (NOD2) mutation and fibrostenosing disease phenotype.  Growth factors are 
produced in areas of pyloric metaplasia (Longmann, Douthwaite et al. 2000; Pera, 
Heppell et al. 2001) and this could influence Paneth cell numbers.  There was no 
evidence to suggest there was more severe inflammation and ulceration in CARD15 
(NOD2) patients. 
Consistent with other published data there was no association with granulomas and 
CARD15 (NOD2) genotype (Pierik, de Hertogh et al. 2005).  No association was found 
between the number of lymphoid aggregates and CARD15 (NOD2) genotype.  This is 
not surprising as CARD15 (NOD2) has not been found in lymphocytes but is found 
almost exclusively in monocytes and Paneth cells. 
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This was a straightforward investigation of the histological features of Crohn’s disease 
and Paneth cell morphology.  The features of Crohn’s disease, pyloric metaplasia and 
Paneth cells were identified reliably without the need for special stains.  An advantage 
of this is the subsequent availability of archival tissue.  Cases were selected with a 
robust diagnosis of Crohn’s disease in a relatively homogenous population.  All people 
had severe disease Crohn’s disease requiring surgery.  This investigation was cheap 
and simple using H&E and lysozyme for Paneth cell and histological features 
identification.  There was an equal proportion of smokers and non-smokers.  The 
investigator (CH) was taught to identify features of Crohn’s disease in patient whom 
the diagnosis is already established rather than ability to assess the histological features 
to make a diagnosis. 
There are a number of weakness in this investigation.  Sections studied were of a 
longitudinal 2-dimensional nature with a single cut through crypt which is a 3-
dimensional structure.  This may well not be representative of entire crypt.  Often 
partial cells are seen which is an artefact of the sectioning process.  H&E identifies 
Paneth cells but does not differentiate them from intermediate cells, these may be what 
we are seeing higher up the crypts.  This may be indicated in the higher number of 
Paneth cells counted with H&E over lysozyme.  Lysozyme is not found in intermediate 
cells, only mature Paneth cells (Calvert, Bordeleau et al. 1988).  Measuring the height 
distribution of Paneth cells in number of cells is a simple measure that allows for errors 
in magnification.  However this may not be representative of entire crypt due to 3-
dimentional structure.  It assumes that the Paneth cells lie around the base of the crypt 
equally all the way round.  A number of patients had received disease modifying 
therapy and this was not controlled for.  There were a limited number of sections due 
to tissue availability.  This is a small study that therefore limits power to detect a small 
effect.   
A better way to investigate Paneth cell morphology would be by microdisection of the 
entire crypt, and then count whole crypt Paneth cells.  This would necessitate fresh 
tissue sampling.  Ideally all Paneth cells would be isolated for counting.  
Immunohistochemistry to human defensin-5 or other unique Paneth cell product could 
be used to more accurately identify the Paneth cells.  A more simple method would be 
to count multiple sections through the entire crypt.  This would then be more 
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representative.  This study used pre-cut sections, i.e. those that had been originally 
used on clinical grounds post operation.   
Pyloric metaplasia was again identified just using H&E staining.  To take this forward, 
the finding of an association between pyloric metaplasia and the carriage of CARD15 
(NOD2) mutation needs replication in a larger cohort of patients.  If the finding holds 
true a further investigation would be to investigate the 3-dimensional structure of 
pyloric metaplasia.  It would be better to use a specific marker e.g. trefoil peptide to 
identify areas of pyloric metaplasia.  Again a 2-dimensional method was used to 
attempt to quantify a 3-dimensional structure.  It would be better to section the entire 
area to quantify volume rather than area of pyloric metaplasia. 
Lymphoid aggregates are common, easily identifiable on H&E staining.  The volume 
of lymphocyte load may be more useful than absolute number.  The nature of 
lymphocytes could be useful. It would be worth exploring in future studies with cell 
markers to identify the cell lineages found in lymphoid aggregates to see if there is 
over-representation of various T cells.   
Only a very small amount of the resection specimen is cut therefore reducing the 
chances of finding all granulomas.  This study assumed equal distribution of 
granuloma throughout specimen.  There may have been a reduced sensitivity in 
identifying granuloma compared with experienced pathologists as granulomas are 
notoriously difficult to reliably identify.  In order to ensure no granuloma were missed 
it would be better to sample and examine the entire resection specimen.  In a clinical 
setting this is not so practical.  It would be better to use an immunological marker of 
granulomas, e.g.  CCR5- Th1 marker an epitheliod cell marker to accurately identify 
all granulomas.   
There are no published studies investigating the histological phenotype and CARD15 
(NOD2).  Previous work has concentrated on the presence or absence of granulomas 
only.  This work was carried out blind to genotype and smoking phenotype.  
Unfortunately there are only 11 homozygotes included in this study.  We have 
demonstrated a difference in Paneth cell morphology in CARD15 (NOD2) genotypes 
that warrents further investigation.  There may be an association between pyloric 
metaplasia and CARD15 (NOD2).   This justifies further investigation of cell 
proliferation in Crohn’s disease. 
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5 Chapter 5 The Influence of IL-6, COL1A1, and VDR gene 
polymorphisms on bone mineral density in Crohn's 
disease 
5.1 Introduction and aims 
We investigated the potential relationship between well recognised, apparently 
functional single nucleotide polymorphisms (SNP) of VDR, IL6 and COL1A1 and bone 
mineral density (BMD) in a cohort of well characterised patients with Crohn’s disease.   
The SNPs investigated were: The Fok1 and Taq1 polymorphisms of VDR, the G to C 
SNP at position –174 of IL6 and a polymorphism at the Sp1 transcription factor 
binding site of COL1A1.  The influence of CARD15 (NOD2) mutations and BMD were 
studied. 
This project looking at the genetics of bone mineral density in Crohn’s disease started 
before the work for the MD.  The patient recruitment was done by Dr Thompson, Dr 
Bartram and Dr Mansfield.  The genotyping was performed by Dr A Sutherland-
Craggs.  The analysis of the data and the preparation of the manuscript undertaken by 
myself. 
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5.2 Materials and methods 
5.2.1 Patients 
Patients were recruited from the inflammatory bowel disease register at the Freeman 
Hospital and the Royal Victoria Infirmary, Newcastle upon Tyne, and the Queen 
Elizabeth Hospital, Gateshead.  All patients had a diagnosis of Crohn’s disease and 
were under the care of either a surgical or medical gastroenterologists and were 
diagnosed by a combination of radiology, endoscopy and biopsy.  Only patients aged 
between 24 and 70 years were included, and women who were pregnant or planning a 
pregnancy were excluded because of the potential risk from exposure to ionizing 
radiation during bone densitometry.  Initial demographic data were collected by 
questionnaire including age, smoking history, reproductive and menstrual history in 
women.  Details including duration and site of disease, corticosteroid use in months, 
surgical and drug history were obtained both through direct interview and from the 
medical notes.  Prior to bone densitometry height and weight were measured and body 
mass index calculated.  The Newcastle upon Tyne Joint Ethics Committee granted 
ethical approval. 
For comparison, when testing the hypothesis that VDR genotype is associated with 
Crohn’s disease a geographically and racially matched cohort of healthy controls was 
recruited from in vitro fertilisation donors and healthcare workers. 
5.2.2 Bone mineral density measurement 
BMD was measured at the lumbar spine (LSP) and total left hip using dual energy x-
ray absorptiometry (DEXA) as previously described (Bartram, Peaston et al. 2003).  
Osteoporosis is defined by WHO as a bone density 2.5 or more standard deviations 
below the mean value for young adults and osteopenia as a T score of -1 to -2.5 at any 
site (Kanis 1994).  Classification as normal BMD, osteopenic or osteoporotic is 
dependent on the site with the lowest BMD T score. 
5.2.3 Genotyping 
5.2.3.1 Determination of VDR Taq1 genotype 
A 340 bp fragment which included the site of the T to C polymorphism at codon 352 in 
exon 9 of the VDR gene on chromosome 12 was amplified in a 25µl reaction mixture 
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containing 200 µM each of dATP, dCTP, dGTP and dTTP (ABgene, Surrey, UK), 
10mM tris-HCl pH 8.3, 50mM KCl, 0.01% gelatin., 1U Taq Polymerase (ABgene, 
Surrey, UK), 0.5 µM of each primer  and 1µl (approx. 0.2 to 0.5 µg) template DNA on 
a Perkin-Elmer GeneAmp 9700.  The alleles relating to this polymorphism are 
designated “t” (Taq I site present) or T (Taq I site absent). 
The primers used were: 5’CAgAgCATggACAgggAgCAAg-3’ forward and 
5’gggTgTACgTCTgCAgTgTg-3’reverse (Oswel, Southampton, UK).  
The PCR amplification conditions were as follows: initial denaturation at 94°C for 6 
min followed by 35 cycles of, 94°C for 45 seconds, 63°C for 60 seconds, followed by 
72°C for 75 seconds and a final extension at 72°C for 7 minutes.   
Following amplification, 15µl of the product was digested with 2.5 units of Taq I 
(ABgene, Surrey, UK), at 650C.  Digested restriction fragments were separated on 
2.5% (w / v) agarose (Sigma, Poole, Dorset, UK) gels, with 1x Tris-Borate-EDTA 
(TBE) running buffer (Sigma, Poole, Dorset, UK)  Samples of known genotype were 
run as controls and a water negative (DNA free) control in each batch.    
Bands were visualised on an Alpha Innotech Imager system and assigned as follows: 
T/T, 340 bp only, T/t, 340 bp, 293 bp and 47 bp, t/t, 293 bp and 47 bp. 
5.2.3.2 Determination of VDR Fok1 genotype. 
A 265 bp fragment which includes the site of a C to T polymorphism at the start codon 
was amplified as above.  The alleles which result from this change are designated “f” 
(FokI site present) or “F” (FokI site absent). 
The primers used were: 5’ACgTggCCCTggCACTgACTCTgCTCT-3’ forward and 
5’ATggAAACACCTTgCTTCTTCTCCCTC-3’reverse (Oswel, Southampton, UK).  
The PCR amplification conditions were as follows: initial denaturation at 94°C for 5 
min followed by 32 cycles of, 94°C for 45 seconds, 58°C for 45 seconds, followed by 
72°C for 45 seconds and a final extension at 72°C for 7 minutes.   
Following amplification, 15µl of the product was digested with 4 units of FokI 
restriction endonuclease (ABgene, Surrey, UK), at 370C.  Digested restriction 
fragments were separated on 2% (w / v) agarose (Sigma, Poole, Dorset, UK) gels as 
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described above.  Genotypes were assigned as follows: F/F, 265 bp only, F/f, 265 bp, 
169 bp and 96 bp, f/f, 169 bp and 96 bp.  
5.2.3.3 Determination of IL6 -174 genotype 
A 431 bp fragment which includes the site of a G to C polymorphism at position –174 
in the promoter region of the IL6 gene was amplified as above.  On digestion with 
NlaIII, the wild-type sequence with G at position -174is not digested, whereas a C at -
174 creates a restriction site for NIaIII and is digested.  The primers used were: 
5’CAgAAgAACTCAgATgACTgg-3’ forward and 5’gTggggCTgATTggAAACC-
3’reverse (Oswel, Southampton, UK). 
The PCR reaction conditions for amplification were as follows: initial denaturation at 
95°C for 5 min followed by 5 cycles of, 95°C for 30 seconds, 58°C for 60 seconds, 
followed by 72°C for 60 seconds, followed by 25 cycles of, 95°C for 30 seconds, 56°C 
for 60 seconds, followed by 72°C for 60 seconds, followed by 5 cycles of, 95°C for 30 
seconds, 54°C for 60 seconds, followed by 72°C for 60 seconds and a final extension 
at 72°C for 7 minutes.   
Following amplification, 15µl of the product was digested with 2.5 units of NlaIII 
restriction endonuclease (ABgene, surrey, UK), at 370C.  Digested restriction 
fragments were separated on 2% (w / v) agarose gels, as described above.  For the 
various genotypes, the following band patterns were obtained: G/G 229 bp, 173 bp and 
29 bp; G/C 229 bp, 173 bp and 122 bp; C/C 229 bp, 122 bp, 51 and 29 bp. 
5.2.3.4 Determination of COL1A1 genotype 
A 280 bp fragment which included the site of the G T polymorphism at the Sp1 
binding site in the first intron of COL1A1 gene was amplified as above.  The primers 
used were: 5’CTGGACTATTTGCGGACTTTTTGG-3’ forward and 
5’GTCCAGCCCTCATCCTGGCC-3’ reverse (Oswel, Southampton, UK). 
The PCR reaction conditions for amplification were as follows: initial denaturation at 
94°C for 5 min followed by 30 cycles of 94°C for 1 min, 64°C for 1 min and 72°C for 
1 min. 
Following amplification, 10µl of the product was digested with 1 unit of Msc1 
restriction endonuclease (New England Biolabs), at 37°C.  Digested restriction 
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fragments were separated by polyacrylamide gel electrophoresis on 10% 
polyacrylamide gels, with 1xTBE running buffer (Sigma, Poole, Dorset, UK).  
Samples of known genotype were run as controls, and water as a negative (DNA free) 
control in each batch. 
Following electrophoresis for 4 hours at 160mV, bands were visualised on an Alpha 
Innotech Imager system. The patterns corresponding to the various genotypes were as 
follows: homozygous wild-type (GG) 280 bp only, heterozygous (GT) 280 and 260 bp 
and homozygous mutant (TT) 260 bp only. 
5.2.3.5 CARD15 (NOD2) genotyping 
This was performed as previously reported in Cuthbert et al 2002 (Cuthbert, Fisher et 
al. 2002) in Prof C. Mathew’s laboratory, Department of Medical and Molecular 
Genetics, Guy’s, Kings and St. Thomas’ School of Medicine, London. 
5.2.3.6 Statistical analysis 
To look for differences in BMD at the hip and LSP between genotypes analysis of 
variance (ANOVA) was employed.  Where this was significant Tukeys test for 
multiple comparisons was used to compare differences between groups.  This was 
carried out using SPSS for Windows v 11.1. 
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5.3 Results 
5.3.1 Demographics 
245 patients with Crohn’s disease were studied, 158 female, age range 24 years to 70 
years mean age of 44.4 years, standard deviation 11.4 years.  96 (61%) patients were 
pre menopausal with 62 (39%) post menopausal at the time of the study.  75 (30%) had 
previously smoked, 92 (37%) had never smoked and 78 (32%) were current smokers.   
73 (30%) were on oral corticosteroids at the time of the study, 144 (59%) had 
previously had oral corticosteroids and 28 (11%) had never had oral corticosteroid 
treatment.  Mean duration of steroid use 45 months, range 0 to 372 months, median 21 
months.  Duration of disease range 6 months to 50 years mean 14.3 years, SD 9.5 
years.  54 (22%) were osteoporotic at any site, 106 (43%) were osteopenic at any site 
and 160 (65%) had normal bone density. 
There were no significant differences between any genotypes and age, BMI, pre/post 
menopausal, smoking or steroid use, data not shown. 
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5.3.2 Genotype 
All genotypes were in Hardy-Weinberg equilibrium.  Genotype distributions are shown 
in Table 26.  Comparing genotype distribution of COL1A1, IL6 and VDR Fok1 with 
those of 257 healthy controls there were no statistically significant differences.  There 
was no difference in VDR Taq1 genotype frequency between patients with Crohn’s 
disease and controls, p=0.10.  Control genotype frequency CC 40 (15%), TC 115 
(45%) and TT 102 (40%). 
 
Table 26 Genotype distribution 
VDR Taq 1 genotype CC TC TT 
n=244 37 (15%) 130 (53%) 76 (31%) 
VDR Fok1 genotype FF Ff ff 
n=240 85 (35%) 121 (50%) 33 (14%) 
IL6 genotype CC GC GG 
n=213 32 (15%) 76 (36%) 104 (49%) 
COL1A1 genotype GG GT TT 
n=180 95 (53%) 49 (27%) 36 (20%) 
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5.3.3 Genotype and bone mineral density 
5.3.3.1 VDR Taq1  
There was no significant difference in BMD at the LSP or hip between VDR Taq1 
genotypes.  There was also no difference in T score at the LSP and hip and VDR Taq1 
genotype, Table 27. 
5.3.3.2 VDR Fok1  
There was no significant difference in BMD at the LSP or hip between VDR Fok1 
genotypes.  There was also no difference in T score at the LSP and hip and VDR Fok1 
genotype, Table 27. 
5.3.3.3 IL6   
At the LSP there was a significant difference in BMD between IL6 genotypes 
(p=0.041).  This difference was between the GG and CC genotypes by pair-wise 
comparison allowing for multiple testing.  The CC genotype having a higher mean 
BMD at 1.03 g/cm2 than the GG genotype at 0.95 g/cm2 respectively, 95% confidence 
interval for difference 0.0032 to 0.1524. There was only a trend towards significance 
between T score and genotype p=0.065, Table 27. 
At the hip there was a significant difference in BMD between IL6 genotypes (p=0.014) 
(Table 27).  The CC genotype had a higher mean BMD of 0.93 g/cm2 compared to the 
GG mean BMD of 0.48 g/cm2, 95% confidence interval for difference 0.0186 to 0.159.  
The difference between genotype groups when BMD was expressed as T score was 
statistically significant p=0.013.  Mean T score was for CC genotype –0.709 and for 
GG genotype –1.37.  The 95% confidence interval for the difference was 0.119 to 
1.208. 
5.3.3.4 COL1A1  
There was no significant difference in LSP BMD between COL1A1 genotypes, 
p=0.144.  There was also no significant difference in T score at the LSP between 
genotypes, p=0.14 and p=0.24, Table 27.   
At the hip there was a significant difference in BMD between COL1A1 genotypes 
(p=0.034), (Table 27).  This was between the homozygous wild-type (GG) and 
heterozygous (GT) genotypes.  The mean BMD for the GG genotype was 0.88 g/cm2 
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and for GT 0.81 g/cm2, with the 95% confidence interval for difference 0.0051 to 
0.1307.  There was also a significant difference in T scores between genotypes 
p=0.025.   Again the GG genotype had a higher T score –1.03 than the GT genotype 
which was –1.59 with a 95% confidence interval for difference 0.066 to 1.063. 
 
Table 27 Bone mineral density g/cm2, mean (standard deviation) for each genotype. 
Genotype LSP BMD LSP T score Total hip BMD Hip T score 
VDR Taq1 
CC 0.98 (0.13) -0.73 (1.19) 0.86 (0.15) -1.15 (1.20) 
TC 0.98 (0.16) -0.70 (1.47) 0.87 (0.15) -1.12 (1.25) 
TT 0.96 (0.15) -0.95 (1.44) 0.84 (0.15) -1.29 (1.17) 
VDR Fok1 
Ff 0.95 (0.18) -1.04 (1.67) 0.85 (0.19) -1.30 (1.54) 
Ff 0.97 (0.15) -0.80 (1.41) 0.85 (0.14) -1.21 (1.15) 
FF 0.99 (0.15) -0.65 (1.35) 0.89 (0.15) -1.05 (1.16) 
IL6 
CC 1.03 (0.15) † -0.33 (1.41) 0.93 (0.14) † -0.71 (1.03) † 
GC 0.99 (0.17) -0.69 (1.50) 0.87 (0.14) -1.06 (1.09) 
GG 0.95 (0.15) -0.98 (1.37) 0.48 (0.15) -1.37 (1.25) 
COL1A1 
GG 0.98 (0.14) -0.75 (1.33) 0.88 (0.15 -1.03 (1.19) 
GT 0.94 (0.15) -1.15 (1.39) 0.81 (0.14) † -1.59 (1.18) † 
TT 0.99 (0.16) -0.59 (1.51) 0.87 (0.15) -1.08 (1.27) 
CARD15 
(NOD2) 
Wild-type 0.98 (0.15) -0.77 (0.15) 0.87 (0.15) -1.14 (1.22) 
Heterozygote 0.96 (0.17) -0.89 (1.50) 0.85 (0.15) -1.26 (1.14) 
Homozygote 0.97 (0.16) -0.95 (1.44) 0.88 (0.17) -1.27 (1.23) 
 † indicates a significant effect, p<0.05 
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5.3.3.5 CARD15 (NOD2)  
There was no significance in BMD or T score between CARD15 (NOD2) genotypes, 
table 2.  The frequencies of CARD15 (NOD2) genotypes compared to controls are 
shown in Table 28.  As expected there was a higher frequency of CARD15 (NOD2) 
mutations in the Crohn’s disease population than the control group. 
Table 28 CARD15 (NOD2) genotype frequency 
 CARD15 (NOD2) genotype 
Wild Type Heterozygote Homozygote 
Control 
n=104 
77 
(91%) 
7 (7%) 0 
Crohn’s 
disease n=223 
167 (75%) 
46 
(21%) 
10 
(4%) 
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5.4 Discussion 
This is a large study of the relationship between genes and BMD in a well 
characterised population of patients with Crohn’s disease.  When analysed by genotype 
there was no difference in duration of disease, steroid use, age, BMI or smoking status 
allowing valid comparisons to be made. 
A significant association was found between IL6 polymorphisms and lower BMD at 
the LSP and hip in patients with Crohn’s disease.  The largest difference being seen at 
the hip where the GG (49%) genotype had a 9.6% lower mean BMD than the CC 
(15%) genotype, at the LSP there was a 7.5% difference.  From the analysis, the C 
allele appears to produce a protective effect as the GC heterozygote has significantly 
higher BMD than the GG homozygote.   
The finding of an association between IL6 polymorphisms and BMD in Crohn’s is 
consistent with previous work (Schulte, Dignass et al. 2000).  Schulte et al 2000 
studied only 83 patients with a mixture of Crohn’s disease and ulcerative colitis.  IL6 
polymorphisms have also been associated with lower BMD in post-menopausal 
women (Ferrari, Garnero et al. 2001) and with lower peak bone mass in healthy males 
(Lorentzon, Lorentzon et al. 2000).  Although in another small study of 75 patients 
with Crohn’s disease from a cohort of 105 patients with inflammatory bowel disease, 
no association was found between IL6 polymorphism and BMD (Schulte, Goebell et 
al. 2001).  This last study however was a much smaller study than the present 
investigation and BMD was expressed as Z score only, rather than as absolute BMD.  
In addition the effect of IL6 seen in the present investigation is relatively small and the 
earlier study was significantly underpowered by comparison. 
IL6 is thought to be involved in bone remodelling and hence development of 
osteoporosis through stimulation of osteoclast development and regulation of bone 
resorption (Manolagas 1995; Manolagas and Jilka 1995; Manolagas 1998).  Higher 
levels of IL6 have been found in patients with Crohn’s disease (Pollak, Karmeli et al. 
1998) and serum levels of IL6 have been found to predict bone loss in post-menopausal 
women (Scheidt-Nave, Bismar et al. 2001).  Studies in vitro have shown that the CC 
IL6 genotype results in lower stimulated IL6 promoter activity and in vivo with lower 
levels of plasma IL6 (Fishman, Faulds et al. 1998).  In post-menopausal women CC 
IL6 polymorphism was found to be associated with lower bone resorption and less of a 
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loss in BMD compared with GG genotype (Ferrari, Garnero et al. 2001).  It is possible 
that in Crohn’s disease, a chronic inflammatory condition that results in higher serum 
levels of IL6, the CC genotype is protective against IL6 mediated bone resorption. 
This study found a significantly lower BMD at the hip in Crohn’s disease patients with 
heterozygous COL1A1 (27%) genotype compared with homozygous wild-type (53%).  
At the hip the heterozygous genotype resulted in a 6% reduction in BMD.  At the hip 
there was also a significant reduction in T score to a level below that where therapy is 
recommend in glucocorticoid induced osteoporosis (Eastell, Reid et al. 1998). 
This study is in agreement with other published work on COL1A1 gene 
polymorphisms.  COL1A1 gene polymorphisms have been associated with low BMD 
and fractures in other populations (Grant, Reid et al. 1996; Uitterlinden A G, Burger H 
et al. 1998).  A recent meta-analysis including 6800 subjects also found a significantly 
lower BMD at the lumbar spine in the heterozygous group compared to homozygous 
wild-type but no significant difference in the homozygous TT group (Mann and 
Ralston 2003). 
COL1A1 gene polymorphisms at the Sp1 binding site are thought to be functional, 
altering the level of transcription and production of collagen and therefore the physical 
properties of bone (Mann, Hobson et al. 2001).  Osteoblasts derived from heterozygote 
subjects were found to have altered production of the collagen α1(1) chain relative to 
the α2(1) when compared to wild-type individuals.  The same study found that bone 
strength was reduced in people with heterozygotes compared with wild-type subjects. 
In this analysis there was no association between BMD and either two of the VDR 
SNPs studied. A meta-analysis of 16 studies in 1996 found a small effect for VDR 
polymorphisms (Cooper and Umbach 1996), with a 2.4% difference in BMD between 
genotypes.  Such a small effect has limited clinical significance.  The numbers in this 
study are adequate to detect a difference of between 4% and 5% between genotypes. 
No association has been found in this study between VDR Taq1 polymorphism and 
susceptibility to Crohn’s disease.  This is in contrast to previous published data of 245 
patients with Crohn’s who were found to have an increased frequency of tt genotype 
(synonymous with CC in this study) (Simmons, Mullighan et al. 2000).  The results 
here are in agreement with a small study of 95 patients with Crohn’s disease in which 
no association was found (Martin, Radlmayr et al. 2002). 
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The clinical application for genotyping data is to identify those patients with Crohn’s 
disease who are more at risk for developing osteoporosis.  Multiple risk factors for 
development of osteoporosis have been identified including body mass index and 
steroid use (Siffiledeen, Fedorak et al. 2004).  Development of risk stratification by 
genotype as well as clinical risk may enable targeted treatment with agents such as 
pamidronate (Bartram, Peaston et al. 2003) or other bisphosphonates (Adadchi, Bensen 
et al. 1997) or calcium supplements (Sambrook, Kotowicz et al. 2003) dependant on 
risk.  Patients could be tested prior to starting corticosteroids for example and those at 
greater risk of developing osteoporosis be targeted with more aggressive screening and 
treatment.  Crohn’s disease patients are younger than other disease groups previously 
studied therefore earlier identification of those at risk has potential to be 
therapeutically important. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
162 
6 Chapter 6 Genetics 
It has long been recognised that Crohn’s disease has a strong genetic element.  Crohn 
reported regional enteritis in two sisters (Crohn 1934).  A further case report of 
regional enteritis in 3 siblings was published in 1939 (Brown and Scheifley 1939).  The 
genetic basis of Crohn’s disease has been extensively investigated.  A review in 1971 
by McConnell (McConnell 1972) surmised that a family history of siblings with 
Crohn’s disease was more common than a vertical family history.  It was hypothesized 
that there was both a shared environment and shared genetic predisposition.  The 
inheritance pattern was not Mendelian but a complex polygenic disorder with a 
combination of environmental and genetic factors determining the development of 
Crohn’s disease.  It was suggested by the authors that there may be a number of genes 
in common between Crohn’s disease, ulcerative colitis and ankylosing spondylitis.   
Complex segregation analysis has  suggested that Crohn’s disease follows a recessive 
pattern of inheritance (Küster, Pascoe et al. 1989) (Orholm, Iselius et al. 1993).  By 
contrast ulcerative colitis was thought to represent the effects of a dominant gene with 
incomplete penetrance.   
Some of the earliest genetic studies used candidate gene analysis.  There are a number 
of limitations in this method; it can only be used with known genes, multiple genes 
needs correction for multiple testing, there is publication bias with positive findings 
more likely to be published.  There needs to be geographical and ethnic matching of 
cases and controls.  The probability of false positive results is high.   
The advantages of this technique is that a relatively small case-control population can 
be used and is therefore good at finding genes with small effect, an advantage in 
complex diseases with multiple genes with small effect.  A modification of candidate 
gene analysis has subsequently been used to attempt to identify relevant genes within 
susceptibility loci highlighted in genome-wide linkage and genome-wide association 
studies. 
The genetics of inflammatory bowel disease was advanced by the development of 
genome-wide linkage studies.  The first linkage map was published in 1992 using 814 
polymorphic markers across the entire genome (Weissenbach, Gyapay et al. 1992).   
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The genome-wide scan published by Hugot in 1996 identified an area of linkage on 
chromosome 16 (Hugot, Laurent-Puig et al. 1996).  This was to be identified later as 
CARD15 (NOD2) (Hugot, Chamaillard et al. 2001; Ogura, Bonen et al. 2001).   
A haplotype on chromosome 5q31 was identified in 2000 (Rioux, Silverberg et al. 
2000) and association with Crohn’s disease has been replicated in other studies(Rioux, 
Daly et al. 2001; Negoro, McGovern et al. 2003; van Heel, Fisher et al. 2004; 
Vermeire, Pierik et al. 2005; Onnie, Fisher et al. 2006).  DLG5 on chromosome 10q23 
is a further area of interest (Stoll, Corneliussen et al. 2004) however association is 
variable in studies (Yamazaki, Takazoe et al. 2004; Daly, Pearce et al. 2005; Noble, 
Nimmo et al. 2005; Török, Glas et al. 2005; Vermeire, Pierik et al. 2005; Yamada and 
Yamamoto 2005; Büning, Geerdts et al. 2006; Ferraris, Torres et al. 2006; Friedrichs, 
Brescianini et al. 2006; Lakatos, Fischer et al. 2006; Medici, Mascheretti et al. 2006; 
Newman, Gu et al. 2006; Tremelling, Waller et al. 2006). 
Despite the evidence that Crohn’s disease has a strong heritability up until recently 
2006 there were only 2 genetic loci that could be reliably replicated; CARD15 (NOD2) 
and 5q31 with a third on chromosome 10q23 with less consistent replication together 
with the MHC region on chromosome 6.  The combined, modest effect of these genetic 
loci is not sufficient to account for the genetic load in Crohn’s disease.  It was put 
forward in 1996 that large-scale testing by association analysis was going to be 
necessary to detect the multiple genes of modest effect implicated in complex diseases 
(Risch and Merikangas 1996).  The technology; that is the human genome project, 
development of HapMap and large scale genotyping methods, however did not become 
available until recently and the first published genome-wide association scan was in 
2005 (Yamazaki, McGovern et al. 2005).   
Genome wide association studies use a case-control method to investigate association 
between disease and thousands of SNPs throughout the genome.  Technological 
progress through the human genome project and the development of the HapMap has 
enabled this technique.  The HapMap is a schematic of the human genome in which a 
minimal number of SNPs can be used to tag common haplotype blocks, rather than 
using every known SNP throughout the genome.  The technique can use either SNPs 
evenly spaced across the entire genome or use the HapMap to tag common haplotypes.  
Allele frequencies are then compared between cases and controls. Large sample size 
and well matched ethnic and geographical controls are needed due to the multiple 
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testing employed and the modest increase in disease risk conferred by any variant.  
Statistical methods have had to be developed to enable interpretation of the large 
number of results produced. 
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7 Chapter 7 Conclusions 
Crohn’s disease is a common chronic disease with an incidence in Northern Europe of 
3.9-7 per 100 000 person years (Shivananda, Lennard-Jones et al. 1996).  It is a cause 
of increased morbidity and mortality in predominantly people of working age with a 
significant cost to the overall population (Hellier, Sanderson et al. 2006).  Crohn’s 
disease is a relapsing and remitting condition with a wide spectrum of severity.  There 
are currently no reliable, objective predictors of disease progression at presentation.  It 
would be useful to be able to stratify patients according to risk of severe disease in 
order to target more aggressive treatment to the high risk groups.   
The majority of people with Crohn’s disease will require surgery at some point in the 
disease course and many people require multiple operations.  Carriage of a CARD15 
(NOD2) mutation is reliably associated with ileal disease as demonstrated in a recent 
meta-analysis (Economou, Trikalinos et al. 2004).  The purpose of this investigation 
was to establish whether CARD15 (NOD2) carriage was associated with shorter time to 
re-operation in terminal ileal Crohn’s disease.   
This is a large investigation of the time to second operation in people who have 
undergone terminal ileal resections for Crohn’s disease.  The influence of gender, age 
at diagnosis, time to first surgery, disease behaviour, smoking habit and azathioprine/6-
mercaptupurine use was investigated.  The influence of CARD15 (NOD2) genotype 
and 5q31 haplotype carriage on time to second operation in people with Crohn’s 
disease was explored.   
No difference was found in survival to second operation and gender or age at 
diagnosis.  This study demonstrates that CARD15 (NOD2) genotype does not 
significantly influence time to second operation in terminal ileal Crohn’s disease.  
There was a trend to longer median survival to second operation in patients carrying 
two CARD15 (NOD2) mutations.  Carriage of the 5q31 haplotype was not associated 
with shorter survival to second operation.   
Smoking significantly reduced the median time to second operation from 173 months 
to 113 months, a clinically important difference of 5 years.  Those who had never 
smoked had a median time to second operation of 288 months (24 years) compared to 
113 months (9.4 years) in current smokers.  Thiopurine use was associated with a 
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shorter time to second operation, 184 months in those never exposed, 103 months in 
those currently on thiopurine and 113 months in those who had ever had thiopurines. 
Previous investigations showing a positive association of CARD15 (NOD2) mutation 
with shorter time to second operation had small number of patients who had undergone 
more than one operation for Crohn’s disease (Brant, Picco et al. 2003).  By taking an 
unselected cohort of patients with Crohn’s disease, there will be a bias of patients with 
ileal disease having CARD15 (NOD2) mutations.  These patients are also more likely 
to have surgery for Crohn’s disease.  Therefore there is bias towards a positive 
association with CARD15 (NOD2).  By taking a cohort of patients all of whom have 
had resections for Crohn’s disease, this bias is reduced and the influence of CARD15 
(NOD2) can be more accurately investigated.  
The effect of smoking on time to second operation is not unexpected.  It has previously 
been reported that cessation of smoking improves outcome (Cosnes, Beaugerie et al. 
2001).  This demonstrates that our cohort can detect differences in outcome and 
therefore acts as a positive control.   
5q31, IBD5, is a haplotype with an established association with Crohn’s disease (Ma, 
Ohmen et al. 1999; Duerr, Barmada et al. 2000).  We investigated whether 5q31 
haplotype carriage was a risk factor for reduced time to second operation in terminal 
ileal Crohn’s disease.  In our cohort of patients with terminal ileal Crohn’s disease, 
there was no significant effect found with carriage of 5q31 haplotype and time to 
second operation.  This may because this study does not have the power to detect a 
weak effect of this haplotype.  However that weak effect is unlikely to be of clinical 
significance.  Smoking reduced time to second operation in all patients, whether they 
carried one or two of the disease associated haplotypes. 
The strengths of this study are its large size, robust diagnostic criteria and length of 
follow-up data.  The study includes 346 people with terminal ileal resections for 
Crohn’s disease, all of whom have a robust histological diagnosis of Crohn’s disease.  
The mean length of follow up was 213 months, range 4 to 663 months.  The mean 
length of follow up from first operation was 168 months, range 0 to 663 months.  The 
mean time to first operation was 45 months, range 0 to 481 months.  The mean time to 
second operation was 93 months. 
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Previous reports have suggested that Paneth cells from people with Crohn’s disease 
and associated CARD15 (NOD2) mutations have reduced defensins (Wehkamp, Harder 
et al. 2004; Wehkamp, Salzman et al. 2005).  In order to investigate a possible link 
between Paneth cells, CARD15 (NOD2) and Crohn’s disease in situ hybridization 
technique was used to estimate the quantity of mRNA for the antimicrobial peptides in 
Paneth cells of normal terminal ileum and that of patients with Crohn’s disease.   
This investigation has confirmed that Paneth cell secretory granules contain mRNA for 
antimicrobial peptides; lysozyme, sPLA2 and human α-defensins 5 and 6.  The 
expression of mRNA can be detected in archival material preserved in paraffin wax, 
however tissue of 30 years old does not have reliable detection.  TNF-α mRNA can be 
demonstrated in Paneth cells, although not in secretory granules.   
No difference in the expression of defensin mRNA was demonstrated between sections 
from people with Crohn’s disease and CARD15 (NOD2) mutations.  There was no 
difference when a correction was made for the area of density measured, thereby 
reducing error due to Paneth cell numbers,  This is consistent with a recent report in 
Gut using quantitative real-time PCR that did not show a difference in defensin 
expression in CARD15 (NOD2) mutations (Simms, Doecke et al. 2008).  The reduction 
previously reported is likely to be due to inflammation rather than a defensin 
deficiency as a result of CARD15 (NOD2) mutation.  This study used sections with 
minimal inflammation in order to maximise yield from the in situ and therefore this 
provides further evidence that the previously reported reduction in defensin gene 
expression is a function of Paneth cell number rather than an effect of CARD15 
(NOD2) mutations. 
TNF-α is a proinflammatory cytokine that is found in Paneth cells (Keshav, Lawson et 
al. 1990). It is implicated in the pathogenesis of Crohn’s disease.  Treatment with anti-
TNF antibody is known to be of benefit in Crohn’s disease.  The expression of TNF-α 
in Paneth cells was investigated.  TNF-α mRNA expression was demonstrated in 
Paneth cells.  There was an increase in TNF-α expression in sections from patients 
with terminal ileal Crohn’s disease compared to controls.  No difference was seen 
between CARD15 (NOD2) genotypes.  Of interest sections from three different patients 
with terminal ileal Crohn’s disease did not express TNF-α.  This represents 10% of the 
total number of Crohn patients.  None of the patients had received treatment with anti-
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TNF-α antibody.  The finding of a difference in TNF-α mRNA expression acts as a 
positive control for this technique. 
In contrast to this investigation it has been shown by quantitative real-time PCR 
techniques that expression of α-defensin is reduced in biopsies from human ileum with 
Crohn’s disease, and reduced still further in patients who carry two mutations in the 
CARD15 (NOD2) gene (Wehkamp, Harder et al. 2004; Wehkamp, Salzman et al. 
2005).  Simms et al found no difference in defensin expression (Simms, Doecke et al. 
2008).   
An advantage of this technique was that it enabled use of archival tissue and thereby 
increased the pool of available tissue from patients carrying CARD15 (NOD2) 
mutations.  All patients used in this study had confirmed Crohn’s disease.  As each 
section was examined by hand, areas of minimal inflammation were identified and 
used for the in situ process.  This therefore reduces the confounder of inflammation 
and suggests any difference found would be an underlying defect rather than a function 
of inflammation, and therefore Paneth cell number.  The sections were grouped 
therefore minimizing intra-experimental variation. 
In situ hybridization is a relatively insensitive method for detection of differential 
expression of mRNA, however it would be expected to demonstrate a significant 
deficiency in defensin expression that was suggested by the Wehkamp group.  This 
present study demonstrates differential TNF-α expression.  The difference in results 
seen may be accounted for by the fact that the method of in situ hybridization is 
highlighting defensin mRNA expression within secretory granules and therefore may 
be a marker of propepide formation.  Defensins undergo post-translational processing 
on release from the secretory granules to the active peptide form.  There may still be a 
defect in this process leading to a deficiency in functional peptide formation that would 
not be shown by this technique. 
It was hoped that a histological phenotype would be found associated with carriage of 
CARD15 (NOD2) mutations.  CARD15 (NOD2) is thought to be an intracellular 
receptor for muramyl-dipeptide (MDP), a component of the bacterial cell wall.  
Functional mutations in the CARD15 (NOD2) gene associated with Crohn’s disease are 
likely to affect CARD15 (NOD2) function, however the precise effect on the receptor 
cascade had not been established (Fritz, Ferrero et al. 2006).  As mutations in CARD15 
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(NOD2) are thought to affect bacterial handling, the hypothesis was that there may be 
more severe inflammation and a different histological phenotype associated with 
CARD15 (NOD2) genotype. 
No differences in lymphoid aggregates, granulomas and overall inflammation score 
was seen in CARD15 (NOD2) genotypes.   
This investigation found a novel association between pyloric metaplasia and CARD15 
(NOD2) mutations.  Pyloric metaplasia is readily recognised with Haematoxylin and 
eosin staining (Wong, Stamp et al. 2000).  A follow-up study using histopathology 
reports did not replicate this finding.  This may be because pyloric metaplasia is not 
conventionally seen as pathognomic of Crohn’s disease or required to make a 
diagnosis.  The initial finding of an association warrants further study. 
This investigation found an association of an increased number of Paneth cells and 
Crohn’s disease.  No association was found between CARD15 (NOD2) genotype and 
Paneth cell number.  A significant association was found between Crohn’s disease and 
the height of Paneth cells within the crypt.  This may well be a function of the 
increased number of Paneth cells.  Paneth cells may play an integral part in innate 
immune response.  They are found in greater numbers in inflammatory conditions, as 
demonstrated in this investigation and in Kelly (Kelly, Feakins et al. 2004).  This may 
be as a result of a functional deficiency leading to an increase in Paneth cell 
proliferation, or this may be a part of an “immune overdrive” response to commensal 
flora. 
The novel finding of an association between CARD15 (NOD2) genotype and the 
presence of pyloric metaplasia needs to be replicated in an independent cohort.  Future 
investigations should include a more detailed cell populations found in lamina propria 
in Crohn’s disease.  This could involve immunophenotyping of cells within 
granulomas and lymphoid aggregates.  The recent finding of an association between 
Crohn’s disease and mutations in genes involved in autophagy; ATG16L1 and IRGM 
warrant investigation.  It would be interesting to look for manifestations of defective 
autophagy; and whether this is manifest as granuloma formation.  The patterns of 
expression ATG16L1 and IRGM, IL23 within tissue sections could be investigated. 
In a number of sections “budding” of the crypts was noted.  This may be a sign of 
abnormal crypt proliferation and warrants further investigation.  It was observed in too 
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few sections to be useful statistically.  Further studies using cell proliferation markers 
such as MIB and Ki67 may be useful to identify the site of origin of the budding. 
Osteoporosis is an important complication of Crohn’s disease as it is potentially 
preventable and is a cause of morbidity and mortality.  A positive association between 
IL-6 genotype and bone mineral density was found.  This was a statistically significant 
finding, however is probably not clinically significant.  IL-6 genotype may be a 
surrogate marker for increased IL-6 expression and thereby increased intestinal 
inflammation.   
There was no significant association with bone mineral density and VDR or COL1α1 
genotype.   
To date, genetic studies have not been helpful in the prediction of disease progression 
in individuals or populations.  However, genetic findings have been extremely useful 
in highlighting potential pathogenic pathways that were previously not associated with 
Crohn’s disease.  Up until recently there was only one gene reliably associated with 
Crohn’s disease; CARD15 (NOD2).  This is a PRR for MDP and is thought to be a 
cytosolic receptor involved in a proinflammatory cascade with activation of NFκB.   
This study was carried out between August 2004 and March 2006.  Since then there 
have been many significant genetic findings in Crohn’s disease, see Chapter 6 
Genetics.  As part of this project, DNA and phenotype data was collected on a large 
cohort of patients.  This significantly contributed to published studies in the genetics of 
inflammatory bowel disease.  The most recent published genetic studies (Parkes, 
Barrett et al. 2007; Prescott, Fisher et al. 2007; Tremelling, Cummings et al. 2007; 
WTCCC 2007; Barrett, Hansoul et al. 2008; Fisher, Tremelling et al. 2008; Anderson, 
Massey et al. 2009), to which the DNA collection from Newcastle as part of this 
project has significantly contributed, have highlighted a role for the IL12/IL23 
pathway and for primitive immune defence of autophagy.   
The IL12/IL23 pathway involves activation of naïve CD4+ T cells into producing IL17 
and can be termed TH17.  It has been shown that blocking the IL12 pathway prevents 
intestinal inflammation in murine models of colitis (Neurath, Fuss et al. 1996; 
Davidson, Hudak et al. 1998).  Further investigation however found that many of the 
effects on intestinal inflammation previously thought to be due to IL12 were secondary 
to IL23 (Yen, Cheung et al. 2006).  IL 23 and IL12 are heterodimers sharing a common 
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subunit p40.  IL12 is made up of p40 and p35 units and IL23 p40 and p19 subunits 
(McGovern and Powrie 2007).  Activation of IL23 receptor leads to increased 
inflammatory cytokines including TNF-α, IL6, interferon-γ and IL17.  The IL23 
receptor is expressed by activated T cells and cells of the myeloid lineage including 
macrophages and dendritic cells.  Induction of CD4+ T cells by IL23 leads to the 
generation of Th17, activated T cells are thought to play an important role in intestinal 
inflammation.  Most recently SNPs in IL23 have been shown to be associated with 
Crohn’s disease (Duerr, Taylor et al. 2006; Libioulle, Louis et al. 2007; Tremelling, 
Cummings et al. 2007; Yamazaki, Onouchi et al. 2007).   
Autophagy is the major intracellular degradation system delivering cytoplasmic 
components to lysozyme and is the method by which most long lived proteins and 
organelles are degraded.  A double membrane structure is formed around the 
cytoplasmic components or bacteria.  This then fuses with lysozymes and the contents 
of the vacuole are then disrupted and recycled.  ATG16L1 is a gene whose product is 
involved in the process of autophagy.  Recent studies have highlighted its role in 
Paneth cells and the pathogenesis of Crohn’s disease (Cadwell, Liu et al. 2008). 
This is translational research which aims to link the molecular genetic research with 
clinical work.  This project attempted to do this.  The ultimate aim is of the direct 
clinical application of individual genotypes e.g. in prediction of prognosis has been 
looked for in this project and importantly is still not reached.  The information and 
structure from this project now exists to examine for the clinical implication with the 
new genetic discoveries.  The commonest genetic variant CARD15 (NOD2) has been 
found to be associated with ileal disease, otherwise it has been unhelpful in the clinical 
setting.  Other variants are rare, even if they were found to be useful in disease 
classification, unless significant difference they are too rare to be of use in testing 
patients.   
The genetic collection developed during this project has been a core resource used in 
major publications of genetics of inflammatory bowel disease in the last three years.  
With more genes this is being expanded to meet the needs of the next project.  The 
resection based collection is unique and allows integration for histological features that 
other collections cannot achieve.   
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It was hoped that genetic variants would be useful in predicting disease progression 
and would be found to influence disease phenotype and aid in classification of disease.  
However to date, this has not been the case.  Genetics has helped direct research 
around complex immune pathways, it suggests that many defects in a complex immune 
pathway rather than single defect results in Crohn’s disease. 
Ultimately genetics have not been particularly helpful in predicting disease progression 
or phenotype.  However it has directed investigation into the pathogenesis and 
common pathways for disease development.  While genetic research started out by 
suggesting that Crohn’s disease was many separate genetic diseases is now likely that 
it is a more homogenous disease process of defective innate immune response to 
commensal flora.   
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8 Appendix  
8.1 Patient forms 
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8.1.1 Immunohistochemistry 
Poly-l-lyscine slides 
Xylene 
100% ethanol 
<100% ethanol solutions made up using milli-Q filtered water 
0.3% and 3% hydrogen peroxide in methanol made up from 30% H2O2 stock. 
PBS, phosphate buffered saline 
Bovine albumin 
Goat serum 
Rabbit Anti lysozyme antibody 
Biotinylated goat anti rabbit antibody 
ABC reagent 
DAB-H2O2 
Haematoxylin 
DPX 
Horse serum 
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8.2 Publications arising from this paper 
The Newcastle cohort of 250 patients contributed to the 1748 strong Crohn’s disease 
cohort in the Wellcome Trust Case Control Consortium genome-wide association 
study (WTCCC 2007).  Patients were recruited from the inflammatory bowel disease 
register and through clinic attendance at the Freeman Hospital and the Royal Victoria 
Infirmary, Newcastle upon Tyne, and the Queen Elizabeth Hospital, Gateshead.  All 
patients had a diagnosis of Crohn’s disease and were under the care of either a surgical 
or medical gastroenterologists and were diagnosed by a combination of radiology, 
endoscopy and biopsy.  Family and smoking history were taken by direct questioning 
where at all possible.  Phenotyping data was collected by review of hospital notes and 
recorded on standardised forms.  All patients gave written informed consent to 
participate.  Within the small team involved in Newcastle my role was to identify 
patients, perform phlebotomy with informed consent and collect detailed phenotype 
information.  At the completion of my MD thesis we had collected 1800 patients.   
10ml venous blood was obtained from each patient into commercial plastic tubes 
containing EDTA using standard precautions.  Blood samples were then labelled with a 
unique code and frozen at –20°C until DNA extraction.  Blood samples were kept 
frozen while transported to the Genetics Department, Guys, Kings and St. Thomas’ 
School of Medicine, London.  
The Newcastle cohort was included in a metanalysis of 3 genome-wide association 
studies (Barrett, Hansoul et al. 2008).  3230 Crohn patients and 4829 controls were 
combined.  This gave the advantage of power.  The combined sample gave a 74% 
power to detect an odds ratio of 1.2 enabling alleles with a small effect to be identified.  
32 areas have now been identified of interest in Crohn’s disease. 
The following papers have included the Newcastle cohort: 
(Anderson, Massey et al. 2009) (WTCCC 2007) (Parkes, Barrett et al. 2007) (Fisher, 
Tremelling et al. 2008) (Barrett, Hansoul et al. 2008) 
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8.3 Summary of recent gene findings 
NOD2 (16q21) is part of the NOD1/Apaf (Ogura, Inohara et al. 2001) family and 
encodes a protein with 2 capsase recruitment domains (CARD) and 6 leucine rich 
repeats (LRR).  It is expressed in peripheral blood leucocytes and Paneth cells of the 
small intestine (Lala, Ogura et al. 2003; Ogura, Lala et al. 2003).  NOD2 recognises 
MDP derived from LPS (Inohara, Ogura et al. 2003) and leads to NFκB activation 
(Morré, Ouberg et al. 2004; Maeda, Hsu et al. 2005).  Functional mutations in NOD2 
are associated with Blau syndrome (Miceli-Richard, Lesage et al. 2001), an aseptic site 
granulomatous disorder. 
DLG5 (10q23) (Discs, large homolog 5) is one of a subset of the membrane-associated 
guanylate kinase (MAGUK) superfamily.  It is composed of a catalytically inactive 
guanylate kinase domain.  It is thought to act as a scaffolding molecule at sites of cell-
cell contact.  The protein product localizes to the plasma membranes and cytoplasm 
(Nakamura, Sudo et al. 1998; Wakabayashi, Ito et al. 2003). 
TNFSF15 (9q32) (Tumour necrosis factor ligand superfamily, member 15) is 
expressed in endothelial cells 
IL23R (1p31.3) is a subunit of the receptor for IL23A/IL23.  It pairs with the receptor 
molecule IL12RB1/IL12Rβ1.  Both are required for IL23A signalling.  The protein 
associates constitutively with JAK2 and binds to the transcription activator STAT3.  
The IL23A α subunit p19 is located on chromosome 12q13.2 
ATG16L1 (2q37.1) (Autophagy related, 16-like 1) is a component of a large protein 
complex essential for autophagy.   
PHOX2b (4p12) (paired-like homoebox 2b) is a DNA associated protein localized to 
the cell nucleus.  It is a transcription factor involved in the development of several 
major noradrenergic neurone populations and the determination of neurotransmitter 
phenotype.   
FAM92B (16q24.1) (family with sequence similarity 92, member B) hypothetical 
protein.   
NCF4 (22q13.1) (neutrophil cytosolic factor 4) is a cytosolic regulatory component of 
the superoxide-producing phagocyte NADPH-oxidase.  NCF4 is preferentially 
expressed in cells of the myeloid lineage. 
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IRGM (5q33.1) (immunity-related GTPase family, M) probably plays a role in 
autophagy and control of intracellular mycobacteria (Singh, Davis et al. 2006). 
NKX2-3 (10q24.2) (NK2 transcription factor related, locus 2) transcription factor 
PTPN2 (18p11.3-p11.2) (protein tyrosine phosphotase, non-receptor type 2) is part of 
the PTP family whose signally molecules regulate cell processes. 
NELL1 (11p15.2-p15.1) is a cytoplasmic protein that contains epidermal growth factor 
like repeats that may be involved in cell growth regulation and differentiation. 
CCR6 (6q27) (chemokine c-c motive receptor 6) part of the β chemokine receptor 
family expressed in immature dendritic cells and memory T cells. 
IL12B (5q31.1-q33.1) (subunit p40) encodes subunit p40 that forms a heterodimer with 
p35 (common to IL23).  IL12 is expressed in activate macrophages and is an inducer of 
Th1 cell development. 
STAT3 (17q21.31) (signal transducer and activator of transcription 3) is involved in 
cellular processes-cell growth and apoptosis. It is activated through phosphorylation in 
response to cytokines and growth factors; IFNs, EGF, IL5, IL6, LIF and BMP2, 
STAT3 then translocates to the nucleus where it activates transcription. 
LRRK2 (12q12) (leucine rich repeat kinase 2) is a cytoplasmic protein associated with 
the mitochondrial outer membrane. 
CDKAL1 (6p22.3) CDK regulatory associated subunit associated protein like 1 
ICOSLG (21q22.3) inducible T-cell co-stimulator ligand 
ITLN1 (1q22-q23.5) intelectin 1 
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8.4 Figures 
Figure 1 From (Cosnes, Beaugerie et al. 2001); Kaplan-Meier estimates of the risk of 
flare-up in the 3 groups.  The numbers above the curves indicate the numbers of 
patients at risk in each group at 18 and 36 months after inclusion, respectively.  P value 
refers to comparison between quitters and continuing smokers. .................................. 43 
Figure 2 (a) Schematic of Paneth cells, shaded, situated at the base of crypts of 
Lieberkühn.  B Haematoxylin and eosin staining of human small intestine highlighting 
the eosinophillic granules within Paneth cells (arrow). ................................................ 53 
Figure 3 Pyloric metaplasia on Haematoxylin and eosin staining of human small 
intestine (arrows). ......................................................................................................... 54 
Figure 4 Haematoxylin and eosin stained section of human small bowel showing (a) 
giant cell (x20) and (b) epitheloid granuloma (x5) (arrows) ........................................ 55 
Figure 5 Kaplan Meier survival curve for cohort, n=347.  Time in months to second 
operation.  Crosses represent censored data.  Dotted line represents 50% cumulative 
survival.  Mean survival 225 months.  Median survival 135 months. .......................... 70 
Figure 6 Kaplan-Meier survival curve of Vienna age at diagnosis and time (months) to 
second operation.  There is no difference in time to second operation between groups.  
A1=age at diagnosis <40 years, A2 =age at diagnosis >40 years.  Dotted lines represent 
50% cumulative survival. .............................................................................................. 73 
Figure 7 Kaplan-Meier survival curve for smoking and time to second operation.  
Smoking significantly reduces time to second operation p=0.002.  Mean time to second 
operation from first operation; 279 months-never smoked, 193 months –ex-smokers, 
148 months-current smokers.  Median time to second operation from first operation: 
203 months-never smoked, 140 months-ex-smokers, 113 months-current smokers.  
Dotted lines represent 50% cumulative survival. ......................................................... 75 
Figure 8 Kaplan-Meier survival curve of surgery at the time of diagnosis of Crohn’s 
disease and surgery later in diagnosis.  There is no significant difference in time to 
second operation. .......................................................................................................... 76 
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Figure 9 Kaplan-Meier survival curve for operation within 12 months of diagnosis and 
time to second operation.  There is no significant difference in time to second 
operation.  Dotted line represents 50% cumulative survival. ....................................... 77 
Figure 10 Kaplan-Meier survival curve for thiopurine use and time to second 
operation, p=0.000.  Thiopurine use was significantly associated with shorter time to 
second.  Mean time to second operation from first operation; 242 months-no thiopurine 
use, 167 months –previous thiopurine use, 141 months-current thiopurine use.  Median 
time to second operation from first operation: 184 months-no thiopurine use, 113 
months –previous thiopurine use, 103 months –current thiopurine use.  Dotted lines 
represent 50% cumulative survival. .............................................................................. 78 
Figure 11 Kaplan-Meier survival curve for CARD15 (NOD2) genotype and time to 
second operation.  There is no difference in survival. .................................................. 79 
Figure 12 Kaplan Meier survival curve for carriage of 5q31 haplotype and time to 
second operation (months).  There is no difference in survival. ................................... 80 
Figure 13 Kaplan-Meier survival curve of decade of first small bowel resection and 
time to second small bowel resection (month).  There is no significant difference in 
time to second small bowel resection over the decade of first small bowel resection. . 81 
Figure 14 Bar chart displaying CARD15 (NOD2) genotype distribution over the decade 
of first small bowel operation.  The genotypes are normally distributed. .................... 82 
Figure 15 Transcription gel left to right; (a) DNA ladder, TNF-α (x2), (b) DNA ladder, 
HD5 (x2), HD6 (x2), (c) DNA ladder, lysozyme (x4), sPLA2 (x4), HD5 (x4) ............ 96 
Figure 16 Dot blot quantitation of mRNA probes ........................................................ 98 
Figure 17 In situ hibridization with anti sense probes showing labelling of mRNA in 
Paneth cells, arrows, images of control (ileum) sections at x40.  (a) lysozyme (b) 
sPLA2 (c) human defensin 5 (d) human defensin 6 ................................................... 103 
Figure 18 In situ hibridization using sense probes showing no mRNA labelling.  This is 
the negative control. Images at x40 (a) lysozyme (b) sPLA2 (c) human defensin 5 (d) 
human defensin 6 ........................................................................................................ 104 
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Figure 19 In situ hibridization images of jejunum controls showing labelling of mRNA 
in Paneth cells.  Probes: (a) lysozyme (b) sPLA2 (c) human defensin 5 (d) human 
defensin 6 .................................................................................................................... 105 
Figure 20 In situ hibridization anti sense and sense probes for TNF-α (a) antisense 
TNF-T7 (b) sense TNF-T3 showing labelling of TNF-α in Paneth cells and 
macrophages with the antisense probe (arrow). .......................................................... 106 
Figure 21 Mean density (arbitrary units) for RNA probes studied compared over 
CARD15 (NOD2) genotypes.  There was no difference in mean density between 
sections.  Density is uncorrected to the standard. ....................................................... 107 
Figure 22 Mean density (arbitrary units) corrected to the HD-5 labelled jejunum 
standard compared between CARD15 (NOD2) genotype groups for the RNA probes 
studied.  There is no significant difference in mean density. ...................................... 108 
Figure 23 Total density measured for each section for each RNA probe compared 
between CARD15 (NOD2) genotypes ........................................................................ 109 
Figure 24 Sum of density corrected to jejunum standard for each RNA probe compared 
between CARD15 (NOD2) genotypes ........................................................................ 110 
Figure 25 mean density of each RNA probe compared between control sections and 
Crohn’s disease sections ............................................................................................. 111 
Figure 26 Mean density of RNA probes corrected to jejunum standard between control 
sections and Crohn’s disease sections ......................................................................... 112 
Figure 27 Total density of RNA probes compared between control sections and 
Crohn’s disease sections ............................................................................................. 113 
Figure 28 Total density corrected to jejunum standard compared between control 
sections and Crohn’s disease sections ......................................................................... 114 
Figure 29 Mean density (arbitrary units) of mRNA probe and age at operation.  There 
is no significant association between mRNA probe density and age at operation. .... 115 
Figure 30 Mean TNF-α density between control sections and Crohn’s disease sections.  
There is a significant difference in expression of TNF-α in Crohn’s disease sections 
compared to controls, p=<0.001. ................................................................................ 116 
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Figure 31 Mean density for each section for RNA probe for TNF-α.  There is reduced 
light transmission indicating increased TNF expression in Crohn’s disease sections. 117 
Figure 32 Schematic of Paneth cell height measurement.  Maximum Paneth cell height 
= 2. .............................................................................................................................. 124 
Figure 33 Comparison between mean Paneth cell count and lysozyme and H&E 
staining identification.  (PCC=Paneth cell count, H&E=haematoxylin and eosin 
staining, Lyz=lysozyme immunohistochemistry) ....................................................... 127 
Figure 34 Error bars showing 95% confidence intervals indicating no significant 
difference in Paneth cell count (top) and Paneth cell height (bottom) between 
successive resections.  (PCC= Paneth cell count, PCH=Paneth cell height, H&E= 
haematoxylin and eosin stain, Op_No= operation number) ....................................... 129 
Figure 35 Mean Paneth cell count compared between control and Crohn’s disease 
section.  H&E (a) p=0.014, lysozyme (b) p=0.1. (PCC= Paneth cell count) .............. 131 
Figure 36 Scatterplot with linear regression plot showing no significant association 
between  Paneth cell count (mean) and age in Crohn’s disease, F 3.211, p=0.08. ..... 132 
Figure 37 Scatterplot with linear regression plot showing no significant association 
between age and Paneth cell count (mean) in controls, F2.021, p=0.193................... 133 
Figure 38 Mean Paneth cell count using H&E (a) and Lysozyme (b) identification and 
CARD15 (NOD2) genotype.  There is no significant difference between genotypes.  
(PCC=Paneth cell count)............................................................................................. 134 
Figure 39 Comparison between Paneth cell height (cells) and H&E and lysozyme 
identification (PCH=Paneth cell height). .................................................................... 136 
Figure 40 Mean Paneth cell height between Crohn’s disease and control measured in 
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Figure 41 Mean Paneth cell height and CARD15 (NOD2) genotype (a) H&E staining, 
(b) lysozyme immunohistochemistry. ......................................................................... 138 
Figure 42 There was no significant difference in the mean pyloric metaplasia score 
between CARD15 (NOD2) genotypes (Cor_PM= corrected pyloric metaplasia score).
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Figure 43 Pyloric metaplasia was significantly more likely in CARD15 (NOD2) 
compound heterozygotes/homozygotes than wild type (p=0.024) Crohn’s patients.  
Pyloric metaplasia was significantly more likely in CARD15 (NOD2) heterozygotes 
than wild type Crohn’s patients (p=0.024). ................................................................ 141 
Figure 44 Bar chart to demonstrate the finding of pyloric metaplasia (PM) in Crohn’s 
disease sections as mentioned in the pathology report.  There is no significant 
difference in the presence of pyloric metaplasia and the number of NOD mutations. 142 
Figure 45 There was no significant difference in ATG16L1 genotype and the presence, 
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Figure 46 There was no significant difference in the presence of granuloma in 
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